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High performance liquid chromatography (HPLC) has been reported as a means of
demonstrating the multicomponent nature of "mTc radiopharmaceuticals. HPLC has not,
however, been widely reported as a satisfactory technique for measuring the radiochemical
purity (RCP) of "mTc radiopharmaceuticals. Inadequate techniques based on thin-layer and
paper chromatography are in widespread use for this purpose. The aim of the work
described in this thesis was therefore to carry out a scientific investigation to establish if
quantitative HPLC is a technique that can be used to measure the RCP of "mTc
radiopharmaceuticals.
An on-line radiation detector was developed and evaluated. This was constructed from a
length of column outlet tubing positioned inside the well or across the face of a sodium
iodide crystal scintillation detector. The different configurations of tubing and crystal were
used to create different sensitivities of detection. Chromatograms were recorded with
either a counter-ratemeter/printer system or a computer-based multichannel analyser. At
6,000 counts per second, the highest count-rate encountered in the course of the work, the
loss due to dead-time in the multichannel analyser was satisfactorily low at 0.5%.
For successful measurement of RCP, none of the radiolabelled species in a
radiopharmaceutical must be retained on the HPLC column and thereby escape detection.
A technique for measuring recovery from the column was therefore developed. This
involved injecting the sample onto the column with a loop-valve injector, collecting the
eluate and measuring the count-rate from it relative to the count-rate from an accurately
pipetted sample of the radiopharmaceutical.
An HPLC technique was developed for measuring the RCP of 99mTc-MAG3. This used a
250 x 5 mm ODS column eluted with ethanol/10 mM phosphate buffer pH6 (5:95) for 10
minutes then methanol/water (90:10) for 10 minutes. This technique revealed the presence
of 6 radiolabelled species in 99mTc-MAG3. Recovery from the column was consistently in
the order of 100%. HPLC was shown to be superior to both a thin-layer and a paper
chromatographic technique and was then used to demonstrate that, contrary to previously
published data, 99mTc-MAG3 is stable for 6 hours. This finding was confirmed with
clinical studies in 40 patients. HPLC was then used to investigate the effect on RCP and
stability of various conditions that might arise during routine preparation of 99mTc-MAG3.
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RCP and stability were not found to be affected by the volume of "mTc generator eluate
used during preparation, dilution, agitation, the introduction of air or the use of a "mTc
generator eluate with a "Tc:"mTc ratio of 16.
The search for an HPLC technique for measuring the RCP of "mTc-DMSA was
unsuccessful since this radiopharmaceutical was found to adsorb strongly on three column
packings. However, a number of discoveries were made. A previously published HPLC
method for analysis of "mTc-DMSA was shown to be unsatisfactory. Contrary to previous
findings, the level of "Tc in the "mTc used to prepare "mTc-DMSA was not found to
affect the radiopharmaceutical. "mTc(V)-DMSA was shown to be a common impurity in
"mTc-DMSA with the concentration of this impurity decreasing with time. The method of
preparation was shown to influence the "mTc(V)-DMSA content of "mTc-DMSA.
An HPLC technique was developed for measuring the RCP of "mTc-exametazime. This
was carried out by gradient elution of a 150 x 4.6 mm PRP-1 column. The gradient
consisted of 20 mM phosphate buffer pH 7.4 (100%) to phosphate buffer/tetrahydrofuran
(75:25) over six minutes, then held for 4 minutes. This technique revealed five
radiolabeled species in "mTc-exarnetazime. Recovery from the column was consistently in
the order of 100%. HPLC was found to give comparable results to an established
technique in which both thin-layer and paper chromatography are used. HPLC was then
used in the development of a routine technique for using sodium iodide to stabilize "mTc-
pertechnetate that is dispensed for the preparation of "mTc-exametazime and to confirm
that RCP of "mTc-exametazime is influenced by the age of "mTc-pertechnetate from which
it is prepared but not by the brand of generator from which the "mTc is obtained.
The conclusion from this work is that HPLC is a satisfactory technique for measuring the




A radiopharmaceutical is a medicinal product which incorporates a radionuclide.
Radiopharmaceuticals are widely used in both the diagnosis and treatment of disease and are
fundamental to the branch of medicine known as Nuclear Medicine.
The most commonly used radiopharmaceuticals contain the radionuclide technetium-99m
(99mTc). These are employed in the detection of disease by the technique of radionuclide
imaging. The simplest radionuclide imaging techniques to investigate particular organs of
the body involve administering to the patient a radiopharmaceutical which localizes in the
tissue of interest. This can be healthy or diseased tissue depending upon the mode of action
of the radiopharmaceutical. Administration is usually, but not exclusively, by the
intravenous route. Once the radiopharmaceutical has localized as required, the gamma-rays
that are emitted can be detected from outside the patient's body with a gamma-camera.
From the spatial distribution of the gamma-rays detected, this instrument constructs an
image of the distribution of the radiopharmaceutical in the part of the body that is under
investigation. From this image, the presence of disease may be seen. This basic technique is
known as static imaging and provides essentially anatomical detail of the organ being
investigated e.g. the detection of thyroid nodules, skeletal metastases and pulmonary emboli,
although the manner in which the radiopharmaceutical is handled by the organ can provide
information on function e.g. the relative uptake of a radiopharmaceutical by each kidney is
used as an indication of relative kidney function.
The more sophisticated technique of dynamic imaging involves using a gamma-camera to
record the concentration of a radiopharmaceutical in an organ over a period of time to
provide functional information e.g. the assessment of kidney function by following the time
course of excretion of a radiopharmaceutical that is excreted by glomerular filtration or
tubular secretion and the measurement of cardiac function by imaging the blood pool of the
heart throughout the cardiac cycle.
Radiopharmaceuticals containing "mTc are available for the investigation of most organs of




A typical radiopharmaceutical is composed of two parts - an organ-specific component and
a radionuclide. After the radiopharmaceutical has been administered to the patient, the
organ-specific component is the means by which the radionuclide is transported to the part
of the body that is under investigation. Various organ-specific agents are used in "mTc
radiopharmaceuticals e.g. particles, colloids, relatively simple molecules, proteins and
antibodies. The radiation that is emitted by the radionuclide is the means by which the
distribution of the radiopharmaceutical is imaged. A number of factors account for the pre¬
eminence of "mTc as a radionuclide for diagnostic imaging:
• It has a half-life of 6 hours. This is short enough to result in only a modest
radiation dose to the patient yet long enough to allow most investigations to
be performed.
• Only gamma radiation is emitted. This avoids subjecting patients to the high
radiation doses that are associated with beta or alpha emitters.
• The gamma radiation has an energy of 140 keV. This is ideally suited to
detection with a gamma-camera.
• It can be obtained from a radionuclide generator. This makes "mTc
relatively cheap in comparison to radionuclides that must be prepared in a
cyclotron or nuclear reactor and readily available in the high activities that are
needed for imaging procedures.
During the early stages of development, a "mTc radiopharmaceutical is often prepared from
individual ingredients which are weighed out and processed when required. This is
commonly referred to as an "in-house" preparation. However, experience has shown that
radiopharmaceuticals only become used widely if they are available commercially. To gain
widespread acceptance, the procedure by which a "mTc radiopharmaceutical is prepared
must be relatively straightforward and sufficiently robust to result in a product of the required
quality regardless of the variations in preparative technique that will inevitably exist from
radiopharmacy to radiopharmacy. The way in which this has been achieved by the
radiopharmaceutical industry is through the development of the radiopharmaceutical kit.
This is a vial or combination of vial and ampoules and/or pre-filled syringes containing the
ingredients required for the preparation of the radiopharmaceutical with the exception of the
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radionuclide. In the case of "mTc radiopharmaceuticals, a typical kit is a multi-dose vial
that contains a sterile freeze-dried powder.
The first step in the preparation of a "raTc radiopharmaceutical is elution of a "mTc
generator. This provides Sodium Pertechnetate [99mTc] Injection which is a sterile solution
of sodium pertechnetate (99raTc) in Sodium Chloride Injection. The volume of Sodium
Pertechnetate [99mTc] Injection that contains the required activity of "mTc is then injected
into the radiopharmaceutical kit. Sodium Chloride Injection can also be added to achieve a
suitable radioactive concentration. For most radiopharmaceuticals, labelling of the "mTc to
the organ-specific component is instantaneous but in a few cases the reconstituted kit must
be incubated at room temperature or placed in a boiling water-bath for a specified time to
promote the labelling reaction. After preparation, the kit can be issued from the
radiopharmacy as a single or multi-dose container depending on the activity of "mTc that
has been used for reconstitution. Alternatively, aliquots of the contents of the reconstituted
kit can be dispensed into syringes or vials to provide individual patient doses which are then
despatched to the nuclear medicine department.
The manufacturers of kits subject their products to rigorous quality assurance procedures to
demonstrate that radiopharmaceuticals of high quality are produced. However, it is
impossible for a manufacturer to anticipate all the possible conditions to which its product
might be subjected during use. Several apparently innocuous factors are known to have
deleterious effects on the quality of "mTc radiopharmaceuticals:
• Haney et al. (1971) and Chia & De Schrijver (1982) have shown that the
presence of excessive levels of aluminium in "mTc generator eluates that are
used in the preparation of "mTc sulphur colloid injection can cause instability
of this radiopharmaceutical.
• various authors have shown that "mTc radiopharmaceuticals can adsorb to the
interior surface of particular glass vials (Porter et al., 1975, Millar, 1984,
Millar & Stewart, 1985).
• Slater et al. (1983) have demonstrated that when a Gillette syringe is used
during the preparation of "mTc-tin colloid, a radiolabeled impurity can be
formed in the radiopharmaceutical due to substances leaching from the rubber
plunger of the syringe.
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• Sampson and Keegan (1985) have shown that the radiochemical purity of
"mTc-pentetate is influenced by the presence of air and the preparation of
the radiopharmaceutical with "mTc from a generator which requires an
eluent that contains an oxidant.
• Hilditch et al. (1986) have shown that agitation during transport can induce an
increase in the particle size of "mTc-tin colloid.
• Murray et al. (1986) have shown that the use of a bactericidal swab
containing chlorhexidine and cetrimide to disinfect the caps of
dimercaptosuccinic acid (DMSA) kits can cause the formation of a """re¬
labelled impurity in "mTc-DMSA.
• Palmer (1992) has shown that the introduction of chlorhexidine into a kit
during the preparation of "mTc-hydroxymethylene diphosphonate produces
an unacceptably high level of "mTc-labelled colloidal impurity.
Each of these phenomena is outwith the control of the radiopharmaceutical kit manufacturers
and it would be unreasonable to expect a manufacturer to investigate all the combinations of
generator, syringes, needles, swabs, vials, Sodium Chloride Injection, etc that might be used
in different radiopharmacies during the reconstitution of each of its products. Consequently,
the responsibility for ensuring that the procedure and materials used to prepare a
radiopharmaceutical result in a satisfactory product lies with the radiopharmacy in which
preparation is undertaken. A quality assurance programme to demonstrate satisfactory
radiochemical purity is therefore a vital component of the work in any hospital
radiopharmacy.
The aspect of quality that gives rise to many of the problems outlined above is the
radiochemical purity of the radiopharmaceutical. Radiochemical purity is defined in the
British Pharmacopoeia 1993 (B.P.) as:
The ratio, expressed as a percentage, of the radioactivity of
the radionuclide concerned that is present in the source in
the chemical form declared to the total radioactivity of that
radionuclide present in the source.
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For the majority of "raTc radiopharmaceuticals, the B.P. stipulates that radiochemical purity
must be not less than 95%. The consequence of low radiochemical purity is that the "mTc
does not behave in the required manner after the radiopharmaceutical has been administered
to the patient. For example,
• the presence of "mTc-pertechnetate impurity in a radiopharmaceutical will
give rise to the localisation of "mTc in the thyroid, salivary glands, stomach,
kidneys and bladder. If a significant amount of this impurity is present in the
lung imaging radiopharmaceutical "mTc-macroaggregated albumin, the
resulting "mTc in the stomach can interfere with the detection of lung disease
since the stomach lies behind the left lung. The presence of "mTc-
pertechnetate impurity can give rise to similar problems in cardiac and bone
imaging.
• the presence of colloidal "mTc in a radiopharmaceutical results in "mTc
becoming localised in the liver, spleen and bone marrow. If a significant
amount of this impurity is present in a bone imaging radiopharmaceutical,
those parts of the skeleton in the vicinity of the liver and spleen are not
distinguishable. In a similar manner, colloidal "mTc in a
radiopharmaceutical for kidney imaging can interfere with detection of the
right kidney since the liver lies in front of this organ.
• in the cerebral blood flow imaging radiopharmaceutical "mTc-exametazime,
the higher the concentration of the impurity described as secondary "mTc-
exametazime complex, the lower the uptake of "mTc in the brain.
The techniques that have been developed for measurement of the radiochemical purity of
"mTc radiopharmaceuticals are almost exclusively chromatographic with thin-layer, paper,
gel filtration and electrophoresis being the most common.
1.2 Thin-layer and paper chromatography techniques
Thin-layer and paper chromatography have been widely reported as convenient methods for
determining the radiochemical purity of "mTc radiopharmaceuticals (Billinghurst 1973,
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Pauwels & Feitsma 1977, Zimmer and Pavel 1977, Zimmer et al. 1982, Robbins 1983 &
1984). With few exceptions, these techniques depend upon either the radiopharmaceutical
and some impurities being retained at the point of application while other impurities migrate
with the solvent front or some impurities being retained at the point of application while the
radiopharmaceutical and other impurities migrate with the solvent front. In practice, it is
often necessary to use both techniques to identify the common impurities that can be present
in a "mTc radiopharmaceutical. After development, the relative amounts of the "chemical
form declared" and impurities are determined from the distribution of radioactivity along the
chromatogram. This can be determined either by using a chromatogram scanner and
integrating the areas of the peaks or by cutting the chromatogram into transverse strips,
measuring the count-rate from each strip in a gamma-counter and thereby quantifying the
relative activities in the peaks. This latter technique is commonly referred to as the
"cut-and-count technique".
A typical example is the method described in the B.P. for determination of the radiochemical
purity of Technetium [99mTc] Pentetate Injection. In this technique, a first chromatogram is
run on Instant Thin Layer Chromatography - Silica Gel (ITLC-SG, Gelman) using butan-2-
one as the solvent. In this system, 99mTc-pentetate and unbound reduced 99mTc impurity
remain at the origin while 99mTc-pertechnetate impurity migrates with the solvent front.
From this chromatogram, the level of 99mTc-pertechnetate impurity can be determined. A
second chromatogram is run on ITLC-SG using 0.9% sodium chloride in water as the
solvent. In this system, the unbound reduced 99mTc impurity is retained at the origin while
99mTc-pentetate and 99mTc-pertechnetate impurity migrate with the solvent front. From this
chromatogram, the level of unbound reduced 99mTc impurity in the radiopharmaceutical can
be determined. Radiochemical purity is then calculated by subtracting the sum of the levels
of 99mTc-pertechnetate and unbound reduced 99mTc impurities from 100. Similar techniques
are specified in the B.P. for determination of the radiochemical purity of Technetium [99mTc]
Tin Pyrophosphate Injection and Technetium [99mTc] Medronate Injection.
Thin-layer techniques such as the one described have a number of advantages:
• migration of the solvent up the ITLC-SG plate is fast. The analysis is
therefore performed quickly. Given that most 99mTc radiopharmaceuticals are
formed through chemical reduction of the Tc, the complexes can be
susceptible to oxidation. A rapid technique therefore limits the time for
degradation of the radiopharmaceutical during the analytical procedure. A
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rapid technique also makes it possible, if necessary, for the
radiopharmaceutical to be analysed before it is administered to the patient.
• the ITLC-SG stationary phase is easily cut. This makes it particularly
suitable for the cut-and-count technique.
• the ease with which ITLC-SG can be cut allows small plates to be used. This
has been exploited in the miniaturized techniques that have been developed
(Zimmer and Pavel 1977, Zimmer et al. 1982). Plates measuring 1 x 6 cm are
used commonly in these techniques. In addition to developing rapidly, the
small chromatograms make these techniques inexpensive to perform.
The thin-layer techniques are not without their problems. Results have been shown to be
influenced by a range of technical artifacts such as size, drying and placement of the sample
(Kowalsky & Creekmore 1982) and two multicentre trials have shown wide variations in
results obtained (Eckelman et al. 1981, Millar 1986). However, the major disadvantage of
these techniques is that they are specific for radiolabeled impurities, not the desired
radiolabeled species i.e. the "chemical form declared" as it is termed in the definition of
radiochemical purity. They would therefore be more properly described as tests for "mTc-
pertechnetate and unbound reduced "mTc impurities than tests for radiochemical purity. It is
quite conceivable that an impurity with identical chromatographic behaviour to the active
chemical form could be present in the radiopharmaceutical and yet remain undetected. The
limitation of these techniques is that species are either retained at the origin or migrate with
the solvent front. Reliance on this crude origin/solvent front approach cannot result in a
specific technique.
A much more satisfactory situation would be to have a chromatographic system in which each
species in the radiopharmaceutical exhibits a specific characteristic i.e. Rf value in the case of
thin-layer and paper chromatography or retention time in the case of a column
chromatographic technique. In this situation it would be less likely, although still possible,
that an impurity would exhibit the same characteristic as one of the other species.
A few thin-layer systems of this type have been developed for "mTc radiopharmaceuticals.
Chiotellis et al. (1978) have shown that when the gall bladder imaging agent "mTc-N-(2,6-
dimethylphenylcarbamoylmethyl)-iminodiacetic acid (99mTc-HIDA) is analysed on ITLC-SG
using 2% sodium chloride as the mobile phase, the "mTc-HIDA migrates with an Rf of 0.5.
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Ohta et al. (1984) have developed a system for analysis of pentavalent "mTc-
dimercaptosuccinic acid (99mTc(V)-DMSA) which uses a conventional silica gel thin-layer
plate and a mobile phase of butanol: acetic acid: water (3:2:3). Under these conditions,
"mTc(V)-DMSA migrates with a Rf of 0.4 - 0.6, "mTc-pertechnetate impurity migrates with
an Rf of 0.65 - 0.8 while "mTc(IV)-DMSA and unbound reduced "mTc remain on the origin
(Westera et al. 1985).
1.3 Electrophoresis
Billinghurst (1973) and Pauwels & Feitsma (1977) investigated electrophoresis as a
technique for the routine analysis of "mTc radiopharmaceuticals but concluded that it offered
no advantages over the more rapid and easily performed thin-layer chromatographic
techniques. Electrophoresis on cellulose acetate has been used by Baker et al. (1975) for
the analysis of "mTc-pyridoxylideneglutamate, a radiopharmaceutical for hepatobiliary
imaging. However, this technique has not found widespread application. The slow speed of
separation and poor reproducibility have prevented its adoption as a routine quality control
technique for radiopharmaceuticals (Carpenter 1986).
1.4 Gel permeation chromatography
Gel permeation chromatography using Sephadex G25 (Pharmacia) has been suggested as a
suitable technique for the analysis of "mTc radiopharmaceuticals due to its ability to separate
"mTc-pertechnetate, labelled compound and unbound reduced "mTc (Eckelman et al. 1971).
The rationale for this technique is that the labelled compound is larger than the fractionation
range of the gel and is therefore eluted at the void volume of the column. "mTc-pertechnetate
is smaller than the fractionation range and is therefore eluted at the total volume of the
column. Unbound reduced "mTc is irreversibly adsorbed onto the gel at the top of the
column. Valk et al. (1973) have shown that when this technique is used to analyse the renal
imaging radiopharmaceutical "mTc-gluconate, the Sephadex gel can attract the "mTc from
the gluconate molecule thereby giving an erroneously high value of the level of unbound
reduced "mTc in the radiopharmaceutical. Steigman and Williams (1974) demonstrated that
this phenomenon could be overcome by eluting the Sephadex column with a solution of the
complexing compound rather than the 0.9% sodium chloride solution used in the technique
described originally. As an alternative means of overcoming the problem, Billinghurst and
17
1. Introduction
Palser (1974) suggested the use of Bio-Gel (Bio-Rad Laboratories) in place of Sephadex
since, while it retains the ability to adsorb any unbound reduced "mTc in the
radiopharmaceutical, it does not have the power to strip "mTc from the labelled compound.
Despite these findings, gel permeation chromatography which is practised in this way can be
likened to the origin/solvent front approach of the miniaturized thin-layer techniques in that it
is not specific for the labelled compound. Its popularity was short-lived , probably due to it
being more technically demanding than the thin-layer techniques.
Gel permeation chromatography has been shown to be valuable in the analysis of labelled
proteins and other large molecules. In these situations, it is necessary to choose a gel with a
fractionation range that encompasses the sizes of the molecules to be separated. This has been
shown to be valuable for the demonstration of "mTc-labelled tin colloid impurity and albumin
polymers in "mTc-human albumin (Pettit et al. 1978 & 1980, Dekker et al. 1982). Gel
permeation chromatography on a Sepharose-4B column has also been used to demonstrate the
presence of a "mTc-labelled colloidal impurity in "mTc-labelled cardiac myosin antibody
fragment (Khaw et al. 1982).
1.5 The case for high performance liquid chromatography
High performance liquid chromatography is used widely as an analytical technique for
determining the purity of pharmaceuticals. In the field of radiopharmacy it has the potential to
overcome the shortcomings of the popular but inadequate thin-layer techniques that have been
described earlier. Most importantly, HPLC is a highly specific technique and should be
capable of providing a peak with a specific retention time for each radiochemical species in a
radiopharmaceutical. The analysis is carried out in an oxygen-free environment which should
prevent degradation of the radiopharmaceutical during analysis. HPLC can be a rapid
technique to perform and should, if necessary, allow measurement of radiochemical purity
before the radiopharmaceutical is administered to the patient.
Early attempts to use HPLC for the analysis of "mTc radiopharmaceuticals resulted in little
more than sophisticated and expensive methods for the quantitation of "mTc-pertechnetate
impurity (Russell and Majerik, 1979, Wong et al., 1981). The reason for this inadequacy was
the choice of chromatographic systems in which the radiopharmaceuticals were eluted from
the HPLC columns as unretained solutes while any "mTc-pertechnetate impurity was eluted
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at some time later. This strategy is no different to the thin-layer origin/solvent front
approach criticized earlier.
HPLC has been used widely during the development of new radiopharmaceuticals and in the
investigation of the radiolabeled species that are present in new and existing
radiopharmaceuticals.
The agents that have been most extensively investigated by HPLC are undoubtedly the bone
imaging radiopharmaceuticals "mTc-ethylenehydroxydiphosphonate (EHDP) and "mTc-
methylene diphosphonate (MDP). "mTc radiopharmaceuticals have traditionally been
thought of as discrete chemical entities but Srivastava et al. (1982) used a reversed phase
HPLC column in conjunction with a complex eluent containing an ion-pairing agent to
demonstrate that "mTc-EHDP consists of eight major "mTc-labelled species and "mTc-
MDP consists of four. More recently, Hoch and Pinkerton (1986) used a similar
chromatographic system but with a macroporous reversed-phase column to demonstrate the
presence of many more radiolabelled species in "mTc-MDP. Analysis of "mTc-EHDP
and "mTc-MDP has also been performed using an ion exchange column and a simple eluent
consisting of 0.85M sodium acetate (pH 8.4) to reveal the multicomponent nature of these
radiopharmaceuticals (Pinkerton et al., 1980, Tanabe et al., 1983). DeLigny and co-workers
have also used HPLC to carry out extensive investigations of the nature, formulation and
analysis of "mTc-EHDP and "mTc-MDP (DeGroot et al. 1985, 1986 & 1987, Gelsema et al.
1987, Huigen et al. 1988a & b, Nieuwland et al. 1989, Tji et al. 1990).
Loberg and Fields (1978) used HPLC on an octadecylsilyl (ODS) column with an
acetonitrile/phosphate buffer mobile phase during work to establish the structure of the gall
bladder imaging radiopharmaceutical "mTc-HIDA. Fritzberg and Lewis (1980) used similar
chromatographic conditions for a comparison of five "mTc-iminodiacetate agents and an
investigation of the behaviour of these radiopharmaceuticals in plasma and bile.
The effect of the presence of Tc99 during the preparation of "mTc-dimercaptosuccinic acid,
a radiopharmaceutical for kidney imaging, has been studied by Moretti et al. (1982) using an
ODS column and phosphate buffer mobile phase.
High performance gel permeation chromatography has been used by Vallabhajosula et al.
(1982), Hosain and Hosain (1982) and Muller (1985) to analyse the blood pool imaging
radiopharmaceutical "mTc-human albumin. These investigations have demonstrated the
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presence of up to five radiolabeled species in this radiopharmaceutical. In previous work
using conventional gel permeation chromatography, Pettit et al. (1978) succeeded in
identifying only three components in "mTc-HSA. The advantages of the HPGPC technique
for the analysis of this radiopharmaceutical are therefore speed and higher resolution.
Blower et al. (1991) have used gradient elution of a styrene-divinylbenzene polymer column
with an acetonitrile/trifluoroacetic acid mobile phase in the course of their work to determine
the chemical identity of pentavalent "mTc-dimercaptosuccinic acid (99mTc(V)-DMSA).
Using HPLC to obtain quantitative information on the composition of a radiopharmaceutical
is not as straightforward as using thin-layer chromatography. As the solvent migrates up a
thin-layer plate, all the radioactive material that was applied to the origin becomes
distributed along the plate as one or more spots. During analysis of the chromatogram all
the radioactive material that was applied to the plate is detected. This is not necessarily the
case with HPLC. A fraction of the sample that is injected onto the column may become
irreversibly bound to the column packing and remain undetected. If this adsorbed fraction is
an impurity in the radiopharmaceutical, calculation of the radiochemical purity from the
chromatogram will give an erroneously high result. Conversely, if the adsorbed fraction is
the labelled species, the calculated radiochemical purity will be erroneously low. If HPLC
is to be a valid method of determining radiochemical purity, measurement of the recovery
from the column is essential to ensure that no adsorption has taken place.
A consistent feature of the above reports on the use of HPLC in the investigation of "mTc
radiopharmaceuticals is that recoveries from the columns are not quoted. While the
techniques have undoubtedly been of value in determining the identity of radiolabeled species
or demonstrating the multi-component nature of radiopharmaceuticals, they are not
necessarily satisfactory techniques for the measurement of radiochemical purity since the
question of adsorption of "mTc onto the column has not been addressed.
20
1. Introduction
1.6 Aims and objectives
The aim of this project was therefore to carry out a scientific investigation to establish if
quantitative HPLC is a technique that can be used to measure the radiochemical purity of
"mTc radiopharmaceuticals.
The objectives to be met in achieving this aim were:
1. To develop, construct and evaluate an HPLC radiation detector for use with
"mTc radiopharmaceuticals.
2. To develop HPLC techniques for measuring the radiochemical purity of the
radiopharmaceuticals "mTc-mercaptoacetyltriglycine, "mTc-dimercaptosuccinic
acid and "mTc-exametazime.
3. To evaluate the use of non-silica column packing materials in determining the
radiochemical purity of these "mTc radiopharmaceuticals.




A range of equipment was used to perform the experimental work that is described in the
following chapters. Some of the instruments such as the HPLC pumps and nucleonics were
commercially available while others such as the HPLC radiation detector and thin-
layer/column scanner were developed for the project and constructed "in house". This
chapter contains a description of each piece of equipment that was used. Throughout the text
of this thesis I have restricted identification of suppliers to name only. Full names and
addresses are contained in Appendix I.
2.1 HPLC pumps
Two pumps were used in the course of this work. The older was a Series 2/1 (Perkin-
Elmer). This is a dual piston reciprocating pump capable of only isocratic operation. The
newer of the two was a Model PU4100 (Philips Scientific). This is also a dual piston
reciprocating pump and was chosen for its ability to perform single, isocratic and gradient
elution. Its programmable operation was also a distinct advantage. The majority of the
investigations were carried out with this instrument.
2.2 Injection valves
A Model 7120 (Rheodyne) injection valve was used in conjunction with the Perkin-Elmer
pump and a Model 7125 injection valve (Rheodyne) was used in conjunction with the Philips
PU4100 pump. Both valves were fitted with 20 gl sample loops.
2.3 HPLC columns
Hypersil-ODS (Shandon Scientific) is a fully capped octadecylsilyl adsorbent for reversed
phase HPLC. A 250 x 5 mm analytical column was packed in-house with 5 f±m adsorbent
using a Shandon column packer. The efficiency of these columns was typically 50,000 plates
per metre as measured with a phenol/para-cresol test mixture.
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Hypercarb (Shandon Scientific) is an HPLC adsorbent that consists of rigid porous
graphitised carbon spheres 7 pm in diameter. This was supplied in a 100 x 4.6 mm pre¬
packed column. The typical efficiency of the column as quoted by the manufacturer was
20,960 plates per metre. The potential advantages of this column are its high chemical
resistance over a pH range of 1 to 14 and its freedom from the unreacted silanol sites that can
be present in the conventional silica-based ODS reverse phase columns. These sites possess
highly retentive properties and might therefore retain a significant proportion of the
extremely low mass of radiolabelled compound that is present in a "mTc
radiopharmaceutical. Hypercarb is also interesting in that there is no documented report of
its use for the analysis of "mTc radiopharmaceuticals.
PLRP-S (Polymer Laboratories) is a spherical rigid macroporous polystyrene/
divinylbenzene HPLC packing. A 250 x 4.6 mm analytical column was used. This was
supplied pre-packed with 8 /rm adsorbent of 300 A pore size. The analytical column was
protected by a 5 x 3 mm PLRP-S guard column. The typical efficiency of this column as
quoted by the manufacturer is 42,960 plates per metre. In common with Hypercarb, this
column was chosen for its freedom from unreacted silanol sites and its stability over the pH
range of 1 to 13.
PRP-1 (Hamilton) is a macroporous copolymer of styrene and divinylbenzene similar to
PLRP-S. It was supplied as a pre-packed 150 x 4.1 mm analytical column. The 10 pm
particle size adsorbent was used. The analytical column was protected by a 25 x 2.3 mm
PRP-1 guard column. The typical efficiency of this column as quoted by the manufacturer is
31,020 plates per metre. In common with Hypercarb and PLRP-S, this adsorbent is free
from unreacted silanol sites and is stable over the pH range of 1 to 14.
Injector-to-column and guard column-to-analytical column connections were made using




The gamma radiation detector was constructed from a length of stainless-steel column
outlet tubing (internal diameter = 0.3 mm) positioned inside or across the face of a
5 x 5 cm sodium iodide crystal detector with a 1.5 x 4 cm well. Typical configurations of
tubing and crystal are shown in Figure 2.1. The different arrangements gave flow-cell
volumes of between 2 and 10 /xl and were used to achieve different sensitivities of
detection. Configurations A, B and C gave relative sensitivities of 1.5, 1.0 and 3.6
respectively. In configuration A, replacement of the stainless-steel tubing with polyether-
etherketone (PEEK) tubing resulted in a 30% increase in detection sensitivity due to the
lower attenuation of gamma radiation in PEEK. The whole assembly was surrounded by
lead shielding. Two nucleonic systems were used to create the chromatograms from the
output of this detector.
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Figure 2.1. Diagrammatic illustrations ofdetector cell configurations.
25
2. Equipment
2.5 MS310 counter-ratemeter system
This was the older of the two systems. The signal from the detector was taken to a counter
ratemeter Model MS310 (J & P Engineering) which also provided the high voltage supply to
the detector. The analogue output from the MS310 counter-ratemeter was taken to a chart
recorder Model E22 (Linseis) to provide chromatograms. The digital output from the
MS310 was taken to a printer Model 412L (Datac) via a print controller module Model
MS 190 (J & P Engineering) to record the counts detected. When a counting time was set on
the MS310 and counting was started, the instrument counted for the set time, the counts were
printed, the display of the instrument was reset to zero and counting was restarted
automatically. This process resulted in a listing of the counts detected against time. From
this listing, the group of counts corresponding to a peak on the chromatogram could be
identified and summed to give the total counts in the peak.
2.6 Accuspec system
In this, the newer of the two systems, the signal from the detector was taken to a SpecMate
preamplifier/amplifier (Canberra Nuclear Data). The SpecMate also supplied the high
voltage to the photomultiplier of the detector.
The output from the SpecMate was taken to an AccuSpec multichannel analyser (Canberra
Nuclear Data). The AccuSpec system consists of both hardware and software components
which are installed in a personal computer (PC). The hardware consists of a PS2/2 Model 30
PC (IBM) with the Accuspec FMS (Fast Multichannel Scaling) acquisition board installed in
one of the computer's input/output channel slots. The software consists of the Accuspec
Display and Acquisition software version 4.0 which was run under the Microsoft Disk
Operating System (MS-DOS) version 4.01. The multichannel analyser was used in
multiscaling mode to record chromatograms which were then stored on the computer's hard
disk for subsequent analysis, manipulation and print-out. Chromatograms were produced by
using an Accuspec utility to convert the data into Lotus 1-2-3 format, transferring it to
SigmaPlot 4.1 software (Jandel) and printing with a LaserJet 4 printer (Hewlett Packard).














Collection of eluate for
measurement of recovery
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Figure 2.2. Diagrammatic illustration ofHPLC equipment.
2.7 Measurement of detector dead-time
Multichannel analysers are notorious for suffering from count loss due to dead time at
relatively low count-rates. In HPLC, peaks on the chromatogram can be extremely sharp.
Count-rates can therefore be very high for short periods and any equipment used as a
radiation detector for HPLC must be capable of handling these high count-rates without
suffering loss of counts. To measure the count loss due to dead-time in the Accuspec
system, a "mTc source which would give a count-rate of approximately 30,000 counts per
second (cps) was prepared and placed in the detector. The counting window of the Accuspec
was set up for the 140 keV gamma-ray of "mTc. The source was counted using a dwell time
of 60 seconds for all 4096 channels. This gave a total counting time of 4096 minutes which
represents 11.3 half-lives for "mTc. The source was then removed from the detector and
background counts were recorded for 70 minutes. An average background count per channel
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was calculated and subtracted from the "mTc counts detected in each of the 4096 channels.
On the assumption that dead-time was insignificant up to 5,000 cps, the numbers of the
channels containing count-rates between 250 and 5000 cps were noted at 250 cps intervals.
The channel numbers were then plotted against the logarithm of the recorded count-rates.
Using a linear regression, the equation for the line was obtained. This equation was
consistent with a half-life of 6.02 hours. The correlation between channel number and
logarithm of the count-rate (r = 1.00) justified the assumption that dead time is insignificant
at count-rates up to 5,000 cps. Using the equation, the numbers of the channels which would
contain count-rates between 1,000 and 30,000 cps were calculated at 1,000 cps intervals.
The count-rates observed in these channels were noted. These observed count-rates were
plotted against the true count-rates. This plot is shown in Figure 2.3. At 10,000, 20,000 and
30,000 cps, the losses due to dead-time were shown to be 2, 6 and 9% respectively.
The highest count-rate detected in a chromatogram obtained in the course of this work was
6,000 counts per second. At this count-rate, the loss due to dead-time was 0.5%. At no
time, therefore, was loss of counts due to dead time a significant factor.
Figure 2.3 Effect ofdead-time on the efficiency of the radiation detector.
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2.8 Detector for measuring count-rates from column eluates
To determine the recoveries from HPLC columns, it was necessary to measure the count-
rates from column eluates and aliquots of the samples being analysed. Given that the
samples injected onto the columns were 20/zl aliquots of radiopharmaceuticals containing
between 50 and 400 MBq of "mTc per ml, eluates could contain up to 8 MBq. This activity
is too high to be counted in a conventional gamma-counter with a sodium iodide crystal
detector. These eluates were therefore counted 15 cm above a detector of this type. This was
achieved by using a platform which was fitted to the lead shielding around the detector. The
platform was marked to enable samples to be positioned reproducibly above the detector.
The arrangement of the detector and platform are shown in Figure 2.4. The detector was







Figure 2.4 Radiation detector configuration for counting recovery samples.
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2.9 Thin-layer and paper chromatogram scanner
In experiments that involved the analysis of radiopharmaceuticals by thin-layer and paper
chromatography, the distribution of activity on the plate or paper strip was measured using a
radiochromatogram scanner. This instrument was constructed by positioning a shielded
sodium iodide crystal detector above a moving table provided by a chart recorder. A slit
collimator was placed between the detector and the table with the slit at right angles to the
direction of travel of the table. A slit width of 2 mm was used throughout the experiments.
The collimator was positioned 5 mm above the bed. The detector was connected to the




Figure 2.5 Diagrammatic illustration of thin-layer and paper radiochromatogram scanner.
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2.10 HPLC column scanner
To locate the position of "mTc retained in an HPLC column, the column was scanned using a
modification of the thin-layer/paper radiochromatogram scanner. Whereas in the
configuration for scanning thin-layer and paper chromatograms the collimator was
positioned 5 mm above the bed, in this modified equipment for HPLC columns, the distance
between the collimator and bed was increased to 20 mm to allow passage of the column
through the instrument. As before, the detector was connected to the Specmate/Accuspec













Figure 2.6 Diagrammatic illustration ofscannerfor HPLC columns.
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A number of techniques were used throughout the course of my investigations. Those that
were common to more than one investigation are described in this chapter. Those that were
specific to a particular investigation, e.g. the technique used to prepare a
radiopharmaceutical, are described in the chapter dealing with that aspect of the work.
3.1 Preparation of mobile phases
Mobile phases were prepared from HPLC grade solvents and chemicals. Water to the
standard of Water For Injections B.P. was used in the preparation of aqueous components.
Mobile phases were filtered through glass fibre filters with a pore size of 0.2 /rm (Whatman)
to remove particulate contamination and then degassed by sparging with helium for
5 minutes.
3.2 Sample injection technique
The introduction of the sample onto the HPLC column was performed according to the
conventional complete loop filling technique described by Rheodyne. A potential drawback
of this technique is that it requires an excess of sample to be available. However, this does
not present a problem with "mTc radiopharmaceuticals since they tend to be prepared in
volumes of a few millilitres. Adequate sample is therefore available. Apart from its ease of
execution, the advantage of the complete loop filling technique is that it delivers the highly
reproducible sample volumes that are required if recovery from the HPLC column is to be
measured by collection and counting of the activity of the eluate. Sample injection was
carried out as follows. With the valve in the "Load" position and mobile phase being
pumped through the valve to the column, water was injected into the needle port to flush
the sample loop. At the end of this procedure the loop contained water. Approximately
300 (jl\ of the radiopharmaceutical to be analysed was drawn into a 1 ml disposable syringe.
Approximately 200 /r 1 of air was drawn into the syringe which was then held upright and
tapped to bring all the solution to the plunger. The 22 gauge sample needle supplied with
the valve was fitted to the syringe and inserted into the needle port of the injection valve.
The sample was discharged slowly from the syringe. This had the effect of expelling the
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flushing water from the sample loop then passing the air in the syringe through the loop and
finally filling the loop with sample. The discharge from the loop vent tube was directed
into a vial which was contained inside a lead shield. This arrangement was used to prevent
the discharged radioactive liquid from increasing the background radiation in the vicinity of
the detector. Passing 200 /d of air through the loop ahead of the sample prevented mixing
of sample and flushing water which might have resulted in dilution of the sample.
Immediately after filling the loop, the valve was switched to the "Inject" position, the
acquisition of the chromatogram was started and the sample syringe was removed from the
valve, again to minimise the background radiation in the vicinity of the detector. The valve
was left in the "Inject" position until the end of the analysis.
3.3 Recording of chromatograms from HPLC
The high voltage and gain of the Specmate pre-amplifier/amplifier and the energy window
of the Accuspec multichannel analyser were set to detect the 140 keV gamma ray emitted by
"mTc. The dwell time of the Accuspec was set to a suitable time - this was typically
2 seconds per channel. Immediately after injection of the sample onto the column, the
Accuspec was switched on and the counts from the detector were acquired until the final
peak had eluted from the column. At the end of acquisition, the data were saved on the
hard disk of the computer. A printed chromatogram was obtained by manipulating the data
using SigmaPlot (Jandel) plotting software.
A similar procedure was adopted when using the older detector system based on the MS310
counter-ratemeter which produced a chromatogram on a chart recorder and a print-out of the
counts detected in each counting interval.
3.4 Measurement of recovery from HPLC columns
When using HPLC for determination of the radiochemical purity of a radiopharmaceutical, it
is possible that a fraction of the sample injected onto the column may become irreversibly
bound to the column packing and remain undetected. If this adsorbed fraction is an impurity
in the radiopharmaceutical, calculation of the radiochemical purity using the counts from the
radiation detector will give an erroneously high result. Conversely, if the adsorbed fraction is
labelled compound, an erroneously low radiochemical purity will be calculated. It is
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important therefore to measure the recovery from the column to ensure that no adsorption has
taken place. This can be achieved by injecting a known volume of sample onto the column,
collecting the eluate and comparing the count-rate from it with the count-rate from a
standard prepared by pipetting an identical volume of the sample. If the count-rates from
sample and standard are identical, recovery is 100%. There is, however, a drawback to this
technique. Samples were injected onto the columns using loop-valve injectors fitted with
20 ill loops. This is known to be a highly reproducible method of applying samples to
HPLC columns. However, Rheodyne, the manufacturer of the valves, acknowledges that
the volume quoted for a sample loop is only nominal and can vary from the actual volume
by as much as 20%. This is due to the + 0.001" tolerance on the internal diameter of the
tubing. The 20 /xl loops used in my work are made from tubing of 0.02" bore. Since the
volume tolerance on these loops is therefore + 10%, there was every likelihood that the
nominal 20 /x 1 loop would not deliver the same volume as a 20 /xl pipette. It was necessary
therefore to calibrate one against the other. To do this, 25 x 20 /xl aliquots of a Sodium
Pertechnetate [99mTc] Injection were pipetted into vials using a 20 /xl fixed volume capillary
pipette (SMI). With no column fitted to the Rheodyne valve and using water as the mobile
phase, 25 loopfuls of the same 99mTc solution were delivered directly into vials containing
approximately 15 ml of water. During this process, the outlet tubing from the valve was
positioned below the surface of the water. This was done to ensure that no sample was lost
as spray when the valve was switched from the "Load" to the "Inject" position and the
system was momentarily put under pressure. The volume in each vial was made up to
20 ml and the solution was mixed thoroughly. Using the equipment described in 2.8, the
count-rate from each of the 50 vials was measured. The counting time was chosen to result
in the detection of a minimum of 10,000 counts to minimize the effect of statistical
variation that results from the random nature of radioactive decay. "Pipette" and "loop"
samples were counted alternately to minimize the effect of any possible instability in the
counting equipment. A record was made of the time at which each vial was measured and
after subtraction of background counts, the counts detected were decay-corrected back to
the time of measurement of the first vial. The average counts from the "loop" samples
were divided by the average counts from the "pipette" samples to give the correction
factor.
As part of the analysis of a radiopharmaceutical by HPLC, the recovery of the sample from
the column was measured as follows. After injection of a sample of the radiopharmaceutical
onto the column, the eluate was collected in a vial. At the end of the collection period, i.e.
when the radiation detector was registering only background counts from the eluate, the
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vial was removed from the instrument and its contents were thoroughly mixed. Aliquots of
the radiopharmaceutical were pipetted into three identical vials using the 20 /xl pipette. The
20 /xl samples were diluted to a volume equal to the volume of eluate collected and mixed
thoroughly. The count-rate from the solution in each of the four vials was measured using
the equipment described in 2.8. As above, a counting time that resulted in the detection of
at least 10,000 counts was chosen. After subtraction of background counts and correction
for the discrepancy between the volumes of loop and pipette, recovery from the column
was calculated by expressing the count-rate from the eluate as a percentage of the mean
count-rate from the three standards.
To establish the range within which a measurement of recovery could be considered
satisfactory, the error associated with the technique was determined by measuring the error
in each step of the procedure. The error associated with delivery of the sample from the
Rheodyne valve was measured by the following technique. With no column attached to the
valve, a 20 /xl sample of a sodium pertechnetate [99mTc] solution was delivered into each of
25 universal containers. As in the earlier experiment to calibrate the valve against the
pipette, the valve outlet tube was positioned under water in the universal containers during
delivery of the samples. The solution in each container was made up to 20 ml with water,
mixed thoroughly and counted using the equipment described in 2.8. Counting was
performed for a time that resulted in the acquisition of at least 50,000 counts as this is
typical of the total counts acquired during a recovery measurement. A record was made of
the time at which each vial was counted. The counts detected were then corrected for the
decay since the time at which the first vial was counted. The coefficient of variation for
delivery from the valve was found to be 1.0%. The error associated with pipetting of the
standards was measured in a similar manner. A 20 /xl sample of a sodium pertechnetate
[99mTc] solution was pipetted into each of 25 universal containers. The samples were
diluted to 20 ml, mixed and counted. The coefficient of variation for pipetting was found
to be 2.3%. In the technique for measurement of recovery, the standards are prepared and
counted in triplicate. The coefficient of variation must therefore be reduced by a factor of
V3. The error associated with positioning of the containers on the platform over the
detector was determined by counting one universal container of "mTc 25 times, the vial
being removed and replaced between each measurement. Corrections for decay were
applied as before and the coefficient of variation for this part of the procedure was found to
be 0.6%. As before, it is necessary to reduce this repositioning error for the standards by
a factor of -J3. The overall coefficient of variation for the recovery technique was then
calculated as the square root of the sum of the squares of the individual errors and found to
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be 1.8%. With a 95% level of confidence, therefore, a measurement of recovery that falls
within two coefficients of variation of 100%, i.e. between 96.4% and 103.6%, can be
considered satisfactory.
3.5 Quantitative analysis of chromatograms
Quantitative analysis was undertaken to determine the percentage of the total activity of the
radiopharmaceutical that is represented by each peak in the chromatogram. At the start of the
chromatogram, the counts in a number of channels were used to calculate the mean
background counts per channel. This was typically calculated from the counts in the first 10
channels. With none of the columns used in the course of this work was there any possibility
of a compound being eluted within 20 seconds. The start of the first peak was taken as the
channel in which the count-rate increased in relation to the background. The end of the
peak was taken as the channel after which the count-rate either returned to background or
began to increase due to the elution of a second species. Using these criteria, the start and
end of each peak were determined. One of the Accuspec's features is the facility to include
all the channels between two markers in a region of interest from which the software
calculates and displays the number of counts in the region. By using this feature to place
regions around the relevant parts of the chromatogram, the counts in each peak were
determined. Based on the number of channels that constituted each peak, the background
counts in each peak were calculated from the mean background counts per channel
established at the start of the chromatogram. The background counts were then subtracted
from the counts in each peak. The percentage of the total activity contained in each peak
was then calculated by expressing the counts in the peak as a percentage of the total counts
in the chromatogram.
When using the MS310 detector system, identification of the peaks on the print-out was
performed according to the criteria described above. Calculation of the counts in each peak
was carried out manually by addition of the counts in the counting intervals that had been
deemed to form the peak. The subsequent background correction and calculation of the
percentage of total activity in each peak was carried out as described above.
The times taken to record chromatograms were sufficiently short to obviate the need for




3.6 HPLC column scanning
When measurement of recovery from the HPLC column indicated that a proportion of the
sample had been retained, the column was removed from the instrument and scanned using
the equipment shown in Figure 2.6. The collimator slit was set at 2 mm and the column was
moved past the detector at a speed of 1 cm/minute. Scanning was started 3 cm before the top
of the column and ended 3 cm after the bottom of the column had passed the detector. The
profile of the "raTc retained in the column was recorded using the Accuspec multichannel
analyser. A print-out of the profile of activity was produced using the SigmaPlot software
as described previously. The use of scanning for quantitation of "mTc retained on a
column was not attempted since the stainless-steel fittings result in different thicknesses of
metal between the column packing and the detector at various points along the column.
This results in varying absorption of the radiation along the length of the column and makes
quantitation impossible. Scanning was therefore used only to localize retained "mTc.
3.7 Paper and thin-layer plate scanning
Scanning of paper chromatograms and thin-layer plates was performed with the same
equipment as was used to scan columns but with the detector positioned only 5 mm above
the moving table (Figure 2.5). During scanning, paper strips and TLC plates with an
aluminium sheet support were covered with a sheet of glass (2 mm thick). This resulted in
a 17% reduction in count-rate due to absorption of the gamma radiation in the glass but was
done to keep all parts of the plate equidistant from the detector and thereby ensure a
consistent efficiency of detection along the length of the plate. Due to their inherent
rigidity, thin-layer plates on a glass support did not have to be treated in this manner.
Scanning was started 3 cm below the origin of the chromatogram and ended 3 cm above the
solvent front. The counts detected from the plate were recorded using the Accuspec
multichannel analyser. The chromatogram was obtained by plotting the data with the
SigmaPlot software as described previously.
3.8 Statistical analysis
Statistical analyses were performed using the Unistat-II statistical software (Unisoft) on a
BBC Master Series microcomputer (Acorn Computers).
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The work described in this chapter was undertaken to establish the suitability of HPLC for
determination of the radiochemical purity of Technetium-99m Mercaptoacetyltriglycine
(99mTc-MAG3) and then to use the HPLC technique to measure the radiochemical purity of
99mTc-MAG3 prepared under a variety of conditions that might arise in routine
radiopharmacy practice.
4.1 Introduction
99mTc-MAG3 is a relatively new radiopharmaceutical that has been developed for gamma-
camera renography (Fritzberg et al. 1986). A number of publications have shown "mTc-
MAG, to be a suitable replacement for 123I- and 131I-iodohippurate and "mTc-
diethyltriaminepentaacetic acid (99mTc-DTPA) in the investigation of renal function (Taylor
et al. 1986, 1987, 1988, Bubeck et al. 1988, Jafri et al. 1988, Russell et al. 1988, Al-
Nahhas et al. 1988). "mTc-MAG3 is now in widespread clinical use. A proposed structure
for the "mTc-MAG3 complex is shown in Figure 4.1 (Fritzberg et al. 1986).
COOH
Figure 4.1 Proposed structure for "mTc-mercaptoacetyltriglycine (MAGJ
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In response to the encouraging clinical results with this radiopharmaceutical, Mallinckrodt
Medical introduced Technescan MAG3, a kit for the preparation of 99mTc-MAG3, to the
U.K. market in 1988. This kit contains 1 mg of betiatide (benzoylmercapto-
acetyltriglycine), 16.9 mg of disodium tartrate and 40 /xg of stannous chloride. Preparation
of 99mTc-MAG3 involves reconstituting the kit with Sodium Pertechnetate [99mTc] Injection
then incubating the vial in a boiling water bath for 10 minutes. Upon addition of the Sodium
Pertechnetate [99mTc] Injection to the kit, a "mTc-tartrate complex is formed. During
heating, the benzoyl moeity is cleaved from the betiatide and exchange of Tc occurs between
the tartrate and MAG3 molecules resulting in the formation of the 99mTc-MAG3 complex.
Thin-layer chromatography, paper chromatography and HPLC have all been used for the
analysis of 99mTc-MAG3. Mallinckrodt (personal communication) has proposed methods for
determining the radiochemical purity of 99mTc-MAG3 that employ each of the three
techniques. Chen et al. (1993) have proposed a thin-layer technique that involves the use of
two plates developed with different solvents. This report included a favourable comparison
with an HPLC technique. In several studies of 99mTc-MAG3, HPLC has been used to
demonstrate that a single radiochemical species predominates in the final product of the
radiolabelling procedure (Fritzberg et al. 1986, Coveney & Robbins 1987, Schaap et al.
1988, Taylor et al. 1988, Brandau et al. 1988). However, none of these reports contain
confirmation that HPLC is a satisfactory technique for measuring the radiochemical purity of
99mTc-MAG3. In particular, none of the HPLC analyses included a measurement of
recovery from the HPLC column. The work described in this chapter was therefore
undertaken to:
1. develop and validate an HPLC technique for measurement of the
radiochemical purity of 99mTc-MAG3
2. use HPLC to measure the radiochemical purity and stability of 99mTc-MAG3
that has been prepared according to several different protocols
4.2 Comparison of thin-layer, paper and high performance liquid chromatography
99mTc-MAG3 was prepared according to the following method recommended by
Mallinckrodt. Sodium Pertechnetate [99mTc] Injection was obtained from a "mTc generator
(Product code MCC20, Amersham), diluted to a radioactive concentration of
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500 MBq/10 ml with Sodium Chloride Injection and injected into a MAG3 kit (Product code
DRN 4334, Mallinckrodt). The vial was placed in a boiling water-bath for 10 minutes then
transferred to a beaker of water at room temperature for 10 minutes. The final product was
stored at room temperature.
Two impurities that might be anticipated in 99mTc-MAG3 are "mTc-pertechnetate and "mTc-
tartrate. "mTc-pertechnetate could be present due to either insufficient reducing agent in the
MAG3 kit or oxidation of the 99mTc-MAG3 after preparation. "mTc-tartrate could be present
due to incomplete exchange of "mTc between the tartrate complex and MAG3. To
investigate the chromatographic behaviour of these potential impurities and determine the
ability of each chromatographic system to separate them from 99mTc-MAG3, samples of each
were prepared. "mTc-pertechnetate was readily available from a "mTc generator. "mTc-
tartrate was prepared by the following technique. Tartaric Acid 4.23 g then stannous
chloride dihydrate 10 mg were dissolved in 100 ml of Water for Injection which had been
purged with nitrogen for 10 minutes - this is the ratio in which tartaric acid and stannous
chloride are present in the MAG3 kit. A 1.0 ml aliquot of this solution was transferred to a
10 ml vial containing a nitrogen atmosphere and Sodium Pertechnetate [99mTc] Injection
(500 MBq/9 ml) was injected into the vial.
Thin-layer chromatography was performed on 5 x 10 cm reversed phase plates (RP18,
Product Code 15685, Merck) as recommended by Mallinckrodt. Immediately before use,
the plates were dried at 120°C for 15 minutes then cooled. The origin was marked 1.5 cm
from the bottom of the plate. The solvent front was marked 6 cm above the origin. Six
spots of the radiopharmaceutical to be analysed were applied to the origin with a 1 ml
syringe fitted with a 25G hypodermic needle. The spots were dried under a stream of
nitrogen before the plate was placed in a chromatography tank containing a solvent of 0.9%
aqueous sodium chloride/methanol/acetic acid (55:45:1). Once the solvent had migrated the
required distance, the plate was removed from the tank and dried under hot air. The plate
was scanned at 1 cm/minute using the thin-layer scanner described in Chapter 2. The
chromatogram was recorded in the Accuspec using a dwell time of 5 seconds. Typical
chromatograms from 99mTc-MAG3, "mTc-pertechnetate and "mTc-tartrate are shown in
Figure 4.2 and contain peaks with Rf values of 0.60, 0.90 and 0.90 respectively.
Paper chromatography was performed on 4 x 18 cm strips of 3MM paper (Whatman) as
recommended by Mallinckrodt. The origin was marked 2 cm from the bottom of the strip.
The solvent front was marked 10 cm above the origin. The solvent was run in the machine
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direction of the paper. The sample was applied and dried in the manner described above.
The strip was then placed in a chromatography tank containing acetonitrile/water (60:40).
Once the solvent had travelled the marked distance, the strip was removed from the tank,
dried and scanned as above. A dwell time of 10 seconds was used. Typical chromatograms
from 99mTc-MAG3, "mTc-pertechnetate and "raTc-tartrate are shown in Figure 4.3 and
contain peaks with Rf values of 0.55, 0.90 and 0.90 respectively.
HPLC was performed using a modification of the method provided by Mallinckrodt. The
equipment used for this analysis consisted of the Philips pump fitted with the Rheodyne 7125
injection valve, a 250 x 5 mm Hypersil-ODS column and the Accuspec-based radiation
detector with the detection cell in configuration C (Figure 2.1). The column was eluted at
1 ml/minute with ethanol/10 mM phosphate buffer pH6 (5:95) for 7 minutes then the pump
switched to methanol/water (90:10) for 10 minutes. The recovery from the column was
measured according to the method described in Chapter 3.4. Typical chromatograms from
99mTc-MAG3, "mTc-pertechnetate and "mTc-tartrate are shown in Figure 4.4 and contain
peaks with retention times of 4.6, 2.8 and 2.1 minutes respectively.
The chromatograms demonstrate that each of the three techniques separates 99mTc-MAG3
from the impurities "mTc-pertechnetate and "mTc-tartrate. None of the techniques separate
the impurities although HPLC did produce a chromatogram containing two peaks. The
coincidence of the "mTc-pertechnetate and "mTc-tartrate peaks on the paper and thin-layer
chromatography could be the result of no radiolabelling having been achieved in the
preparation of "mTc-tartrate, the "mTc remaining in the form of "mTc-pertechnetate and
thereby giving identical chromatograms. However, the two peaks in the HPLC
chromatogram suggest that some radiolabelling did occur. It is possible that the first peak is
due to "mTc-tartrate while the second is due to "mTc-pertechnetate that is present as an
impurity. To determine if "mTc-pertechnetate was present in the "mTc-tartrate, the solution
of "mTc-tartrate was analysed by a miniaturized thin-layer technique. This was performed
using an Instant Thin Layer Chromatography (ITLC/SG, Gelman) plate with butan-l-one as
the solvent. Under these conditions, "mTc-pertechnetate is known to migrate with the
solvent front while radiolabeled species remain at the origin. Analysis of the "mTc-tartrate
solution demonstrated 8% of the activity at the solvent front, presumably due to the presence
of "mTc-pertechnetate. The 92% of the "mTc that remained at the origin demonstrates that
a reasonably high degree of radiolabelling was achieved. It can therefore be concluded that
"mTc-pertechnetate and "mTc-tartrate behave similarly on paper and thin-layer
chromatography but not on HPLC.
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Figure 4.2 Thin-layer chrornatograms of 99m
tartrate.
Tc-MAGr Tc-pertechnetate and "mTc-
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Figure 4.3 Paper chromatograms of Tc-MAGr Tc-pertechnetate and Tc-tartrate
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Figure 4.4 High performance liquid chromatograms of "'"Tc-MAG, "mTc-pertechnetate and
"mTc-tartrate.
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Having demonstrated their ability to separate "mTc-pertechnetate and "mTc-tartrate from
99mTc-MAG3, I decided to compare the suitability of the three techniques for determination
of the radiochemical purity of 99mTc-MAG3. Twelve preparations of 99mTc-MAG3 with
radiochemical purities of between 10% and 100% were analysed by each technique.
To achieve a wide range of radiochemical purities, two methods of obtaining 99mTc-MAG3
that contained radiochemical impurities were used. The first involved taking a sample of the
99mTc/MAG3 mixture before the kit was placed in the boiling water-bath. Without the high
temperature of the water-bath to cleave the benzoyl group from the betiatide molecule, the
exchange of "mTc from tartrate to MAG3 proceeds slowly. This mixture would be expected
to contain "mTc-tartrate and some 99mTc-MAG3 complex that had formed at room
temperature. The second technique was to add Sodium Pertechnetate [99mTc] Injection to
99mTc-MAG3 to create a "mTc-pertechnetate impurity. The results from HPLC are
compared with those from thin-layer and paper in Figures 4.5 and 4.6 respectively.
RCP (%) by HPLC
Figure 4.5 Comparison of the radiochemical purity (RCP) of 99mTc-MAG3 as measured by
HPLC and thin-layer chromatography (TLC).
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RCP (%) by HPLC
Figure 4.6 Comparison of the radiochemical purity (RCP) of "mTc-MAG, as measured by
HPLC and paper chromatography (PC).
Thin-layer and paper chromatography gave consistently higher results than HPLC. This
might be explained by some of the 99mTc-MAG3 complex being retained on the HPLC
column while all the impurities in the radiopharmaceutical are completely eluted. This
would have the effect of depressing the radiochemical purity result. However, the
measurement of recovery from the column gave a result of 100.1 ±1.4% which
demonstrates that this explanation is not valid. A more likely reason for the differences is
that with the thin-layer and paper chromatography techniques one or more impurities have
the same chromatographic behaviour as "mTc-MAGv
To investigate this possibility, 99mTc-MAG3 was analysed by HPLC and the column eluate
was collected in three fractions. The first fraction was the eluate that appeared before the
99mTc-MAG3 peak (see Figure 4.9). This fraction contained the hydrophilic impurities
including "mTc-pertechnetate and "mTc-tartrate. The second fraction was the eluate that
contained the main peak of the chromatogram. This represented pure 99mTc-MAG3. The
third fraction contained the more lipophilic impurities that were eluted after the change of
mobile phase. The three fractions were then analysed by the thin-layer and paper
chromatography techniques. As a result of only 20 /xl of 99mTc-MAG3 being injected onto
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the column, the radioactive concentrations of the samples of column eluate were extremely
low. The activities that were applied to the paper and thin-layer plates were therefore
correspondingly low making scanning of the plates inappropriate. The plates were therefore
cut into 1 cm transverse sections which were then counted in an automatic gamma counter
(Model 1282 Compugamma, LKB Wallac). The chromatograms were then created from the
count-rates in the sections. The results are shown in Figures 4.7 and 4.8. With both
techniques, the impurity that is eluted after the main peak on F1PLC exhibits a similar
chromatographic behaviour to 99mTc-MAG3. On paper chromatography, one or more of the
impurities that are eluted before the main peak on HPLC exhibit a similar chromatographic
behaviour to 99mTc-MAG3. In the presence of these impurities it would therefore be
anticipated that paper and thin-layer chromatography would give higher values of
radiochemical purity than HPLC and that paper chromatography would give higher results
than thin-layer.
Comparison of the techniques across a range of radiochemical purities from 10% to 100% is
perhaps inappropriate. It is likely that any one of the techniques will adequately demonstrate
a radiochemical purity of less than 90%. Below this value, the accuracy of the result is not
critical since the poor quality of the radiopharmaceutical is obvious. It is therefore more
relevant to compare the techniques using 99mTc-MAG3 with a radiochemical purity of
between 90% and 100%. Ten preparations of 99mTc-MAG3 with radiochemical purities in
this range were therefore analysed by each of the three techniques. The mean
results ± standard deviation were: HPLC - 94.6 ± 1.2%, thin-layer chromatography -
95.7 + 1.3% and paper chromatography - 96.2 + 1.2%. As in the previous experiment,
thin-layer and paper gave higher results than HPLC. On analysis with a paired t-test, the
differences were significant (P<0.05). Although statistical significance was found, the
three results are reasonably similar. However, this similarity would not exist in the
presence of higher levels of impurity. From the previous experiment it was concluded that
the impurity which elutes after the main peak on HPLC is primarily responsible for the
difference in results. The results are reasonably similar because this impurity is small
(approximately 2%). In the presence of a higher concentration of the impurity HPLC would
measure a much lower radiochemical purity than paper or thin-layer.
Of the three techniques, HPLC demonstrates the presence of the greatest number of
impurities, gives a main peak that is well separated from the other peaks in the
chromatogram and gives 100% recovery from the column. I therefore concluded that HPLC
is a satisfactory technique for determination of the radiochemical purity of 99mTc-MAG3-
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Figure 4.7 Thin-layer chromatograms of eluate fractions from HPLC analysis.
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Figure 4.8 Paper chromatograms of eluate fractions from HPLC analysis.
49
4. Radiochemical Purity of 99mTc-MAG3 Injection
The next stage of my investigation was to use the HPLC technique to study the
radiochemical purity of 99mTc-MAG3 prepared under a variety of conditions that might arise
in routine radiopharmacy practice.
4.2 Radiochemical purity and stability of 99mTc-MAG3 prepared at 400 MBq/4 ml
When the MAG3 kit was first introduced, Mallinckrodt recommended that the 99mTc-MAG3
should be administered to the patient within one hour of preparation. The reason given for
this short expiry was the potential for the formation of radiochemical impurities in the "mTc-
MAG3 with time. A one hour expiry was recognised as a severe drawback to the routine use
of this radiopharmaceutical since nuclear medicine departments can be more than one hour's
travelling time from the radiopharmacy. Even within an institution, an expiry time of one
hour creates logistical problems on the use of a product and these may be sufficiently
restrictive to preclude the routine use of the product. The next part of this work was
therefore undertaken to investigate the validity of the one hour expiry time. Preparation of
the 99mTc-MAG3 was performed strictly according to the instructions supplied by the
manufacturer of the MAG3 kit. In view of this strict adherence to the manufacturer's
instructions, I assumed that the quality of the resulting 99mTc-MAG3 would represent the
standard against which the results of any subsequent modifications to the preparative
procedure could be judged.
4.2.1 Preparation of 99mTc-MAG3
The "mTc generator was eluted to give an eluate with a radioactive concentration of
>400 MBq/ml. A volume of the resulting Sodium Pertechnetate [99mTc] Injection
containing 400 MBq was diluted to 4 ml with Sodium Chloride Injection B.P. This solution
was injected into a MAG3 kit. The vial was heated, cooled and stored as described earlier.
Five kits from each of three lots of MAG3 kits were reconstituted according to this
technique. The radiochemical purity of the 99mTc-MAG3 in each vial was measured
immediately after preparation, one hour after preparation, i.e. at the expiry time
recommended by Mallinckrodt, and six hours after preparation, i.e. at a more typical expiry
time for a "mTc radiopharmaceutical.
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4.2.2 Measurement of radiochemical purity
The radiochemical purity of the "mTc-MAG3 was measured by HPLC using the technique
evaluated in the previous work. The Perkin-Elmer pump fitted with the Rheodyne 7120
injection valve and the MS310-based radiation detector with the detection cell in
configuration C (Figure 2.1) were used for these analyses. As the Perkin-Elmer pump was
capable of only isocratic elution, the column was eluted at 1 ml/minute with the
ethanol/0.01 M phosphate buffer pH6 (5:95) mobile phase for 10 minutes then the
methanol/water (90:10) mobile phase for 10 minutes. The recovery from the column was
measured according to the method described in Chapter 3.4. The technique described in
Chapter 3.5 was used to calculate the counts in each peak as a percentage of the total counts
in the chromatogram.
To demonstrate the presence of impurities, an expanded version of the chromatogram is
shown in Figure 4.9. The chromatogram reveals the existence of four hydrophilic impurities
(1-4) that elute before the main "mTc-MAG3 peak (5) and one or more lipophilic impurities
that elute in a peak (6) after the change of mobile phase. Peak 3 was shown to have the
same retention time as "mTc-pertechnetate.
600
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Figure 4.9 High performance liquid chromatogram of99mTc-MAG3. %
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Table 4.1 contains the results of the stability study performed on the three lots of MAG3
kits. Of the impurity peaks, the only one which changes over the 6 hours is peak 4 which
approximately doubles in each case. When analysed using a paired Student's t-test, this
change was found to be significant (p<0.05). While this increase is statistically significant,
it is improbable that such a small change could be clinically significant. The increase in
peak 4 is accompanied by a corresponding decrease in the percentage of total activity in the
main 99mTc-MAG3 peak (5). The other impurity peaks remain constant throughout the 6
hours. The recoveries from the column are also included in Table 4.1. The typical
recovery of approximately 100% demonstrates that no radiolabelled species were retained in
the column and thereby eluded detection.
Contrary to the recommended expiry time of one hour, this study has shown that "mTc-
MAG3 prepared according to the manufacturer's instructions appears to be stable for at least
6 hours. Coveney and Robbins (1987) have also demonstrated this longer stability although
their work was performed on the MAG3 kits supplied to the North American market. These
kits contain 1 mg betiatide, 40 mg sodium tartrate dihydrate, 20 mg lactose monohydrate and
200 jag stannous chloride dihydrate. This is a different formula to the kits available in
Europe and the higher concentration of stannous ion could be responsible for enhanced
stability. My unsuccessful attempts (unpublished data) to reproduce the cold fractionation
technique of Thorson et al. (1992) in which the North American kit was used and a similar
observation by Maltby (personal communication) tend to suggest that the American formula
results in a more stable radiopharmaceutical.
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Table 4.1 Results of the analysis of 99mTc-MAG3 prepared at 400 MBq/4 ml.
Lot no. Time after % of the recovered activity in each peak % recovery
ofMAG3 preparation from
kits (hours) 1 2 3 4 5 6 column
8056 0 0.2 0.3 0.6 0.8 95.2 2.9 100.0
+ 0.2 ± 0.1 ± 0.5 ± 0.1 ± 0.7 ± 0.8 ± 3.2
1 0.3 0.3 0.5 1.2 94.4 3.3 96.3
± 0.3 ± 0.2 ± 0.4 ± 0.1 ± 1.2 ± 0.9 ± 3.4
6 0.3 0.3 0.9 1.6 94.2 2.7 99.0
± 0.1 ± 0.1 ± 0.6 ± 0.2 ± 0.7 ± 0.7 ± 3.8
8068 0 0.2 0.3 0.6 0.5 95.9 2.5 100.1
± 0.1 ± 0.1 ± 0.4 ± 0.1 ± 0.7 ± 0.4 ± 0.9
1 0.2 0.3 0.7 0.7 95.7 2.4 100.5
± 0.1 ± 0.1 ± 0.3 ± 0.1 ± 0.6 ± 0.3 ± 0.2
6 0.2 0.3 0.9 1.1 95.2 2.3 100.4
± 0.1 ± 0.1 ± 0.4 ± 0.1 ± 0.7 ± 0.2 ± 0.1
8073 0 0.2 0.2 0.4 0.5 96.5 2.2 100.7
± 0.1 ± 0.1 ± 0.2 ± 0.1 ± 0.3 + 0.2 + 1.1
1 0.2 0.2 0.5 0.7 96.4 2.0 100.8
± 0.1 ± 0.0 ± 0.2 ± 0.1 + 0.2 ± 0.1 ± 1.7
6 0.2 0.3 0.5 1.2 96.0 1.8 100.1
± 0.1 ± 0.1 ± 0.2 ± 0.2 ± 0.4 ± 0.3 ± 4.7
Each value is the mean + standard deviation of 5 results.
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4.2.3 Clinical evaluation
Although the stability study has demonstrated satisfactory radiochemical purity of "mTc-
MAG3 up to six hours after preparation, it is possible that the HPLC technique is not
sufficiently sensitive to reveal the reason for Mallinckrodt assigning a one hour expiry to this
radiopharmaceutical. The MAG3 package insert contains the statement "Small amounts (1-
2%) of "mTc-labelled impurities will be formed during the labelling process. As these
impurities are accumulated in the liver and gall bladder they may influence the late phase
(after 30 minutes) of a dynamic renal study". The lipophilic impurities are the most likely to
undergo hepatobiliary uptake and as Mallinckrodt suggest, these have been detected in the
radiopharmaceutical and constitute a few percent of the total activity (peak 6). However, the
proportion in this peak did not change over a period of six hours. The following clinical
study to measure uptake of "mTc into the liver and gall bladder was therefore undertaken as
a means of confirming the stability of 99mTc-MAG3.
Twenty patients attending for routine diuretic renography were investigated. Each patient
was injected intravenously with 100 MBq of 99mTc-MAG3. Ten of the patients were injected
within 1 hour of preparation of the 99mTc-MAG3 while the other ten were injected between 5
and 6 hours after preparation. The routine diagnostic imaging study was performed, taking
30 minutes. The gamma-camera (Digicamera, Scintronix) was then positioned to acquire
anterior and right lateral static images of the abdomen. The images were recorded in the
gamma-camera system's computer (Model MCS560, Technicare) to assess activity in the
liver and gall bladder. Typical images are shown in Figures 4.10 and 4.11.
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Figure 4.10 Anterior gamma-camera image (top) and diagrammatic illustration (bottom) of
residual "mTc in the abdomen 30 minutes after the administration of99mTc-MAGy
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Figure 4.11 Right lateral gamma-camera image (top) and diagrammatic illustration (bottom)
of residual "mTc in the abdomen 30 minutes after the administration of"mTc-MAGr
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From the anterior image, the depth of the gall bladder in the right lateral projection was
measured. On the right lateral image, four regions of interest (ROI) were created around a
background area, the gall bladder, the parts of the liver that did not overlap gall bladder or
residual renal activity and the whole liver. The counts and number of pixels in each of the
first three ROIs, and the number of pixels in the whole liver ROI were obtained. The counts
in the gall bladder and liver ROIs were corrected for background. The activity in the gall
bladder was then calculated by comparing the counts in the gall bladder ROI to the counts
from a "mTc source of known activity positioned at a distance from the face of the gamma-
camera equal to the depth of the gall bladder. Knowing the activity of 99mTc-MAG3 that had
been injected into the patient, the percentage of injected "mTc in the gall bladder at the end
of the study was calculated. The percentage of injected "mTc in the liver was measured in
the same way except that to estimate the counts in the whole liver, it was necessary to
multiply the counts in the part liver ROI by the ratio of the pixels in the whole liver ROI to
the part liver ROI.
To ensure that the results of this study were not influenced by disparities in the renal
function of the patients in the two groups, a venous blood sample was taken from each
patient for measurement of plasma creatinine. Urine was collected from six patients and
analysed by HPLC to determine the form in which the "mTc is excreted.
Table 4.2 contains the incidence of visualization of the gall bladder and the percentages of
administered activity in gall bladder and liver 30 minutes after administration of "mTc-
MAG3. When analysed using Wilcoxon's nonparametric test for unpaired comparison, gall
bladder activity, liver activity and plasma creatinine in the < 1 hour group were not found to
differ significantly from those in the 5-6 hour group (p>0.05). Only one patient in each
group had abnormal renal function as indicated by a plasma creatinine level of greater than
150 ^mol/litre. It is unlikely, therefore, that the comparison was influenced by disparities in
renal function between the two groups.
Table 4.3 contains the HPLC profile of the "mTc in the urine of six patients along with the
profile of a typical preparation of 99mTc-MAG3 for comparison. The similarity of the two
profiles suggests that the 99mTc-MAG3 is excreted unchanged. The results also demonstrate
that all the impurities in 99mTc-MAG3 are excreted by the kidneys. However, the
concentrations of impurities are lower in the urine than in the original injection showing that
they are excreted less efficiently the 99mTc-MAG3.
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Table 4.2 Results of the clinical study performed with 99mTc-MAG3 prepared at
400 MBq/4 ml.
Time between preparation and
injection
< 1 hour 5-6 hours
No. of images showing gall bladder 5 5
% of injected "mTc in gall bladder median 0.1 0.1
(range) (0.0-0.3) (0.0-0.5)
% of injected "mTc in liver median 4.8 4.4
(range) (3.1 - 12.9) (2.0 - 8.9)
Plasma creatinine (/imol/1) median 90 106
(range) (66 - 529) (79 - 230)
No. of patients with plasma creatinine > 150 /xmol/I 1 1
Table 4.3 Results of the chromatographic analysis of urine compared to a typical preparation
of Tc99m-MAG3
% of the recovered activity in each peak % recovery
from
Sample 12 3 4 5 6 column
Urine (n = 6) 0.1 0.2 0.3 0.4 97.8 1.3 101.0
±0.1 ±0.0 ±0.2 ±0.1 ± 0.6 ± 0.3 ± 2.0
Lot 8068 at 1 hour 0.2 0.3 0.7 0.7 95.7 2.4 100.5
±0.1 ±0.1 ±0.3 ±0.1 ± 0.6 ± 0.3 ± 0.2
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The results of this clinical study confirm the findings of the HPLC analysis in that the
radiochemical purity of 99mTc-MAG3 is stable over a period of six hours.
4.3 Radiochemical purity and stability of 99mTc-MAG3 prepared at 1 GBq/4 ml
During the clinical study described in 4.2.3 it became apparent that less than 100 MBq of
99mTc-MAG3 would be sufficient for the performance of a satisfactory study. In this next
phase of my work, I decided to prepare the 99mTc-MAG3 in such a way as to accommodate
an administered activity of 50 MBq. Also, 99mTc-MAG3 prepared at a radioactive
concentration of 400 MBq/4 ml does not lend itself to routine practice in radiopharmacy
where it is necessary, in the interests of economy, to obtain several patient doses from each
MAG3 kit. To facilitate an administered activity of 50 MBq per patient, I therefore decided
that it would be appropriate to prepare single dose vials containing 175 MBq/2.5 ml. This
activity would allow studies to be performed up to 6 hours after preparation of the "mTc-
mag3.
4.3.1 Preparation of 99mTc-MAG3
99mTc-MAG3 was prepared in an identical manner to that described in 4.2.1 except that the
"mTc generator was eluted in a volume that gave Sodium Pertechnetate [99mTc] Injection
with a radioactive concentration of > 1 GBq/ml. The kit was reconstituted with 1 GBq of
this Sodium Pertechnetate [99mTc] Injection that had been diluted to 4 ml. This is the
maximum activity recommended by Mallinckrodt for reconstitution of the MAG3 kit. After
the 10 minute cooling stage in the beaker of water at room temperature, individual patient
doses were dispensed by withdrawing a 0.7 ml aliquot from the kit, diluting it to 2.5 ml with
Sodium Chloride Injection and injecting the solution into a sterile 10 ml vial containing a
nitrogen atmosphere (Product Code N46, Amersham). The vial was then stored at room
temperature. 99mTc-MAG3 from five kits was prepared according to this technique. As
before, radiochemical purity was measured by HPLC at 0, 1 and 6 hours after preparation.
4.3.2 Measurement of radiochemical purity
Analysis by HPLC was carried out as described earlier except that the radiation detector was
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used in configuration B to accommodate the higher radioactive concentration of the samples.
Table 4.4 contains the results. These are similar to the results obtained with the "gold
standard" 99mTc-MAG3 prepared at 400 MBq/4 ml. Two aspects of the results do however
differ. Peak 3, which has the same retention time as 99mTc-pertechnetate, contains a higher
percentage of the total activity in the more dilute preparation. This could be caused by the
greater demand placed on the labelling reaction by more Tc being used. Alternatively, the
introduction of oxygen that would inevitably be present in the Sodium Chloride Injection
used to dilute the labelled product, could induce oxidation of the 99mTc-MAG3 and result in
the release of 99mTc-pertechnetate. The second difference is that peak 4 does not double
over the six hours of the study. This suggests that dilution has a stabilizing effect on 99mTc-
MAG3. However, the magnitude of these effects is so small that they are unlikely to
influence the clinical efficacy of the radiopharmaceutical. As before, the radiochemical
purity of the 99mTc-MAG3 was greater than 95% and the recoveries from the HPLC column
were satisfactorily high.
Table 4.4 Results of the chromatographic analysis of Tc99m-MAG3 prepared at 1 GBq/4 ml
followed by subdivision and dilution.
Lot no. Time after % of the recovered activity in each peak % recovery
ofMAGs preparation from
kits (hours) 1 2 3 4 5 6 column
8073 0 0.1 0.3 0.8 0.4 96.1 2.3
+ 0.1 +0.1 +0.2 +0.1 +0.3 +0.2
97.8
± 1.5
1 0.2 0.3 0.9 0.5 96.0 2.2
+ 0.1 ±0.1 ±0.4 ±0.1 ±0.4 ±0.3
97.9
± 2.2
6 0.1 0.3 1.1 0.4 95.7 2.4 98.0
+ 0.1 +0.1 +0.2 ±0.1 +0.3 +0.1 +2.6
Each value is the mean + standard deviation of 5 results.
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4.3.3 Clinical evaluation
The in-vivo behaviour of the 99mTc-MAG3 was evaluated as before in a second group of 20
patients. Table 4.5 contains the results which are in agreement with the results from the
first study.
Table 4.5 Results of the clinical study performed with 99mTc-MAG3 prepared at 1 GBq/4 ml
followed by subdivision and dilution.
Time between preparation and
injection
< 1 hour 5-6 hours
No. of images showing gall bladder 3 4
% of injected "mTc in gall bladder median 0.0 0.0
(range) (0.0-0.1) (0.0-0.4)
% of injected "mTc in liver median 4.7 4.0
(range) (1.4-12.3) (2.3-12.4)
Plasma creatinine (/imol/1) median 97 95
(range) (63 - 290) (63 - 324)
No. of patients with plasma creatinine > 150 /xmol/1 2 2
From these results I concluded that 99mTc-MAG3 is stable for six hours when prepared
according to the methods used in this investigation. Arising from this work, 99mTc-MAG3
prepared in this department is now given an expiry time of six hours after preparation.
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4.4 Effect of other factors on radiochemical purity and stability
The 99mTc-MAG3 injections used so far in this investigation have been prepared using
techniques that do not differ markedly from that recommended by Mallinckrodt. However,
while the manufacturer's instructions specify a number of conditions for the labelling
procedure, they do not cover all variables that might affect the quality of the labelled
product. The remainder of this work was therefore undertaken to determine the effect of
various parameters on the quality of 99mTc-MAG3 and to identify the optimal preparative
conditions for high radiochemical purity and stability.
4.4.1 Volume of "mTc generator eluate
The Mallinckrodt instructions specify that the MAG3 kit should be reconstituted with 4 ml
Sodium Pertechnetate [99mTc] Injection, less than 1.0 ml of which is "mTc generator eluate.
It could be assumed, therefore, that if more than 1.0 ml of generator eluate is used, a
product of inferior quality is produced. Conversely, it might be that the smaller the volume
of generator eluate used, the superior the product obtained. To test this hypothesis, "mTc-
MAG3 was prepared using the volumes of eluate at either end of the recommended range,
i.e. 0.1 and 1.0 ml, to determine if using the lower volume would be a means of obtaining a
product with a higher radiochemical purity.
With increasing clinical experience of 99mTc-MAG3, the activities of 100 and 50 MBq that
had been administered in the clinical studies were found to be higher than were necessary to
perform satisfactory investigations. Therefore, while the 1 GBq used to reconstitute the kit
in 4.3 would provide more than enough 99mTc-MAG3 to meet any demands placed on the
radiopharmacy service, it would undoubtedly result in the unnecessary handling of "mTc and
the associated increase in exposure of the radiopharmacy staff to radiation. The use of a
lower activity would have the benefit of reducing the radiation dose to staff and patients.
For this series of experiments, I therefore decided to prepare the 99mTc-MAG3 at a
radioactive concentration of 500 MBq/4 ml. Preparation was carried out as described in
4.2.1. As before, the final product was stored at room temperature. Radiochemical purity
was measured by HPLC immediately after preparation and 6 hours later. I decided to omit
the measurement at 1 hour after preparation since it had not revealed any short-term
instability.
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The results are contained in Table 4.6 and show that the volume of eluate had no effect on
the radiochemical purity. As observed previously the content of peak 4 approximately
doubled over the six hours of the study.
Table 4.6 Results of the chromatographic analysis of Tc99m-MAG3 prepared at
500 MBq/4 ml using 0.1 ml and 1.0 ml of generator eluate.
Conditions Time after %
for preparation —
preparation (hours) 1
of the recovered activity in each peak % recovery
from
column
0.1 ml eluate 0 0.2 0.1 0.3 0.6 96.4 2.4 99.0
± 0.2 ± 0.1 ± 0.1 ± 0.1 ± 0.4 ± 0.5 ± 2.3
6 0.2 0.2 0.4 1.3 96.2 1.8 99.6
± 0.1 ± 0.1 ± 0.2 ± 0.3 ± 0.2 ± 0.2 ± 2.3
1.0 ml eluate 0 0.1 0.1 0.2 0.6 96.7 2.3 101.5
± oo ± 0.1 ± 0.1 ± 0.1 + 0.3 ± 0.2 ± 1.2
6 0.1 0.1 0.5 1.2 96.2 1.9 101.5
+ oo ± oo ± 0.2 ± 0.2 ± 0.2 + 0.1 ± 1.8
Each value is the mean + standard deviation of 5 results.
4.4.2 Dilution, aeration and agitation
In radiopharmacies that supply a number of nuclear medicine departments, a policy of
preparing individual patient doses of radiopharmaceuticals is often adopted. Subdividing kits
of "mTc radiopharmaceuticals after preparation is therefore a common practice. This
process of subdivision can be accompanied by dilution during which air can inadvertently be
introduced into the vial. In certain situations, the individual patient doses can be transported
some considerable distance to the nuclear medicine department. During transport, the
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radiopharmaceuticals are invariably subjected to agitation. The effect of dilution, aeration
and agitation of 99mTc-MAG3 was therefore studied in this experiment.
99mTc-MAG3 was prepared as in 4.4.1 using "mTc generator eluate with a radioactive
concentration of 500 MBq/<1.0 ml. A 0.7 ml aliquot of the labelled product was then
transferred to a 10 ml nitrogen-filled sterile vial (Product Code N46, Amersham) and diluted
to 2.5 ml with Sodium Chloride Injection. Air (10 ml) was bubbled through the solution and
then the vial was placed on a rotating axle mixer (Spiramix 5, Denley) for 6 hours. The
radiochemical purity of the 99mTc-MAG3 was measured by HPLC immediately after
preparation and 6 hours later.
The results are contained in Table 4.7 and show that dilution, aeration and agitation have
little effect on radiochemical purity. As was observed in 4.3, dilution results in a slightly
but not unacceptably higher level of "mTc-pertechnetate impurity. As was also observed in
4.3, dilution appears to eliminate the doubling of peak 4 over a six hour period.
Table 4.7 Results of the chromatographic analysis of Tc99m-MAG3 prepared at
500 MBq/4 ml using <1.0 ml of generator eluate followed by dilution, aeration and
agitation.
Time after % of the recovered activity in each peak % recovery
preparation from
(hours) 1 2 3 4 5 6 column
0 0.2 0.3 0.8 0.4 95.9 2.4
±0.1 ±0.1 ±0.5 ±0.1 ±0.7 ±0.3
101.0
± 2.9
6 0.1 0.3 1.0 0.5 95.8 2.3
±0.1 ±0.1 ±0.5 ±0.2 ±0.9 ±0.3
100.6
± 2.4
Each value is the mean ± standard deviation of 5 results.
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4.4.3 Reconstitution volume
At this point in my study, Mallinckrodt Medical issued new recommendations for the
preparation of 99mTc-MAG3. The total volume of Sodium Pertechnetate [99mTc] Injection to
be added to the kit was increased from 4 ml to 10 ml, up to 3 ml of which could be
generator eluate. Under these revised conditions, the recommended shelf-life of the labelled
product was increased from 1 to 4 hours. The effect of this revised procedure was therefore
investigated by preparing 99mTc-MAG3 at an activity of 500 MBq as before but at a volume
of 10 ml. As in the previous experiments a generator eluate volume of < 1.0 ml was used
since the radioactive concentration of the eluates available routinely was >500 MBq/ml.
Radiochemical purity was measured as before. The results are contained in Table 4.8 and
are similar to those obtained previously.
Table 4.8 Results of the chromatographic analysis of Tc99m-MAG3 prepared at
500 MBq/10 ml.
Time after % of the recovered activity in each peak % recovery
preparation from
(hours) 1 2 3 4 5 6 column
0 0.1 0.1 0.1 0.5 96.4 2.8 99.0
±0.1 ±0.0 ±0.0 ±0.1 ±0.5 ±0.4 ± 3.0
6 0.1 0.1 0.3 0.9 96.2 2.5
± 0.0 ± 0.1 ± 0.0 ± 0.1 ± 0.5 ± 0.2
99.9
± 3.1
Each value is the mean ± standard deviation of 5 results.
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4.4.4 Aeration before boiling
In an earlier experiment (4.4.2), the effect of bubbling air through the labelled product was
investigated. I therefore decided also to study the effect of introducing air before the boiling
step of the labelling procedure since it is conceivable that this could occur during the routine
preparation of 99mTc-MAG3. The 99mTc-MAG3 was prepared as in the previous experiment
but 10 ml of air was bubbled through the solution before the vial was placed in the boiling
water bath. Radiochemical purity was measured as before. The results are contained in
Table 4.9 and are similar to those obtained previously. The introduction of air before the
labelling reaction is initiated does not therefore affect radiochemical purity.
Table 4.10 Results of the chromatographic analysis of Tc99m-MAG3 prepared at
500 MBq/10 ml and with air bubbled through the reaction mixture before boiling.
Time after % of the recovered activity in each peak % recovery
preparation from
(hours) 1 2 3 4 5 6 column
0 0.1 0.1 0.1 0.4 96.8 2.5 99.8
±0.0 +0.1 +0.1 +0.1 ±0.5 ±0.4 ± 3.5
6 0.0 0.1 0.2 0.9 96.3 2.5
±0.0 ±0.1 ±0.1 ±0.1 ±0.4 ±0.3
99.3
± 2.1
Each value is the mean ± standard deviation of 5 results.
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4.4.5 Concentration of "Tc in generator eluate
On certain days of the week, principally Mondays, it is not possible to avoid preparing "mTc
radiopharmaceuticals with Sodium Pertechnetate [99mTc] Injection that has been obtained
from a generator that has remained uneluted for a few days. Under these conditions, the
level of Tc99 in the eluate is high. It is theoretically possible that the use of this unusually
high concentration of Tc can be deleterious to the quality of radiopharmaceuticals. The
effect of Tc99 was therefore investigated by preparing 99mTc-MAG3 at a radioactive
concentration of 500 MBq/10 ml as before but using "mTc from the first eluate from a new
generator. From the time between the last separation of molybdenum and Tc performed by
the generator manufacturer and the time of the first elution in the radiopharmacy, it is
possible to calculate that the ratio of "Tc:"mTc in the eluate was 16 (Bauer and Pabst 1982).
Radiochemical purity was measured as before. The results are contained in Table 4.10 and
show that this excess of Tc99 does not affect radiochemical purity.
Table 4.10 Results of the chromatographic analysis of Tc99m-MAG3 prepared at
500 MBq/10 ml using a generator eluate with a "Tc/"mTc ratio of 16:1.
Time after % of the recovered activity in each peak % recovery
preparation from
(hours) 1 2 3 4 5 6 column
0 0.3 0.1 0.1 0.3 96.9 2.3
±0.1 ±0.0 ±0.1 ±0.1 ±0.1 ±0.2
100.1
± 1.3
6 0.1 0.1 0.2 0.8 96.7 2.1
±0.0 ±0.0 ±0.1 ±0.1 ±0.3 ±0.2
99.2
± 0.6
Each value is the mean ± standard deviation of 5 results.
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4.4.6 "Wet labelling"
Preparation of 99mTc-MAG3 according to the manufacturer's revised instructions involves the
withdrawal of the required volume of Sodium Pertechnetate [Tc99m] Injection into a
syringe, dilution of the injection to 10 ml with Sodium Chloride Injection and injection of
the solution into the MAG3 kit. This is a time-consuming process which exposes the fingers
of the member of staff carrying out the procedure to radiation. I therefore decided to
investigate the following means of minimizing the handling of the "raTc. This procedure is
a modification of the "wet labelling" technique that has been in use in this department for
many years (Millar et al. 1981) and involves reconstitution of the kit with Sodium Chloride
Injection before addition of the "mTc.
The MAG3 kit was first reconstituted with 9.0-9.9 ml of Sodium Chloride Injection.
Sodium Pertechnetate [99mTc] Injection (500 MBq/<1.0 ml) was then injected into the vial
to give a total volume of 10 ml. Heating, cooling and analysis of radiochemical purity were
performed as before. The results are contained in Table 4.11 and show that this procedure
gives 99mTc-MAG3 of comparable radiochemical purity and stability to that prepared by the
recommended technique. When using this modified technique, the small volume of
generator eluate can be transferred quickly to the MAG3 kit thus minimizing handling time
and exposure of the fingers to radiation.
Table 4.11 Results of the chromatographic analysis of Tc99m-MAG3 prepared at





% of the recovered activity in each peak % recovery
from
column1 2 3 4 5 6
0 0.1 0.1 0.1 0.3 97.3 2.1 98.6
± 0.0 ± 0.0 ± 0.0 ± 0.0 ± 0.1 ± 0.1 3.3
6 0.0 0.0 0.2 0.8 96.8 2.1 101.9
± 0.0 ± 0.1 ± 0.1 ± 0.1 ± 0.2 + 0.1 ± 1.5
Each value is the mean ± standard deviation of 5 results.
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By this stage of the study, clinical experience had shown that satisfactory clinical
investigations could be performed with 10-20 MBq of 99mTc-MAG3. The following
experiments were therefore performed to investigate the feasibility of dispensing ten 50 MBq
doses from each MAG3 kit. 99mTc-MAG3 was prepared as in the previous experiment. A
1.0 ml aliquot of the 99mTc-MAG3 solution and 1.5 ml of Sodium Chloride Injection were
injected into a sterile, nitrogen-filled, 10 ml vial. The radiochemical purities of the
undiluted and diluted 99mTc-MAG3 were measured by HPLC as before. This procedure was
carried out five times, a kit from a different batch of MAG3 being used on each occasion.
The results are contained in Table 4.12 and show that this technique provides 99mTc-MAG3
of satisfactorily high radiochemical purity and stability. As has been observed in previous
experiments, the diluted 99mTc-MAG3 does not exhibit the doubling of peak 4 that is seen
with the undiluted product. This again suggests that dilution confers stability on "mTc-
MAG3 in solution.
Table 4.12 Results of the comparison of undiluted and diluted 99mTc-MAG3.
Conditions Time after % of the recovered activity in each peak % recovery
for preparation from
preparation (hours) 1 2 3 4 5 6 column
Undiluted 0 0.1 0.1 0.1 0.3 97.5 1.9
+ 0.1 +0.1 +0.1 +0.1 +0.3 ±0.2 + 2.2
96.8
6 0.1 0.1 0.2 0.8 97.1 1.7
+ 0.1 +0.1 +0.1 +0.1 +0.5 +0.4
98.0
± 1.2
Diluted 0 0.1 0.2 0.1 0.3 97.5 1.8
+ 0.0 +0.1 +0.0 +0.1 +0.4 +0.4
98.4
+ 1.7
6 0.1 0.2 0.2 0.3 97.1 21.
+ 0.0 +0.1 ±0.1 ±0.2 ±0.4 ±0.3
100.4
± 1.3
Each value is the mean ± standard deviation of 5 results.
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4.5 Summary
In the work described in this chapter I have:
1. developed an HPLC technique for determining the radiochemical purity of
99mTc-MAG3
2. demonstrated that the HPLC technique is superior to thin-layer and paper
chromatographic techniques for measuring the radiochemical purity of
99mTc-MAG3
3. demonstrated that the recovery of 99mTc-MAG3 from the HPLC column is
consistently in the order of 100%
4. used the HPLC technique to demonstrate that 99mTc-MAG3, prepared under
the conditions described, is stable for six hours rather than the 1 hour
quoted by the manufacturer, and confirmed this finding with clinical studies
in patients
5. used HPLC to demonstrate that the radiochemical purity and stability of
99mTc-MAG3 is not influenced by the volume of "mTc generator eluate used,
dilution, agitation, the presence of air in the reaction vial or the use of a
"mTc generator eluate with a "Tc:"mTc ratio of 16:1
6. developed a modified method of preparing 99mTc-MAG3 which should help
to minimize the radiation dose to the fingers of members of the
radiopharmacy staff
From these findings, it can be concluded that the HPLC technique is a satisfactory means
measuring the radiochemical purity of "mTc-MAG3.
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The work described in this chapter was undertaken to develop an HPLC method for
determining the radiochemical purity of "mTc-Dimercaptosuccinic Acid Injection and then
to use the HPLC technique in an investigation of the effects of factors that influence the
preparation of this radiopharmaceutical in routine practice.
5.1 Introduction
Technetium-99m Dimercaptosuccinic Acid Injection (99mTc-DMSA) was introduced by Lin
et al. (1974) as a radiopharmaceutical for imaging of the kidneys. Since then, kits for the
preparation of this commonly used radiopharmaceutical have been marketed by several
manufacturers.
Following intravenous injection, "mTc-DMSA is taken up and fixed by the proximal
tubules of the kidneys. Six hours after intravenous administration to a patient with normal
kidneys, 20 - 35% of the injected "mTc has become localised in each kidney and 10 - 15%
has been excreted in the urine. Subsequent imaging with a gamma-camera provides good
definition of the cortical outline with diseased tissue appearing on the image as areas of
reduced or no activity. Kidney imaging with "mTc-DMSA is a commonly performed
investigation for the detection of conditions such as calculi, tumours, cysts, abscesses and
scarring.
The uptake of the radiopharmaceutical is dependent on the presence of viable kidney tissue,
therefore, in addition to providing images which demonstrate purely morphological detail,
the uptake of "mTc-DMSA can be used as an indicator of kidney function. Measurement
of the relative uptake of "mTc-DMSA into each kidney is a procedure that is used routinely
to determine relative kidney function. The results obtained with this technique are not
influenced by the absolute uptake of the "mTc-DMSA, i.e. the activity of "mTc in each
kidney expressed as a percentage of injected activity, since both kidneys are affected
equally by any factors, such as radiochemical purity, that might influence uptake. It has
been suggested, however, that the absolute uptake of "mTc-DMSA by a kidney can be used
as a measure of absolute function. In this situation, the radiochemical purity of the "mTc-
DMSA will influence the result of the investigation. If "mTc-DMSA with significant levels
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of radiochemical impurities is used, less "raTc will be present in the form that is
concentrated by the kidneys and low uptake will be observed. A high radiochemical purity
is therefore necessary if "mTc-DMSA is to be used in this way.
Moretti et al. (1982) and Saccavini (personal communication) have reported that when
sodium pertechnetate [99mTc] containing a high concentration of "Tc is used to prepare
"mTc-DMSA, a radiopharmaceutical of low radiochemical purity is produced. In the
course of their work, HPLC was used for analysis of the "mTc-DMSA but the recovery
from the column was not reported. The validity of the technique is therefore open to
question and the results must be treated with caution. The study demonstrated that when
"mTc-DMSA is prepared at a DMSA/Tc ratio of 104, a single radiolabeled species is
formed and the radiopharmaceutical is concentrated by the kidney. However, when the
"mTc-DMSA is prepared at a DMSA/Tc ratio of 102, several radiolabeled species are
formed and the radiopharmaceutical is concentrated less avidly by the kidneys. The
possibility of varying amounts of Tc being used arises from the length of time for which
the "mTc generator has remained uneluted before being used to provide "mTc for the
preparation of the "mTc-DMSA. The following calculations illustrate this situation.
The Amersham International kit for the preparation of "mTc-DMSA contains 1 mg of
DMSA. The molecular weight of DMSA is 182.22. The kit therefore contains 5.5 x 10"6
moles of DMSA. Applying Avogadro's number, this represents 3.3 x 1018 molecules of
DMSA.
Amersham International recommend that the DMSA kit is reconstituted with a maximum of
1.48 GBq of "mTc. Using equation 5.1, the number of atoms of "mTc in 1.48 GBq is
found to be 4.6 x 1013.
t A
N = — (Eq 5.1)
0.693
where N = number of atoms in the source
t:/ = the half-life of the radionuclide expressed in seconds
A = the activity of the source expressed in Bq
Assuming that the 1.48 GBq of "mTc is obtained from a generator, the previous elution of
which was 24 hours earlier, equation 5.2 (Bauer & Pabst, 1982) can be used to calculate
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that the ratio of "Tc to "mTc in the eluate is 2.6.
99 Tc
= kT ~ kM 1 - e
99Tc w kM e~kt,t -kMt e





T decay constant cf "mTc
decay constant of 99Mo
time lapse
the probability of 99Mo decaying to "mTc
The number of atoms of 99Tc present in the 1.48 GBq of 99mTc is therefore 1.2 x 1014. The
total number of atoms of Tc used to reconstitute the DMSA kit is therefore 1.7 x 1014. The
DMSA/Tc ratio in the kit is therefore 1.9 x 104 which is higher than the ratio found to be
satisfactory by Moretti et al. (1982).
If the "mTc generator remains uneluted for a five day period such as a bank holiday
weekend or the interval between manufacture and first elution in the radiopharmacy, the
99Tc/"mTc ratio in the eluate is 27.8. The number of atoms of Tc in 1.48 GBq of "mTc is
therefore 1.3 x 1015 giving a DMSA/Tc ratio of 2.5 x 103. After a five day period, the
ratio does not fall to the level that was found to be unsatisfactory by Moretti et al. (1982).
To achieve the DMSA/Tc ratio of 102 that was found unsatisfactory by Moretti et al.
(1982), the generator must remain uneluted for 17 days. This situation is inconceivable in
routine radiopharmacy practice. A 50 GBq generator, which is a higher activity generator
than is found in many radiopharmacies, would yield only 700 MBq after 17 days. This is a
lower activity than is required in all but the smallest of radiopharmacies. It is also less than
half of the maximum activity that Amersham recommend for reconstitution of their DMSA
kit. A DMSA/Tc ratio of 102 is therefore of little practical interest.
The work described in this chapter was therefore carried out to:
1. determine the validity of the HPLC technique of Moretti et al. (1982)
2. develop and validate an HPLC technique for measuring the radiochemical
purity of "mTc-DMSA
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3. use HPLC to determine if the radiochemical purity of "mTc-DMSA is
affected by the levels of "Tc that may be present in Sodium Pertechnetate
[99mTc] Injection in routine practice
4. use HPLC to determine if the technique of "wet labelling" influences the
radiochemical purity of 99mTc-DMSA
5.2 Analysis of "mTc-DMSA on Hypersil-ODS
The purpose of the first part of this investigation was to reproduce the work of Moretti et
al. (1982). The equipment used was the Philips PU4100 pump, the radiation detector in
configuration A (Figure 2.1), the Accuspec system and a 100 x 5 mm Hypersil-ODS
column. The chromatographic conditions were a linear gradient elution of the column at a
flow-rate of 1 ml/minute. The column was equilibrated with 10 mM phosphate buffer pH3
for at least 30 minutes. Immediately after injection of the sample of 99mTc-DMSA, the
elution gradient was started. This changed the mobile phase from 100% 10 mM phosphate
buffer pH3 to 100% 10 mM phosphate buffer pH6 over 10 minutes.
The 99mTc-DMSA was prepared by reconstituting a DMSA kit (Product Code N107,
Amersham). This kit contains 1.00 mg DMSA, 0.42 mg stannous chloride dihydrate,
0.70 mg ascorbic acid, 2.90 mg sodium chloride and 50.00 mg inositol as a freeze-dried
powder in a rubber-capped vial with a nitrogen atmosphere. Reconstitution was carried out
with Sodium Pertechnetate [99mTc] Injection (1.5 GBq/2 ml). This is the maximum activity
recommended by Amersham for reconstitution of this kit. The previous elution of the
generator from which the Sodium Pertechnetate [99mTc] Injection was obtained had been 24
hours earlier. These conditions result in a DMSA/Tc ratio of 104. Three hours after
reconstitution of the kit, a 20 ^ 1 sample of the 99mTc-DMSA was injected onto the HPLC
column. Recovery of 99mTc from the column was measured as described in Chapter 3.4.
A chromatogram containing one peak with a retention time of 12.5 minutes was detected.
The chromatogram is shown in Figure 5.1. Recovery from the column was only 65%.
Once the chromatogram had been acquired, the column was removed from the instrument
and scanned using the equipment described in Chapter 2.10 and shown in Figure 2.6. The
profile of the 99mTc retained on the column is shown in Figure 5.2. All the unrecovered
99mTc was detected at the top of the column. To determine if the 99mTc had become
adsorbed on the stainless steel frit at the top of the column or on the packing material, the
column was placed over the gamma-counter used to determine column recoveries (Figure
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2.4). The column was positioned upside-down with its top nearest to the detector and the
count-rate was measured. The Shandon column system proved ideal for this procedure
since the top frit is exposed when the column is removed from the instrument. The
stainless steel frit was replaced and the count-rate from the column was remeasured. From
these count-rates it was calculated that only 5% of the "mTc retained at the top of the
column was associated with the frit. Most of the "mTc had therefore become bound to the
column packing. The "mTc that appeared to be adsorbed on the frit may have been
adsorbed on particles of column packing that were trapped in the pores of the frit rather
than on the stainless steel itself.
In their experiments, Moretti et al. (1982) used a 150 x 4.6 mm ultrasphere ODS column.
The particle size of the packing material is not quoted. With this column and the
chromatographic conditions described above, a single peak with a retention time of
approximately 15 minutes was detected. On the assumption that the column packings in
our respective experiments had the same particle size and retention properties, correction of
the 15 minute retention time for the smaller column size used in my experiment gives a
retention time of 11.8 minutes. Given the assumptions made, the 12.5 minute retention
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Figure 5.1 High performance liquid chromatogram of "mTc-DMSA on Hypersil-ODS using





















Figure 5.2 Profile of"mTc retained on Hypersil-ODS column.
Two explanations for the adsorption of "mTc at the top of the column can be postulated:
•the "mTc-DMSA may contain more than one radiolabeled species, one or
more of which are irreversibly bound by Hypersil-ODS under the conditions
used in this experiment
• species may have been retained at the top of the column from samples of
radiopharmaceuticals injected previously. These species may either retain a
proportion of the molecules of "mTc-DMSA applied to the column or strip
the "mTc from a proportion of the "mTc-DMSA applied to the column.
This possibility could be tested by repeating the experiment with a new
Hypersil-ODS column.
To investigate this second possibility, a new Hypersil-ODS column was packed. The first
sample to be injected onto this column was "mTc-DMSA prepared as above. A
chromatogram identical to that shown in Figure 5.1 was obtained. Recovery from the
column was 59% which is comparable to that obtained in the earlier experiment. From this
result it can be concluded that the adsorption at the top of the column is not caused by
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interference from species that have been retained from earlier samples. It is therefore
likely that the adsorption can be explained by the presence in "raTc-DMSA of more than
one species, one or more of which become adsorbed on Hypersil-ODS.
To determine the effect of a lower DMSA/Tc ratio, the experiment was repeated with
"mTc-DMSA that had been prepared by reconstituting a DMSA kit with Sodium
Pertechnetate [99mTc] Injection that had been obtained from a generator that had not been
eluted for 9 days. The eluate therefore contained "Tc and "mTc in a ratio of 98:1. Due to
the age of the generator, the radioactive concentration of the eluate was 325 MBq/ml.
Reconstituting a DMSA kit with 2 ml of this eluate therefore resulted in "raTc-DMSA
containing only 650 MBq/2 ml. Nevertheless, this gave a DMSA/Tc ratio of 103. When
this preparation of "mTc-DMSA was analysed as before, a chromatogram identical to that
shown in Figure 5.1, i.e. containing a single peak with a retention time of 12.5 minutes,
was detected. Recovery from the column was again low at 56%.
Although the poor recoveries from the columns are a major limitation on the credibility of
this work, no differences have been detected in "mTc-DMSA prepared at DMSA/Tc ratios
of 104 and 103. In routine radiopharmacy practice it is difficult to imagine circumstances
that would lead to a "mTc generator remaining uneluted for the 9 days that would be
required to result in a DMSA/Tc ratio of 103.
For many years, several "mTc radiopharmaceuticals, including "mTc-DMSA, have been
prepared in the Radiopharmacy at the Royal Infirmary of Edinburgh by a technique that has
become known as "wet labelling" (Millar et al. 1981). In this technique, the
radiopharmaceutical kit is reconstituted with Sodium Chloride Injection rather than Sodium
Pertechnetate [99mTc] Injection. For each patient dose required, an aliquot of the
reconstituted kit is dispensed into an empty sterile vial. The volume of Sodium
Pertechnetate [99mTc] Injection that contains the appropriate activity of 99mTc is then
dispensed into the vial. The labelling reaction therefore takes place in the patient dose vial
rather than in the kit. The term "wet labelling" was used to describe this technique since
the 99mTc is added to a solution rather than a freeze-dried powder. The wet labelling
technique offers a number of advantages in routine radiopharmacy practice:
• depending upon the workload in the radiopharmacy and the manner in
which 99mTc radiopharmaceuticals are prepared, it can lead to a controlled,
almost production line-like, flow of work
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• providing the kit is reconstituted in a standard volume and then a standard
volume of the solution is used for the preparation of each patient dose, wet
labelling ensures that a standard mass of radiopharmaceutical is contained in
each dose. This is good practice, particularly in the preparation of "mTc
Macroaggregated Albumin Injection when the number of particles that are
injected into the patient should be controlled and in situations where
measurement of uptake of the radiopharmaceutical is performed e.g.
measurement of the renal uptake of "mTc-DMSA
• urgently required doses of radiopharmaceuticals can be prepared when
requested without the need to use a fresh kit which involves additional
expense, or the need to prepare additional doses in anticipation of possible
requests which will subject the radiopharmacy staff to unnecessary exposure
to radiation
• the principal benefit of this technique is that the "mTc for each patient dose
is handled only once. When preparing a "mTc radiopharmaceutical by
reconstituting a kit with the total activity of "mTc that is required for all the
patient doses requested, the operator is first irradiated by the "mTc during
kit reconstitution and again while dispensing the individual patient doses
from the reconstituted kit. When using the wet labelling technique, only
one exposure to the "mTc is necessary thereby reducing the radiation dose
received by the operator
As this technique is in routine use, I decided to establish the chromatographic behaviour of
"mTc-DMSA prepared in this way. According to the procedure used routinely, a DMSA
kit was reconstituted with 10.5 ml of Sodium Chloride Injection. A 1.0 ml aliquot of the
resulting solution was transferred to a sterile nitrogen-filled 10 ml vial (Product Code N46,
Amersham). Sodium Pertechnetate [99mTc] Injection (150 MBq/1.5 ml) was then injected
into the vial. As in the first experiment, the previous elution of the generator from which
the Sodium Pertechnetate [99mTc] Injection was obtained had been 24 hours earlier. After
standing at room temperature for three hours, the "raTc-DMSA was analysed by the HPLC
technique described above. As before, a single peak with a retention time of 12.5 minutes
and a recovery of 61% was detected. Under these conditions therefore, "mTc-DMSA
prepared according to Amersham's instructions and the wet labelling procedure are
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chromatographically identical. In the Radiopharmacy, "mTc-DMSA is prepared each
morning by the wet labelling technique and extra doses can be prepared at little additional
cost. As I had been unable to show a difference between "mTc-DMSA prepared by the two
techniques, I decided to use the readily available wet labelled "mTc-DMSA in future
experiments.
In an attempt to increase the recovery from the column 50% methanol was introduced into
the mobile phases used in the previous experiments. As might be anticipated when the
organic component of the mobile phase is increased, the retention time of the peak was
reduced. A single peak with a retention time of one minute was detected. Recovery from
the column was 84%. This was higher than had been observed in the previous experiments
but was still too low to be of practical value. Also, a one minute retention time is probably
that of an unretained solute which is an unsatisfactory condition for an analytical technique.
Increasing the concentration of the phosphate buffers in the mobile phase from 10 mM to
100 mM had no effect on the chromatogram although the recovery was higher at 72%.
Although the results have not demonstrated that Tc concentration or the use of the wet
labelling technique has any effect on radiochemical purity, analysis on Hypersil-ODS has
not been found to be an ideal technique due to the significant adsorption of Tc onto the
column packing. I therefore decided to investigate other column packing materials that
might not exhibit similar adsorptive properties.
5.3 Analysis on Hypercarb
A possible explanation for the adsorption of "mTc onto Hypersil-ODS may be the presence
of uncapped silanol sites in the stationary phase. At the exceptionally low concentrations of
radiolabeled species found in radiopharmaceuticals, typically a few nanograms per ml, the
presence of these sites may assume a greater significance than during more common
analyses of mixtures when microgram quantities of analytes are present. I therefore
decided to investigate Hypercarb as an alternative stationary phase. This HPLC packing
material consists of rigid porous graphitised carbon spheres and has not previously been
used in the analysis of radiopharmaceuticals.
The potential advantages of Hypercarb are that it a) is not silica-based and is therefore free
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from unreacted silanol sites and b) is stable over the complete pH range.
Before attempting to analyse "mTc-DMSA on Hypercarb, I decided to investigate the
recovery of "mTc-pertechnetate since, if this simplest form of Tc is retained, there would
be no point in pursuing the use of this column further. A 100 x 5 mm Hypercarb column
was therefore equilibrated with a common mobile phase of methanol:water (90:10) at a
flow-rate of 1 ml/minute. The equipment described earlier in this chapter was used. A
20 /x 1 sample of Sodium Pertechnetate [99mTc] Injection (approximately 100 MBq/ml) was
injected onto the column and recovery was measured as described in Chapter 3. This
procedure was repeated four times. A chromatogram containing a single peak with a
retention time of 1.5 minutes was detected. The mean recovery from the column was
101.7 ± 0.9% (n=5). This result demonstrates that under the conditions used, there is no
interaction between Hypercarb and Tc that might interfere with the detection of "mTc-
pertechnetate impurity during analysis of "mTc radiopharmaceuticals. However, this
finding cannot be taken as being valid for all mobile phases. It will therefore be necessary
to confirm this high recovery with any other mobile phase that shows promise for the
analysis of "mTc-DMSA.
Using the methanol:water (90:10) mobile phase, "mTc-DMSA was injected onto the
column. After 20 minutes, no peaks had been recorded and no "mTc was detected in the
eluate. When the column was removed from the instrument and scanned, all the "mTc was
detected at the top.
Various mobile phases were then investigated in an effort to resolve the problem of 100%
retention on the column. Experiments were performed at least one day apart to allow
sufficient time for any "mTc retained on the column from the previous experiment to decay
to an insignificant activity. This ensured that recovery measurements would not be affected
by the elution of any "mTc adsorbed during the previous experiment.
•The effect of increasing the organic component of the mobile phase was
investigated by using acetonitrile:dioxan (90:10). These mobile phase
components were chosen since they have been found useful when used with
Hypercarb in other situations (Shandon product literature)
• The effect of a mobile phase of higher pH was investigated by using
methanol: 100 mM ammonium carbonate (90:10). The pH of 100 mM
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ammonium carbonate is 7.9.
• Methanol: 100 mM acetic acid was tried to determine the effect of reducing
pH. Amersham International quote a pH range of 2.3 - 3.3 for "mTc-
DMSA. This mobile phase therefore had the attraction of being in the pH
range of the radiopharmaceutical as 100 mM acetic acid has a pH of 2.7.
The prospect of analysing the radiopharmaceutical using a mobile phase of
similar pH is attractive since it could be envisaged that alteration of pH
during analysis could bring about an alteration in the composition of the
radiopharmaceutical especially when it is known that pH plays an
important part in the labelling reaction
• The effect of a low pH and a higher proportion of organic component was
investigated using methanol: 100 mM acetic acid:dioxan (72:8:20)
With each of these mobile phases, no peaks were detected and no "mTc was recovered
from the column. It therefore appears that Hypercarb has an exceptionally high affinity for
the radiolabeled species that are present in "mTc-DMSA. In view of this complete
adsorption onto Hypercarb regardless of the mobile phase used, I decided not to pursue this
stationary phase further.
5.4 Analysis on PLRP-S
In the course of an incomplete and unpublished investigation into the analysis of "mTc-
DMSA by HPLC, Theobald (personal communication) has reported the detection of
interesting multi-peak chromatograms when using PRP-1 (Hamilton) and PLRP-S (Polymer
Labs) columns. These columns are similar in that they are both packed with a reversed-
phase macroporous copolymer of styrene and divinylbenzene. In my quest for an HPLC
method for anaylsing "mTc-DMSA, I therefore decided to investigate the use of the PLRP-
S column.
As in my previous experiments, the first task was to carry out a preliminary assessment of
the suitability of the PLRP-S column by measuring the recovery of "mTc-pertechnetate. As
before, this was carried out using a mobile phase of methanol:water (90:10). A single peak
was detected at a retention time of 7.5 minutes and with a satisfactory recovery of
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101.0 ± 2.3% (n=5).
The mobile phase used by Theobald consisted of a citrate/phosphate/borate/HCl buffer
containing 1% methanol with most of the interesting results being obtained at pH2-3.
Hydrochloric acid is not recommended for use in HPLC mobile phases as it attacks the
stainless steel components of the instrument. I therefore considered the use of this mobile
phase inadvisable. As a more acceptable alternative I decided to achieve a low pH through
the use of an acetate buffer. The column was therefore equilibrated at 1 ml/minute with a
mobile phase of 100 mM acetate buffer pH3:acetonitrile (90:10). When "mTc-DMSA was
injected onto the column, no peaks were detected and no "mTc was detected in the eluate.
When the column was removed from the instrument and scanned, all the "mTc was
detected in the guard column and at the top of the analytical column. The profile of "mTc
in the column is shown in Figure 5.3.
Guard Top Bottom
column
Figure 5.3 Profile of""'Tc retained on PLRP-S column eluted with 100 mM acetate buffer
pH3: acetonitrile (90:10).
As an alternative means of achieving a low pH, I decided to investigate the use of citric
acid which was one of the acids present in Theobald's mobile phase. Using a mobile phase
of 100 mM citric acid (pH2.2):acetonitrile (90:10) a chromatogram containing three peaks
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was detected. The peaks had retention times of 4.9, 6.5 and 16.1 minutes and the
chromatogram is shown in Figure 5.4. Recovery was only 58% but this was the first
occasion on which I had detected a multi-peak chromatogram with "mTc-DMSA. The
column was removed from the instrument and scanned as before. A profile of activity
identical to that shown in Figure 5.3 was recorded showing that the "mTc retained in the
column was in the guard column and at the top of the analytical column. Various
alterations to the mobile phase such as increasing the proportion of acetonitrile and raising
the pH of the citric acid were introduced in attempts to improve recovery but none were
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Figure 5.4 High performance liquid chromatogram of "mTc-DMSA on PLRP-S eluted with
a mobile phase of 100 mM citric acid: acetonitrile (90:10).
I therefore decided to investigate the effect of a mobile phase with an alkaline pH. This
might be expected to bring all species off the column with the retention time of an
unretained solute since, at high pH, the carboxylic acid groups on DMSA would be
completely ionised. There would however still be the possibility of interaction between the
mercapto groups and the column packing. A mobile phase of acetonitrile: 100 mM
ammonia (70:30) was used and samples were injected onto the column at 5, 30, 60 and 90
minutes after preparation of the "mTc-DMSA. Each chromatogram contained two peaks
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with retention times of 88 and 158 seconds (see Figure 5.5) and recoveries of 107%,
114%, 111% and 115% respectively. Although the chromatograms were not of practical
value since they suggested the presence of only two species whereas the previous work had
revealed at least three, this was the first occasion on which recovery had not been
significantly less than 100%. However, recovery of consistently greater than 100% was an
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Figure 5.5 High performance liquid chromatogram of "mTc-DMSA on PLRP-S eluted with
a mobile phase ofacetonitrile: 100 mM ammonia (70:30).
5.5 Investigation of recoveries of greater then 100%
Since it is impossible for more "mTc to be eluted from the column than was applied, a
recovery measurement of greater than 100% must be the result of a technical artifact.
Several possibilities that could account for the phenomenon were examined.
The development of a fault in the 20 pi pipette used in the recovery measurement could
have led to less than 20 /d of sample being present in the standards against which the
column eluate was counted. This possibility was investigated by recalibration of the 20 /d
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calibration was not found to have changed. This did not therefore explain the measurement
of recoveries greater than 100%.
The counting standards used in the recovery measurement technique were made up in water
whereas the column eluates were 70% acetonitrile. It is possible that the gamma-rays from
"mTc are attenuated less by acetonitrile than by water. For the same activity, the count-
rate measured from an eluate would therefore be higher than that from a standard. This
would lead to the calculation of a recovery of greater than 100%. This possibility was
investigated by pipetting 20 /xl of sodium pertechnetate [99raTc] solution into each of six
vials. The contents of three vials were made up to 30 ml with water and mixed thoroughly.
The contents of the other three vials were made up to 30 ml with acetonitrile:water (70:30)
and mixed thoroughly. The count-rate from each vial was measured with the equipment
used in the recovery measurements. The mean count-rate from the vials containing
acetonitrile:water was 1.4% higher than that from the vials containing water. Although this
small difference would lead to measurement of a recovery of greater than 100%, it is not
great enough to explain the recoveries of approximately 110% that were observed. Also,
the error introduced by attenuation differences could be avoided by preparing standards in
mobile phase.
"mTc-DMSA has been shown to adsorb onto the inside surface of glass vials into which it
has been dispensed (Millar 1984). If a similar effect were occurring on the glass capillary
tube of the 20 /xl pipette that was used to prepare the standards used in the recovery
measurement technique, then the amount of "mTc transferred to the standard vials would be
less than assumed. The low count-rates detected from the standards would therefore result
in the calculation of a recovery of greater than 100%. To determine if this provides an
explanation for the high recoveries, "mTc-DMSA was drawn into the 20 jx\ pipette which
was then placed on the platform of the detector used in the recovery measurement
technique. The count-rate from the "mTc in the pipette was recorded. The contents were
then expelled and the count-rate from the empty pipette was recorded. Approximately 1%
of the original activity was found to be retained in the emptied pipette. Adsorption in the
pipette was not therefore responsible for the recovery measurements of greater than 100%.
With similar reasoning in mind, I considered that the "mTc-DMSA eluted from the column
might become adsorbed on the inside surfaces of the glass collection vial, perhaps as a
consequence of the high pH of the mobile phase. Assuming that a similar effect did not
occur with the standards which were made up in water, attenuation of the gamma-rays
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emitted from the vial of eluate would be lower than from the standard vials. This effect
would be particularly significant if adsorption was predominantly on the base of the vial
since this is the part of the vial nearest to the detector. This situation can be envisaged
since the "mTc was eluted from the column in the first few millilitres of mobile phase that
were collected and would therefore have been in intimate contact with the base of the vial.
To explore this possibility, "mTc-DMSA was injected onto the column and the eluate was
collected in the standard manner. After collection of approximately 10 ml, the vial was
removed from the instrument and the count-rate from it was measured. The solution was
then poured from the vial and the count-rate from the emptied vial was recorded and found
to be approximately 1% of that from the full vial. Residual liquid in the vial was probably
responsible for this activity but I decided not to dry the vial in case adsorbed "mTc was
wiped from the glass. However, the low residual activity was not sufficient to explain the
recoveries of greater than 100% that were measured.
Adsorption of "mTc-DMSA onto the sample loop during the loading of the valve would be
a possible explanation for recoveries of greater then 100% if the adsorbed "mTc was
subsequently removed by the mobile phase when the valve was switched to the "Inject"
position. To investigate this possibility, the radioactive concentration of a "mTc-DMSA
solution before and after it had been passed through the sample loop was measured in the
following experiment. The sample loop of the Rheodyne valve was flushed with water. A
1 ml syringe was filled with a "mTc-DMSA solution and the needle supplied for loading the
valve was fitted to the syringe. Approximately 0.5 ml of the "mTc-DMSA solution was
transferred to a weighed sample tube. With the valve in the "Load" position, the remaining
0.5 ml was passed through the sample loop and collected in a second weighed sample tube.
Both tubes were reweighed and the weight of solution in each was calculated. The count-
rate from each tube was measured by the technique used for recovery measurements. The
count-rate per gram of liquid in each vial was then calculated. This experiment was carried
out three times. On each occasion, the liquid that had not been passed through the loop had
a higher radioactive concentration than the liquid that had. In the three experiments, the
mean count-rates per gram of the samples that had not been passed through the valve were
13% (range 10% to 15%) higher than those of the samples that had not been through the
valve. These findings provide an explanation for the measurement of recoveries greater
than 100%. As these excessive recoveries were only seen when a mobile phase of high pH
was used, a possible explanation for the effect is that at the low pH of "mTc-DMSA
adsorption onto the sample loop occurs during loading of the valve. When the loop is
switched into the flow of a mobile phase with a high pH, the adsorbed "mTc-DMSA is
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washed off the walls of the loop and into the column along with the "mTc-DMSA that is in
solution in the loop. More "mTc than would be present in 20 /d of sample would therefore
be applied to the column.
This phenomenon raises the question of the validity of all the recovery measurements made
so far in this work. The interesting chromatograms have all been obtained using acidic
mobile phases. It could therefore be the case that adsorption in the stainless-steel loop has
occurred but with the mobile phase having a pH similar to that of the "mTc-DMSA, the
adsorbed "mTc was not washed onto the column resulting in the measurement of low
recovery. While this effect has undoubtedly contributed to the low recoveries that have
been detected, column scanning has revealed the presence of "mTc in the guard column and
at the top of the analytical column. Adsorption in the sample loop cannot therefore provide
a complete explanation for low recoveries.
As a possible means of overcoming the phenomenon of adsorption in the valve, I decided to
try replacing the stainless-steel loop with one made from PEEK tubing. The rationale for
this approach was that PEEK is reported to be a particularly inert material and should
therefore exhibit low adsorption characteristics. A 40 cm length of PEEK tubing (internal
diameter 0.25 mm) was cut and fitted to the valve with PEEK fittings (Anachem) in place
of the stainless steel loop. This provided a PEEK loop with a nominal volume of 20 /xl.
The experiment used to detect adsorption in the stainless-steel loop was repeated. The
mean count-rate per gram (n = 5) from the samples of "mTc-DMSA that were not passed
through the loop were only 2% (range 0 to 5%) higher than the mean count-rate per gram
from the samples that were passed through the loop. This much reduced adsorption in
comparison to the stainless-steel loop demonstrates that PEEK tubing is the more suitable
material for use with "mTc-DMSA. In view of these findings, I also replaced the length of
tubing between the valve and the column and the column outlet tubing which constituted the
detector cell with PEEK tubing to minimize adsorption throughout the system.
5.6 Effect of PEEK tubing on recovery
With the sample loop, valve-to-column connection and column outlet/detector cell all
constructed from PEEK tubing, the column was equilibrated with a mobile phase of
100 mM citric acid/acetonitrile (85:15) as before and "mTc-DMSA was injected. The
chromatogram was identical to that obtained previously and shown in Figure 5.4.
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Recovery was only 53% which was comparable to the recoveries obtained previously.
These results confirmed that although the adsorption in the sample loop is an interesting
observation, it does not explain the low recoveries that have been seen throughout this
work. Although adsorption in the loop did not provide a solution to the problem of low
recoveries, I decided to retain the PEEK components for the remaining work on "mTc-
DMSA since they eliminated a possible source of error.
5.7 Identification of the site of adsorption
Figure 5.3 demonstrates that "mTc becomes adsorbed in the guard column and at the top of
the column but does not indicate the exact site of the adsorption. Having identified a
stainless steel component as a site of adsorption in the injection valve, I considered it
possible that the adsorption in the column was on the stainless-steel inlet frits. This would
explain the localisation of "raTc in the guard column and at the top of the analytical
column. If this were the case, it might be possible to replace the stainless-steel inlet frit
with one made from a more inert material.
The following experiment was therefore carried out to identify the site of adsorption. The
guard column was removed and the analytical column was connected directly to the
Rheodyne valve. Using the citric acid/acetonitrile mobile phase as before, a sample of
"mTc-DMSA was injected onto the column. A chromatogram identical to those obtained
previously was recorded. Once the third peak of the chromatogram had been detected, the
pump was switched off and the column was removed from the instrument and scanned as
described in chapter 3.5. A single peak of activity was detected at the top of the column as
before. The column top-fitting, which incorporates the stainless-steel inlet frit, was then
carefully removed from the column and replaced temporarily by a top-fitting from an
identical column. The column was then re-scanned. The profiles of activity along the
column before and after replacement of the top-fitting are shown in Figure 5.6. In both
cases, a single peak of activity was detected at the top of the column. On each profile, a
region of interest was set around the peak of activity and the total counts in the peak were
recorded. After correction for background and the radioactive decay that occurred during
the time that elapsed between the two scans being performed, the counts from the column
after removal of the top-fitting were 86% of the counts that were detected with the original
top-fitting in place. This suggests that some adsorption might have been on the top-fitting
which includes the inlet frit. However, it is possible that column packing material onto
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which some of the "mTc had adsorbed was in the top-fitting, perhaps pressed into the
underside of the frit. Despite this small anomaly, this experiment demonstrates that



























Figure 5.6 Profile of"mTc along a PLRP-S column with and without the column top-fitting.
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5.8 Identification of the presence of "mTc(V)-DMSA
At this stage of my investigations, Blower et al. (1991) published work on the chemical
identity of pentavalent "mTc-DMSA (99mTc(V)-DMSA). This radiopharmaceutical has
been shown to be suitable for imaging of medullary carcinoma of the thyroid (Ohta et al.
1984). It differs from the kidney-imaging "mTc-DMSA in that the "mTc is in the
pentavalent state. There is some doubt as to the valency of the "mTc in the kidney imaging
radiopharmaceutical; Ikeda et al. (1976) attributed a valency state of 3 while Westera et al.
(1985) have attributed a valency state of 4. Most reports in the literature assume the tri-
valent state for "mTc-DMSA, therefore from now on I will refer to the kidney imaging
agent as "mTc(III)-DMSA to distinguish it from the pentavalent species. However, when
referring to "mTc-DMSA of indeterminate composition, I will continue to use the
description "mTc-DMSA.
In the course of their work, Blower et al. analysed "mTc(V)-DMSA by HPLC using
gradient elution of a PRP-1 column (Hamilton) with a 0.1% trifluoroacetic acid in
water/0.1% trifuoroacetic acid in acetonitrile mobile phase. This technique resulted in a
chromatogram containing three peaks which were attributed to the syn-endo, syn-exo and
and isomers of the "mTc(V)-DMSA complex. Could the three peaks detected in my
PLRP-S/100 mM citric acid:acetonitrile (85:15) system be due to the presence of 99mTc(V)-
DMSA in what I have up to now though of as "mTc(III)-DMSA?
To answer this question, the PLRP-S column was equilibrated with the 100 mM citric
acid:acetonitrile (85:15) mobile phase as before. "mTc(V)-DMSA was prepared according
to the following method of Westera et al. (1985). A DMSA kit (Amersham) was
reconstituted with 0.4 ml of Sodium Bicarbonate 8.4% Injection. After dissolution of the
freeze-dried powder, Sodium Pertechnetate [99mTc] Injection (400 MBq/2.1 ml) was
injected into the kit. The solution was incubated at room temperature for 30 minutes. A
20 /d sample of the "mTc(V)-DMSA was injected onto the column and a chromatogram
identical to that obtained with "mTc-DMSA was detected. The chromatogram is shown in
Figure 5.7. However, whereas recovery with "mTc-DMSA was typically 50%, recovery
from "mTc(V)-DMSA was 92%. This result suggests strongly that the chromatogram I
have been detecting was due to the presence of "mTc(V)-DMSA in what I had considered
to be "mTc(III)-DMSA.
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Figure 5.7 High performance liquid chromatogram of "mTc(V)-DMSA on a PLRP-S
column eluted with 100 mM citric acid: acetonitrile (90:10).
To investigate this possibility further, I decided to analyse "mTc-DMSA and 99mTc(V)-
DMSA using the thin-layer chromatographic technique described by Ohta et al. (1984) for
the analysis of "mTc(V)-DMSA. This analysis is carried out using silica gel 60 plates
(Merck) and a mobile phase of butan-l-ol/acetic acid/water (3:2:3). The plates were
spotted 30 minutes after preparation of the radiopharmaceuticals. The mobile phases were
allowed to travel 7 cm then the plates were dried and scanned as described in Chapter 3.7.
The profile of activity along each plate is shown in Figure 5.8. The chromatogram of
"mTc(V)-DMSA shows a single peak of activity at Rf 0.6 while the chromatogram of the
"mTc(III)-DMSA shows a wide peak around the origin and a second well-defined peak at
Rf 0.6. This experiment provides further evidence of the presence of "mTc(V)-DMSA in
"mTc-DMSA that has been prepared by the wet labelling technique.
The B.R (1993) method for measuring the radiochemical purity of "mTc-DMSA, or "mTc-
succimer as it is now called in the B.R, specifies the use of thin-layer chromatography with
ITLC/SG (Gelman) as the stationary phase and butan-2-one as the solvent. In this
chromatographic system, the B.R states that the "mTc-DMSA complex remains on the line
of application and pertechnetate ion migrates near to the solvent front. "mTc-pertechnetate
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Figure 5.8 Thin-layer chromatograms of"mTc(III)-DMSA and yymTc(V)-DMSA' 99m i
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is therefore considered to be the only potential impurity. However, I have demonstrated
that "mTc(V)-DMSA can also be present as an impurity in "mTc-DMSA. I therefore tested
the behaviour of "mTc(V)-DMSA under these chromatographic conditions and found that
all the "mTc remains at the origin. The conclusion from these findings is therefore that the
B.P. technique for determining the radiochemical purity of "mTc-DMSA is inadequate as it
is incapable of detecting "mTc(V)-DMSA when it is present as an impurity.
5.9 Effect of alternative acidic components in the mobile phase
The three peak chromatogram that is attributable to "mTc(V)-DMSA has been obtained
using a mobile phase of containing citric acid and acetonitrile. Blower et al.(1991)
achieved their three peak chromatogram with a mobile phase containing trifluoroacetic acid
and acetonitrile. It is possible, therefore, that a low pH is the important factor and the
means of obtaining this low pH is less important. This was tested by preparing "mTc-
DMSA by wet labelling and, 10 minutes after preparation, analysing the solution using the
following mobile phases: 100 mM citric acid:acetonitrile (85:15), 100 mM acetic
acid:acetonitrile (85:15) and 0.1% trifluoroacetic acid:acetonitrile (85:15). The pH of the
acidic components of these mobile phases were 2.0, 2.6, and 1.9 respectively. All three
mobile phases gave a three peak chromatogram. These are shown in Figure 5.9. This
experiment demonstrates that citric acid has no particular properties that lend it to the
analysis of "mTc-DMSA. The low pH that is required can be achieved through the use of a
number of acids.
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Figure 5.9. High performance liquid chromatograms of "mTc-DMSA using different
mobile phases.
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5.10 Effect of the wet labelling technique on the formation of "mTc(V)-DMSA
The presence of "mTc(V)-DMSA in "mTc-DMSA has not been reported in the literature. I
therefore decided to investigate if this phenomenon is a consequence of the wet labelling
technique that I have used for preparation of the radiopharmaceutical. "mTc-DMSA was
therefore prepared by both the Amersham recommended technique, i.e. by injecting
Sodium Pertechnetate [99mTc] Injection directly into a DMSA kit, and the wet labelling
technique. Thirty minutes after preparation, the two preparations were analysed by both
the HPLC and TLC techniques described previously. The chromatograms from the HPLC
are shown in Figure 5.10 and those from the TLC are shown in Figure 5.11. Both
chromatographic techniques demonstrate the presence of "mTc(V)-DMSA in the
radiopharmaceutical prepared by the wet labelling technique but the absence of 99mTc(V)-
DMSA in the one prepared by the manufacturer's technique. It can therefore be concluded
that wet labelling is responsible for the presence of the "mTc(V)-DMSA complex in "mTc-
DMSA.
To prepare "mTc(V)-DMSA as a radiopharmaceutical in its own right, a DMSA kit for the
preparation of "mTc(III)-DMSA is used but the pFT of the reaction mixture is altered.
Whereas the "mTc(III)-DMSA complex is formed at a pH of 2-2.5, the "mTc(V)-DMSA
complex is formed if the pFl of the reaction mixture is raised to 10. In routine practice,
this higher pH is achieved by dissolving the contents of a DMSA kit in Sodium Bicarbonate
8.4% Injection before addition of the Sodium Pertechnetate [99mTc] Injection. I therefore
measured the pH of "mTc-DMSA that had been prepared by wet labelling to establish if
this technique results in a solution of higher than normal pH which might explain the
presence of "mTc(V)-DMSA in the radiopharmaceutical. However, the pH was found to
be 2.5. Modification of the reaction mixture pH is not therefore the explanation for the
formation of "mTc(V)-DMSA in "mTc-DMSA when preparation is carried out by the wet
labelling technique.
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Figure 5.10 High performance liquid chroinatograms of "'"Tc-DMSA 30 minutes after
preparation by the wet labelling and Amersham techniques.
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Figure 5.11 Thin-layer chroniatograms of"'"Tc-DMSA 30 minutes after preparation by the
wet labelling and Amersham techniques.
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The principal differences between the wet and manufacturer's labelling techniques are that:
• in the manufacturer's technique, the Tc is present as the freeze-dried
components in the kit are dissolving
• when the manufacturer's technique is used, the concentration of DMSA in
the reaction mixture is between 0.125 and 1 mg/ml depending on the
volume of Sodium Pertechnetate [99mTc] Injection with which the kit is
reconstituted. In contrast, wet labelling results in a lower DMSA
concentration of 0.04 mg/ml. This difference in concentration also applies
to the other constituents of the DMSA kit i.e. the stannous chloride,
ascorbic acid and inositol
To test the significance of the first of these differences, "mTc-DMSA was prepared in two
ways. In the first, which is strictly according to the instructions published by Amersham,
Sodium Pertechnetate [99mTc] Injection (1.5 GBq/6 ml) was injected into a DMSA kit.
This represents a situation in which the solution of "mTc is added directly to the freeze-
dried powder in the kit. In the second, a DMSA kit was reconstituted with 5 ml of Sodium
Chloride Injection. Sodium Pertechnetate [99mTc] Injection (1.5 GBq/1 ml) was then
injected into the kit. This represents a modification of the wet labelling technique in which
the solution of "mTc is added to a solution of the kit contents. The 1.5 GBq of "mTc and
6 ml final volume were used since they are the maximum activity and volume
recommended by Amersham for the reconstitution of the kit. The solutions were incubated
at room temperature for 10 minutes after addition of the "mTc. This is the incubation time
recommended by Amersham. Analysis of the solutions was then carried out by HPLC
using the standard PLRP-S/100 mM citric acid:acetonitrile system. The experiments were
performed on separate days to allow time for decay of "mTc retained on the column from
the first. Both solutions produced the 3 peak chromatogram that has been described
previously. Recoveries from the column were comparable at 17.7% and 17.1%
respectively. It can be concluded from this experiment that the way in which the "mTc and
kit contents are mixed does not influence the formation of "mTc(V)-DMSA in the
radiopharmaceutical. When the DMSA kit is reconstituted at the maximum activity and
volume specified by Amersham, 17% of the "mTc is present in the form of an impurity
after the recommended 10 minute incubation time. This could not be considered a
satisfactory product, although in practice, the administration of "mTc-DMSA to a patient
within 10 minutes of its preparation is extremely unlikely. It would therefore appear that
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the factor which influences the presence of "mTc(V)-DMSA is the concentration of the
reaction mixture. The wet labelling technique involves reconstituting the DMSA kit to a
volume of 10.5 ml and then diluting 1.0 ml of this solution to 2.5 ml. This is comparable
to diluting the DMSA kit to a volume of 26.3 ml. To demonstrate conclusively that
concentration is the factor that influences the level of "raTc(V)-DMSA, it would be
necessary to compare "mTc-DMSA prepared by the standard wet labelling technique with
"mTc-DMSA prepared by reconstituting a DMSA kit with 26.3 ml of Sodium Pertechnetate
[99mTc] Injection. Unfortunately this experiment is impossible since the DMSA kit is
supplied in a 10 ml vial.
5.11 Effect of incubation time on the concentration of "mTc(V)-DMSA
Having established that wet labelling is responsible for the formation of "mTc(V)-DMSA in
"mTc-DMSA, I decided to examine the concentration of "mTc(V)-DMSA at times after
preparation. Samples of "mTc-DMSA were prepared by wet labelling at a radioactive
concentration of 130 MBq/2.5 ml and by manufacturer's technique at 1.3 GBq/5 ml. These
activities were chosen to reflect a typical situation in routine practice in which up to ten
patient doses of "mTc-DMSA, each containing 130 MBq, are required from a DMSA kit.
Analysis by HPLC was performed at 10, 30, 60, 120 and 240 minutes after preparation.
Recoveries from the column were measured. To overcome the problem of "mTc retained
on the column from a previous sample being slowly eluted and interfering with the
recovery measurement, each experiment was performed on a separate day. This allowed
sufficient time for any "mTc retained on the column to decay to an insignificant level. The
chromatograms from the 10, 60 and 240 minute analyses are shown in Figures 5.12 and
5.13 To allow comparison between the chromatograms, the counts in each have been
corrected for the different radioactive concentrations of the "mTc-DMSA prepared by the
two labelling techniques and the decay that occurred between preparation and analysis.
The recoveries from the column are shown in Table 5.1.
These results demonstrate that with both labelling techniques:
• the "mTc(V)-DMSA complexes are formed during the preparation of
"mTc-DMSA
• the concentration of "mTc(V)-DMSA decreases with time after preparation
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of the radiopharmaceutical
• the "mTc(III)-DMSA complex/complexes are retained on the column
• the activity of "mTc retained on the column increases with time after
preparation of the radiopharmaceutical
Table 5.1 Results of the comparison of column recoveries





% recovery from column






It would appear therefore, that irrespective of the labelling technique, the formation of
"mTc(V)-DMSA occurs during the preparation of "mTc-DMSA and that over a period of
time the "mTc(V)-DMSA converts to a species that adsorbs on the column. It could be the
case that the formation of "raTc(V)-DMSA is an intermediate step in the formation of
"mTc(III)-DMSA but it is impossible to analyse the reaction mixture fast enough to detect a
situation in which 100% of the "mTc is in the form of "mTc(V)-DMSA. Further
speculation could lead to the proposal that when "mTc(V)-DMSA is prepared as a
radiopharmaceutical, the alkaline pH of the reaction mixture prevents the conversion from
"mTc(V)-DMSA to "mTc(III)-DMSA.
While both labelling techniques result in the formation of "mTc(V)-DMSA in "mTc-
DMSA, the manufacturer's technique is superior since the "mTc(V)-DMSA falls to an
insignificant level within 30 minutes of preparation. As a result of this finding, the routine
preparation of "mTc(III)-DMSA by the wet labelling technique was discontinued in this
radiopharmacy.
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Figure 5.12 High performance liquid chromatograms of 99mTc-DMSA at 10, 60 and 240
minutes after preparation by the wet labelling technique.
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Figure 5.13 High performance liquid chromatograms of "mTc-DMSA at 10, 60 and 240
minutes after preparation by the technique recommended by Amersham.
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5.12 Effect of the presence of "mTc(V)-DMSA on urinary excretion
As confirmation of the undesirability of "mTc(V)-DMSA in "mTc-DMSA, I decided to
compare the renal excretion of "mTc-DMSA with low and high concentrations of 99mTc(V)-
DMSA. The comparison was carried out in a healthy volunteer (AMM) with no history of
kidney disease. Arnold et al. (1975) have shown that approximately 35% of "mTc-DMSA
administered for kidney imaging appears in the 24 hours after administration. In contrast,
Watkinson et al. (1990) have shown that approximately 70% of "mTc(V)-DMSA is
excreted in the urine in 24 hours. "mTc-DMSA that contains a high concentration of
"mTc(V)-DMSA would therefore be expected to show higher renal excretion than pure
"mTc(III)-DMSA.
The following methods for preparing the radiopharmaceuticals were designed to give an
injection of 125 fig of DMSA. This dose was chosen since Amersham state that up to eight
patient doses can be taken from a DMSA kit which contains 1 mg of DMSA. Although
80 MBq is the maximum usual activity recommended by the Administration of Radioactive
Substances Committee (1993) for renal imaging, I decided to use only 5 MBq since the
measurements were to be undertaken in a volunteer and this activity should provide an
adequate count-rate from a sample of urine. The radiation dose from this experiment was
an effective dose equivalent of approximately 100 fiSv which represents 5% of the national
average annual radiation dose from background radiation and 0.2% of the permitted annual
whole body dose that can be received by a radiation worker (Ionising Radiations
Regulations, 1985). Unfortunately, the low radioactive concentration of the
radiopharmaceuticals precluded their simultaneous analysis by HPLC.
To obtain "mTc(III)-DMSA containing a high level of "mTc(V)-DMSA, the
radiopharmaceutical was prepared by the following modification of the wet labelling
technique. The kit was reconstituted with 10 ml of Sodium Chloride Injection and 1.6 ml
of the solution was transferred to a sterile vial. Sodium Pertechnetate [99mTc] Injection
(6 MBq/2.4 ml) was then injected into the vial. After incubation at room temperature for
10 minutes, 3.2 ml (5 MBq) was drawn into a syringe and the count-rate from the solution
was measured with the sodium iodide scintillation detector used in the determination of
HPLC column recoveries (Figure 2.4). A second syringe containing a similar activity was
prepared for use as a standard. The count-rate from the standard syringe was also
measured. The "mTc-DMSA was administered intravenously and the count-rate from the
residual "mTc in the syringe was measured. Urine was collected for 24 hours. The
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contents of the standard syringe were diluted to 1 litre and 5 ml was pipetted into a sample
tube. The volume of urine was measured and 5 ml was pipetted into a sample tube. The
count-rates from the two tubes were measured in an automatic sample counter (Model 1828
Compugamma, LKB Wallac). After correction of all count-rates for background, the
percentage of injected "mTc in the urine was calculated using the formula:
of injected "mTc excreted in urine
100 C V C
u u ss
c„ v cas s is
where C = count-rate from 5 ml of urine
U
C, = count-rate from 5 ml of diluted standard
as
V = volume of urine
U
V = volume of diluted standard
J
C = count-rate from standard syringe
C = count-rate from injected solution i.e. count-rate from syringe
containing the injection minus residual count-rate from syringe
after injection.
The percentage of the injected "mTc that appeared in the urine was found to be 51 %.
To obtain the more "pure" "mTc(III)-DMSA, the radiopharmaceutical was prepared by
reconstituting a DMSA kit with Sodium Pertechnetate [99mTc] Injection (40 MBq/1.0 ml),
incubating the vial at room temperature for 15 minutes then diluting the contents to 6 ml
with Sodium Chloride Injection. A syringe containing 0.75 ml of the radiopharmaceutical
and a standard syringe were prepared and measured as in the first experiment. The
radiopharmaceutical was injected intravenously and the study was performed as described
above. The 24 hour urinary excretion was found to be 15%.
As expected, 99mTc-DMSA containing a high level of 99mTc(V)-DMSA shows much higher
renal excretion than the more pure 99mTc(III)-DMSA. These results are in line with the
value quoted in the literature. The 51% excretion for the radiopharmaceutical containing
99mTc(V)-DMSA is lower than the 70% quoted by Watkinson (1990) but this can be
attributed to some of the 99mTc being in the form of 99mTc(III)-DMSA.
This experiment therefore demonstrates that the presence of 99mTc(V)-DMSA in 99mTc-
DMSA results in higher renal excretion of the 99mTc. In the routine use of 99mTc-DMSA
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for renal imaging, high excretion could lead to an inaccurate diagnosis of renal pathology.
"mTc-DMSA's mode of action is to delineate areas of functioning renal parenchyma. Non¬
functioning tissue appears on the image as areas of reduced or no uptake of "mTc. In a
situation where there is excretion of "mTc into the urine, "mTc in the collecting system of
the kidney could mask an area of reduced uptake in the renal parenchyma. It would be
possible for this situation to arise if "mTc-DMSA is heavily contaminated with 99mTc(V)-
DMSA. It is also the case that the presence of "mTc(V)-DMSA in "mTc-DMSA that is
administered for kidney imaging results in less than 100% of the "mTc being present in the
form that can be concentrated by the kidneys. Uptake will therefore be reduced. If
absolute uptake is being used as a measure of kidney function then an erroneously low
result will be obtained. The concentration of "mTc(V)-DMSA has been shown to vary with
time after preparation. Serial measurements of renal function by absolute uptake will
therefore be affected and may be meaningless. This demonstration of the effect of
"mTc(V)-DMSA on renal excretion therefore demonstrates the importance of "mTc-DMSA
with high radiochemical purity.
5.13 Summary
The work described in this chapter has not resulted in a satisfactory technique for
determining the radiochemical purity of "mTc-DMSA. However, I am unable to conclude
that HPLC as a technique is unsatisfactory for the analysis of "mTc-DMSA since I have
been unable to investigate the many combinations of stationary and mobile phases that
might be used. Chromatographic conditions other than those that I have been able to
investigate may not result in adsorption of the "mTc(III)-DMSA complex on the column
and may be suitable for the analysis of the radiopharmaceutical. Nevertheless, I have
demonstrated the following facts, some of which have implications for the routine
preparation of "mTc-DMSA:
1. The HPLC technique of Moretti et al. (1982) is not satisfactory for
determining the radiochemical purity of "mTc-DMSA.
2. The levels of "Tc in "mTc encountered in routine radiopharmacy practice
have not been shown to influence the radiochemical purity of "mTc-
DMSA.
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3. There is strong adsorption of one or more "mTc/DMSA complexes on the
HPLC column packing materials ODS, PLRP-S, and Hypercarb.
4. There is adsorption of one or more "mTc/DMSA complexes on the
stainless-steel sample loop of the HPLC injection valve.
5. "mTc(V)-DMSA is a common impurity in "mTc-DMSA. The
concentration of this impurity decreases with time.
6. The technique specified in the B.P. (1993) for measuring the radiochemical
purity of "mTc-DMSA is inadequate.
7. Preparation of "mTc-DMSA by wet labelling results in a higher
concentration of "mTc(V)-DMSA than preparation by the manufacturer's
technique. This is a consequence of the higher dilution of the DMSA kit
during wet labelling.
8. Preparation of "mTc-DMSA at the manufacturer's maximum reconstitution
volume results in an unacceptably high level of "mTc(V)-DMSA at the end
of the recommended 10 minute incubation time.
9. The presence of "mTc(V)-DMSA in "mTc-DMSA results in unacceptably
high urinary excretion of "mTc.
Although this work has revealed several previously unknown facts about "mTc-
DMSA, the chromatographic conditions that I investigated have not yielded a
satisfactory technique for determining the radiochemical purity of this
radiopharmaceutical.
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The work described in this chapter was undertaken to validate an HPLC method for
determining the radiochemical purity of "mTc-exametazime and then to use the HPLC
technique in an investigation of the effects of factors that influence the preparation of this
radiopharmaceutical in routine practice.
6.1 Introduction
Technetium-99m [99mTc] exametazime is a relatively new radiopharmaceutical that is used
in tomographic imaging of regional cerebral blood flow (Neirinckx et al. 1987) and for the
in-vitro radiolabelling of autologous leucocytes which are used in imaging sites of
inflammation (Peters et al. 1986). When used in imaging of regional cerebral blood flow,
"mTc-exametazime is injected intravenously into the patient and, being a low molecular
weight lipophilic molecule with zero charge, crosses the blood/brain barrier. Following its
transit of the barrier, "mTc-exametazime interacts with an intracerebral biomolecule,
possibly glutathione, and undergoes a molecular change which prevent its egress from the
brain (Neirinckx et al. 1988). The "mTc therefore becomes trapped inside the brain and
allows imaging to be performed.
For the detection of sites of inflammation by radionuclide imaging, leucocytes are first
isolated from a sample of the patient's blood. The leucocytes are then incubated with
"mTc-exametazime which is taken up by the cells and selectively retained by the
neutrophils. After washing to remove the "mTc that has not been retained in cells, the
radiolabeled leucocytes are reinjected into the patient. Upon reinjection, the "mTc-labelled
neutrophils behave normally and become concentrated in sites of inflammation which can
then be detected by imaging with a gamma-camera.
"mTc-exametazirne is prepared using Ceretec, a commercially available
radiopharmaceutical kit that is manufactured by Amersham International. The Ceretec kit
consists of a vial which contains a sterile freeze-dried mixture of 0.5 mg exametazime
([RR,SS]-4,8-diaza-3,6,6,9-tetramethyl undecane-2,10-dione bisoxime), 7.6 /xg stannous
chloride dihydrate and 4.5 mg sodium chloride. The vial contains a nitrogen atmosphere to
prevent oxidation of the stannous chloride. "mTc-exametazime is prepared by injecting
Sodium Pertechnetate [99mTc] Injection into a Ceretec kit. The pH of the resulting
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intravenous injection is in the range 9.0 - 9.8. Upon addition of "mTc-pertechnetate to the
kit, the "mTc undergoes reduction by the stannous ion and, in the reduced state, forms a
complex with the exametazime. The structure of the complex is shown in Figure 6.1
(Nowotnik et al. 1985).
Me Me
Figure 6.1 Proposed structure of "mTc-exametazime
Amersham International (1989) recommends that the following conditions are observed
when reconstituting a Ceretec kit:
1. The sodium pertechnetate [99mTc] that is used to reconstitute the kit must
have been eluted from a "mTc generator less than two hours previously.
The rationale for this restriction is the build-up of free radicals that are
formed as a result of the energy dissipated in radioactive solutions (Bayne
et al. 1989). If present in a solution that is used to prepare "mTc-
exametazime, these species can cause oxidation of the complex which
results in the release of "mTc in the form of "mTc-pertechnetate impurity.
2. The previous elution of the "mTc generator must have been within the
preceding 24 hours. The longer that a generator remains uneluted, the
greater is the build-up of "Tc and the higher is the "Tc/"mTc ratio in the
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eluate when elution is eventually performed. "Tc is of no value since it
does not emit gamma radiation and, in a labelling reaction, "Tc and "mTc
are indistinguishable. The restriction on the time since the previous elution
is related to the total amount of Tc, i.e. "Tc and "mTc, that can be
accommodated by the Ceretec kit. The "mTc-exametazime complex is
formed at a pH of 9.0 - 9.8. In this pH range, the stannous salts that are
used as reducing agents in "mTc radiopharmaceuticals are relatively
insoluble. The concentration of stannous chloride in Ceretec is therefore
much lower than in other "mTc radiopharmaceutical kits. As a result of
this lower than normal reducing capacity, the amount of Tc that is added to
a Ceretec kit must be carefully controlled otherwise there will be
insufficient stannous ion to reduce all the Tc and a product containing
unlabelled Tc will be produced.
3. Not more than 1.1 GBq of "mTc must be added to the kit. The purpose of
this restriction is also to control the amount of Tc that is added to the kit.
4. Administration of the "mTc-exametazime to the patient must be within 30
minutes of reconstitution of the Ceretec kit. This time limit is a
consequence of the formation of impurities which reduce the radiochemical
purity of the radiopharmaceutical. The lipophilic "mTc-exametazime
complex, commonly referred to as primary "mTc-exametazime complex,
undergoes conversion to a less lipophilic species, referred to as secondary
"mTc-exametazime complex (Neirinckx et al. 1987). This complex does
not cross the blood/brain barrier and is therefore a radiochemical impurity.
"mTc-exametazime also undergoes oxidation with the release of "mTc in
the form of "mTc-pertechnetate impurity. The rates at which these
impurities form are such that satisfactory radiochemical purity can only be
guaranteed up to 30 minutes after reconstitution of the Ceretec kit.
In addition to those described above, unbound reduced "mTc has also been reported as a
radiochemical impurity that can be present in "mTc-exametazime (Neirinckx et al. 1987).
To be suitable for determination of the radiochemical purity of "mTc-exametazime, an
analytical technique should be specific for the primary "mTc-exametazime complex and be
capable of providing a measure of the level of this species. The standard procedure
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recommended by the manufacturer of Ceretec involves the use of a combination of thin-
layer and paper chromatography (Amersham 1989). This procedure suffers from the
disadvantages that it is not specific for the primary "mTc-exametazime complex and the
paper chromatogram takes 100 minutes to run the 15 cm recommended. For a
radiopharmaceutical with a useful life of only 30 minutes, this time seems inappropriate as
a result cannot be made available before the "mTc-exametazime is injected into the patient.
Also, the long analysis time does not facilitate investigation of the radiopharmaceutical over
its 30 minute life.
Various attempts have been made to develop more rapid analytical techniques. Solanki et
al. (1988) investigated the use of paper chromatography on Whatman DE 81, a weakly
basic ion exchange cellulose, with butan-2-one as the solvent. In this system, primary
"mTc-exametazime complex migrates with the solvent front while the radiochemical
impurities remain on the origin. No comparison with any other technique was reported.
The use of paper chromatography on Whatman No.l with diethyl ether as the solvent was
reported by Hung et al. (1988). As with the previous system, primary "mTc-exametazime
complex travels with the solvent front while the impurities remain at the origin. The
results obtained with this technique were compared with results from two other techniques.
Results were in good agreement with those from the standard Amersham thin-layer/paper
technique but in poor agreement with an HPLC technique which was reported to under¬
estimate the percentage of "mTc-pertechnetate impurity and thereby result in an over¬
estimate of primary "mTc-exametazime complex. Ballinger et al. (1988) investigated an
extraction technique in which a sample of "mTc-exametazime is mixed with ethyl acetate.
Primary "niTc-exametazime complex is extracted into the organic phase while the
radiochemical impurities remain in the aqueous phase. Results from this technique were
shown to agree well with results obtained with the standard Amersham thin-layer/paper
chromatography technique. The use of a disposable pre-packed reversed phase
chromatography cartridge (Sep-Pak CI8, Waters Associates) was investigated by Mah et al.
(1989). With this technique, primary "mTc-exametazime complex is retained in the
cartridge while the impurities are washed through with the 0.9% sodium chloride eluent.
Results obtained with this technique were found to agree reasonably well with those from
the standard Amersham technique but poorly with those from the Ballinger solvent
extraction technique.
As discussed in Chapter 1, each of the above techniques can be criticised for their lack of
specificity for the primary "mTc-exametazime complex. The thin-layer and paper
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chromatography techniques rely on the various species in the radiopharmaceutical either
migrating with the solvent front or being retained at the origin. The other two techniques
also rely upon a similar "origin/solvent front" approach. In the extraction technique, the
various species either remain in the aqueous phase or partition into an organic phase while
in the cartridge technique the species are either retained in or eluted from the cartridge.
Although these techniques appear to cope reasonably satisfactorily with the well recognised
impurities in "mTc-exametazime, it is doubtful if they would be adequate for detecting an
unusual impurity which might behave in an identical manner to primary "mTc-exametazime
complex.
An HPLC technique that produces a chromatogram containing a peak which is
characteristic of the primary "mTc-exametazime complex should therefore constitute a
more specific technique for determination of radiochemical purity.
During the development of "mTc-exametazime, HPLC was used to study the various
species present in the radiopharmaceutical (Neirinckx et al. 1987). However, the HPLC
technique was not used to determine radiochemical purity. This was performed using the
thin-layer/paper chromatography technique that was subsequently adopted as the standard
Amersham technique. No comparison of results from the HPLC and thin-layer/paper
chromatography techniques was presented.
The work documented in this chapter was therefore undertaken to:
1. develop and validate an HPLC technique for measuring the radiochemical
purity of "mTc-exametazime
2. use the HPLC technique to develop a method that can be used routinely to
stabilize "mTc-pertechnetate that is supplied for the preparation of "mTc-
exametazime
3. use the HPLC technique to establish if the radiochemical purity and
stability of "mTc-exametazime is influenced by the source and age of the
"mTc-pertechnetate used in its preparation
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6.2 Comparison of HPLC and thin-layer/paper chromatography
The HPLC technique that I chose to investigate was based on the method described by
Neirinckx et al. (1987). The equipment used was the Philips PU4100 pump, the Rheodyne
7125 valve fitted with a 20 g,1 sample loop, the radiation detector in configuration A
(Figure 2.1), the Specmate pre-amplifier/amplifier/high voltage supply and the Accuspec
multichannel analyser. Separation was carried out using gradient elution on a
150 x 4.6 mm PRP-1 column (Hamilton) which was fitted with a 25 x 3 mm guard column.
The column was eluted with 20 mM phosphate buffer pH 7.4 at a flow-rate of 2 ml/min.
Immediately after injection of a 20 ji\ sample of the radiopharmaceutical, tetrahydrofuran
was introduced into the mobile phase in a linear gradient of 0-25% over 6 minutes. The
buffer/tetrahydrofuran mixture (75:25) was maintained for 4 minutes then the
tetrahydrofuran was withdrawn from the mobile phase in a linear gradient 25-0% over 6
minutes. Phosphate buffer was then pumped through the column for a further 12 minutes
before the column was used to perform another analysis. Acquisition of the chromatogram
and measurement of recovery from the column were performed according to the techniques
described in Chapter 3. A typical chromatogram is shown in Figure 6.2.
Retention time (minutes)
Figure 6.2 High performance liquid chromatogram of "mTc-exametazime.
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The chromatogram contains the following four peaks:
I an unidentified impurity
II "mTc-pertechnetate impurity
III secondary "mTc-exametazime
IV an unidentified impurity
V primary "mTc-exametazime
A region of interest was placed around each peak and the counts in each region were
recorded and corrected for background. The counts in each peak were expressed as a
percentage of the total counts in the chromatogram. The percentage in the peak
corresponding to primary "mTc-exametazime complex was taken to be the radiochemical
purity.
The thin-layer/paper chromatographic analysis was performed according to the standard
Amersham technique. This employs a combination of three chromatographic systems as
follows:
System 1: An ascending paper chromatography tank (Shandon) was filled to a depth of
1 cm with fresh acetonitrile/water (50:50) and allowed to equilibrate for one hour. A
2.5 x 30 cm strip was cut from a 46 x 57 cm sheet of Whatman No.l chromatography
paper. The machine direction was marked to ensure that the solvent was run in this
direction. The origin was marked 2.5 cm from the bottom of the strip. The solvent front
was marked 10 cm above the origin. One drop of the "mTc-exametazime to be analysed
was applied to the origin using a 1 ml hypodermic syringe fitted with a 25G needle. The
strip was placed immediately in the chromatography tank. The time taken for the solvent
to travel the 10 cm to the solvent front was approximately 60 minutes. When the solvent
front was reached, the strip was removed from the tank and dried with a hot air blower.
The strip was then cut transversely into 11 x 1 cm sections, starting 5 mm below the origin.
The first section therefore contained the origin and the last section contained the solvent
front. The sections were placed in sample tubes and the count-rate from each was
determined using an automatic gamma sample counter (Model 1282 Compugamma, LKB
Wallac). The counting time was chosen to ensure that at least 10,000 counts were recorded
from the most active section. With this system, unbound reduced "mTc remains at the
origin while primary "mTc-exametazime, secondary "mTc-exametazime and "mTc-
pertechnetate impurity migrate with an Rf of 0.8-1.0. Using the general procedure
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described in Chapter 3 for the analysis of chromatograms, the level of unbound reduced
"mTc (R%) in the radiopharmaceutical was calculated by expressing the counts at the
origin as a percentage of the total counts on the strip.
System 2: An ascending thin-layer chromatography tank (Gelman) was filled to a depth of
1 cm with a fresh solution of 0.9% sodium chloride and allowed to equilibrate for one
hour. A 2.5 x 20 cm plate was cut from a 20 x 20 cm sheet of Instant Layer
Chromatography/Silica Gel (ITLC/SG, Gelman). The origin was marked 2.5 cm from the
bottom of the plate. The solvent front was marked 10 cm above the origin. The sample
was applied as described for System 1 and the plate was placed immediately in the
chromatography tank. The plate was developed, dried, cut and counted as described above.
With this system, unbound reduced "mTc, primary "mTc-exametazime and secondary
"mTc-exametazime remain at the origin while "mTc-pertechnetate impurity migrates with
an Rf of 0.8-1.0. The level of "mTc-pertechnetate impurity (P%) in the
radiopharmaceutical was therefore calculated by expressing the counts at the solvent front
as a percentage of the total counts on the plate.
System 3: This procedure was identical to System 2 except that a solvent of butan-2-one
was used. With this system, unbound reduced "mTc and secondary "mTc-exametazime
complex remain at the origin while "mTc-pertechnetate impurity and primary "mTc-
exametazime migrate with an Rf of 0.8-1.0. The combined level of unbound reduced "mTc
and secondary "mTc-exametazime was therefore calculated by expressing the counts at the
origin as a percentage of the total counts on the plate. The level of secondary "mTc-
exametazime (2°%) was then calculated by subtracting the level of unbound reduced "mTc
(R%) determined with System 1 from the combined level determined with System 3.
The level of primary "mTc-exametazime complex (1°%) was then calculated as:
1°% = 100-(P% + R% + 2°%)
The level of primary "mTc-exametazime complex was taken as the measure of
radiochemical purity.
Each of the above chromatograms was run over a distance of only 10 cm rather than the
15 cm recommended by Amersham. The shorter distance was used due to the unacceptably
long 100 minutes required for the Whatman No. 1/50% acetonitrile system to run the
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recommended 15 cm. A typical set of chromatograms is shown in Figure 6.3. For each
system, the 10 cm distance provides adequate separation of the species in "mTc-
exametazime.
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System 1: Whatman No.l / 50% acetonitrile
Origin Solvent
front
Figure 6.3 Thin-layer and paper chromatograms of Tc-exametazime
116
6. Radiochemical Purity of ""'Tc-exametazime Injection
To compare the results obtained with HPLC and thin-layer/paper chromatography, I used
both techniques to analyse 24 samples of "mTc-exametazime with a wide range of
radiochemical purities (54.6-94.5%). The mean level ± standard deviation of each
species detected is shown in Table 6.1. The mean ± standard deviation radiochemical
purity determined by the thin-layer/paper technique was 81.5 + 10.5% and by the HPLC
technique was 81.2 ± 10.2%. When compared using a paired Student's t-test, these
results were not found to be significantly different (P>0.30). The excellent correlation
(r= 0.98) between the two techniques is shown in Figure 6.4.
Table 6.1 Results of the comparison of High Performance
Liquid Chromatography (HPLC) and Thin-Layer/Paper
Chromatography (TLC/PC) for the analysis of "mTc-
exametazime.
Species % of total activity
HPLC TLC/PC
Unknown 1 0.3 ± 0.3% -
"mTc-pertechnetate 6.8 ± 7.9 6.5 ± 8.7%
2° "mTc-exametazime 7.1 + 3.8 10.4 ± 4.0
Unknown 2 4.6 ± 0.7 -
1 ° "mTc-exametazime 81.2 ± 10.2 81.5 + 10.5
Recovery 98.9 ± 1.1 -
Each value is the mean + standard deviation of five results
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RCP (%) by HPLC
Figure 6.4 Comparison of the radiochemical purity (RCP) of "mTc-exametazime as
measured by HPLC and TLC/PC.
Hung et al. (1988) reported that the HPLC technique used in their study resulted in an
under-estimate of "mTc-pertechnetate impurity when compared to the ITLC/SG:0.9%
sodium chloride system of the Amersham thin-layer/paper chromatographic technique. The
results of the above study do not corroborate this finding in that the levels of "mTc-
impurity measured by the two techniques do not differ significantly.
From the results of my study, it can be concluded that over the range of radiochemical
purities likely to be encountered in practice, the HPLC technique investigated in this work
is satisfactory for determination of the radiochemical purity of "mTc-exametazime.
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6.3 Use of sodium iodide to stabilize sodium pertechnetate [99mTc] dispensed for the
preparation of "mTc-exametazime
A major limitation in the use of "mTc-exametazime is the expiry time of 30 minutes after
reconstitution of the Ceretec kit. A consequence of this short expiry is that the
radiopharmaceutical must be prepared immediately before it is to be used. This may mean
that reconstitution of the kit cannot be undertaken in the radiopharmacy but must be carried
out in the department in which the "mTc-exametazime is to be used. Amersham also
recommend that the kit is reconstituted with sodium pertechnetate [99mTc] obtained from a
generator eluate that is less than 2 hours old. This can represent a logistical problem if the
nuclear medicine department is in a different institution to the radiopharmacy or if the
",nTc-exametazime is to be used more than 2 hours after the time at which the "mTc
generator is eluted routinely. Bayne et al. (1989) have reported that the addition of sodium
iodide to the generator eluate overcomes this problem and extends the shelf-life of sodium
pertechnetate [99mTc] from 2 to 6 hours. I have therefore undertaken the development of a
method by which this procedure can be introduced into routine use. In the course of this
work, the HPLC technique that has been validated for the analysis of "mTc-exametazime
was used to assess the stability of "mTc-exametazime.
As a convenient means of using the stabilization technique routinely, I decided to
investigate a kit approach by preparing batches of vials containing sodium iodide. The
principle behind this technique was that on each occasion that sodium pertechnetate [99mTc]
is required for the preparation of "mTc-exametazime, it will be dispensed into a kit within
30 minutes of generator elution.
6.3.1 Preparation of sodium iodide kits
Most commercially manufactured radiopharmaceutical kits are formulated as freeze-dried
products. Since freeze-drying is not a technique available to most hospital
radiopharmacies, I decided to investigate the suitability of a kit containing a solution of
sodium iodide. Bayne et al. (1989) demonstrated that 400 fig of sodium iodide was
adequate for stabilization of the maximum activity (1.11 GBq) of "mTc recommended for
the reconstitution of a Ceretec kit. I therefore decided to prepare kits containing 440 fig of
sodium iodide in 1.0 ml of Sodium Chloride Injection B.P. The principle behind this
technique is as follows. "mTc generator eluate, diluted to have a radioactive concentration
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of 1.2 GBq in 4.5 ml at the time when the Ceretec kit will be reconstituted, is injected into
a sodium iodide kit. The kit then contains 1.2 GBq of "mTc and 440 /xg of sodium iodide
in 5.5 ml. Amersham recommend that the Ceretec kit is reconstituted to a volume of 5 ml.
Using 5.0 ml of the "mTc/sodium iodide solution prepared as described above results in the
Ceretec kit being reconstituted with 1.1 GBq of "mTc containing 400 /xg of sodium iodide.
Aqueous solution of sodium iodide gradually become coloured on exposure to light and air
due to the liberation of iodine (Martindale 1989). I therefore decided to use vials
containing a nitrogen atmosphere for preparation of the kits which would then be protected
from light. Sodium Chloride Injection B.P. which has a slightly acidic pH is not the ideal
solvent for sodium iodide which is most stable under the slightly alkaline conditions of pH
8-9.5 (Merck Index 1976). However, pH adjustment of the solution used to prepare the
kits was considered inadvisable since pH is known to be important in the labelling of
exametazime. Reconstitution with a pH-adjusted solution might therefore upset the
labelling reaction and result in low radiochemical purity.
Sodium Iodide B.R was therefore dissolved in Sodium Chloride Injection B.R to give a
solution of concentration 440 /xg/ml. Kits were prepared by filtering 1.0 ml aliquots of this
solution through a sterile 220 nm filter into weighed nitrogen-filled vials (Product Code
N46, Amersham). Each vial was reweighed and the weight of solution calculated. From
these weights, the sodium iodide content of each kit was calculated. Five batches of kits
were prepared. From each batch, 10 vials were stored at room temperature, 10 in a
refrigerator at 4°C and 10 in a freezer at -22°C.
6.3.2 Assay of sodium iodide kits
In view of the potential instability discussed above, the first step in determining the
feasibility of the sodium iodide kit concept was to measure the stability of the kits and
determine if it is influenced by the conditions under which they are stored. To measure
stability, I devised a modification of the 1968 B.P. method for assaying the iodide content
of sodium iodide. The modification was necessary due to the small volume of solution in
each kit and the small amount of sodium iodide present. The 1968 method was preferred to
the methods introduced in more recent editions of the B.P. since it was more readily
miniaturized. The analytical technique depends upon hydrochloric acid converting iodide
to iodine which is then titrated with potassium iodate solution. The presence of iodine in
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the kit as a result of oxidation of iodide during storage would not be revealed by this
titrimetric analysis. A separate test for the detection of iodine was therefore necessary.
At 0, 1,4 and 8 weeks after preparation, two kits that had been kept under each storage
condition were used in the modified assay to determine iodide content as follows. One vial
from each pair was centrifuged to bring all the solution to the bottom of the vial. The
rubber cap was removed from the vial. Hydrochloric acid, 1.2 ml, was pipetted into the
vial which was then reweighed. Approximately 0.1 ml of 3 mM potassium iodate solution
was added to the vial to develop a yellow colour and the vial was reweighed. Amaranth
solution (1/100th strength), 0.1 ml, was added to the vial which was reweighed. Potassium
iodate solution, 3 mM, was added until the colour of the solution changed from pink to pale
yellow. The vial was reweighed. From the total weight of 3 mM potassium iodate solution
added, the iodide content of the vial was calculated (each ml of 3 mM potassium iodate
solution is equivalent to 899 pg of sodium iodide). One drop of Starch Mucilage B.P. was
injected into the other vial of the pair. A blue colour developed if > 1 % of the iodine was
present in the from of \r The results of the iodide assays are shown in Table 6.2





(weeks) temperature 4°C -22°C
0 98.6 1+ o 00 - -
1 98.8 ± 1.2 99.5 + 0.5% 98.5 OOt-H+1
4 98.7 ± 0.9 99.0 1+ o 97.9 + 1.9
8 96.9 ± 0.4 98.2 ± 2.0 98.5 ± 2.3
Each value is the mean + standard deviation of five results
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For each storage condition, the iodide content of the kits remained >96% throughout the 8
weeks of the study. No kit was found to contain > 1% of the iodine in the form of I2. As
the method of preparing the kits involves aseptic manipulations which always carry the risk
of bacterial contamination, and none of the temperatures tested affect stability, I chose
refrigeration as the storage condition. This is convenient in routine practice and will inhibit
the growth of any contamination introduced during preparation. I also decided to err on the
side of safety and give the kits an expiry date of four weeks after preparation.
6.3.3 Effect of sodium iodide kits on the stability of "mTc-exametazime
Having established the stability of the sodium iodide kits, the following experiments were
performed to demonstrate their effectiveness in extending the useful life of sodium
pertechnetate [99mTc] that is to be used in the preparation of "mTc-exametazime. With a
four week expiry having been assigned to the sodium iodide kits, I decided that the most
challenging test of their effectiveness would be to use them at expiry.
"mTc was obtained from 30 GBq "mTc generators (Product Code MCC20, Amersham) that
had been eluted previously within 24 hours. The generator eluates were diluted
immediately after elution. "niTc-exametazime injections (1.1 GBq/5 ml) were prepared
according to the following three techniques:
1. 1 h sodium pertechnetate l"mTc]: The volume of generator eluate that
contained 1.3 GBq of "mTc was diluted to 5.5 ml with Sodium Chloride
Injection B.P. and injected into a sterile 10 ml nitrogen-filled vial (Product
Code N46, Amersham). One hour later, 5.0 ml of this solution was
injected into a Ceretec kit.
2. 6 h sodium pertechnetate l"mTc]: The volume of generator eluate that
contained 2.4 GBq of "mTc was diluted to 5.5 ml with Sodium Chloride
Injection B.P. and injected into a sterile 10 ml nitrogen-filled vial. Six
hours later, 5 ml of this solution was injected into a Ceretec kit.
3. 6 h sodium pertechnetate j"mTc] + Nal: The volume of generator
eluate that contained 2.4 GBq of "mTc was diluted to 4.5 ml with Sodium
Chloride Injection B.P. and injected into a four week-old sodium iodide
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kit, giving a total volume of 5.5 ml. Six hours later, 5 ml of this solution
was injected into a Ceretec kit.
Five "mTc-exametazime injections were prepared by each of the three techniques. A
different batch of Ceretec kits was used for each set of three experiments. The "mTc-
exametazime injections were stored at room temperature.
The radiochemical purity of each "mTc-exametazime injection was measured using the
validated HPLC technique. Although the recommended expiry time for "mTc-exametazime
is 30 minutes, measurements were made at 2, 30, 60 and 120 minutes after preparation to
ensure that any tendency towards reduced stability would be clearly demonstrated. The
results are shown in Table 6.3. The changes in the levels of the two principal impurities
("mTc-pertechnetate and secondary "mTc-exametazime complex), with time are shown in
Figure 6.5
The very high recovery of "raTc from the HPLC column (overall mean = 99.8+2.0%, n
= 60) demonstrates that no significant radiochemical impurities in the "mTc-exametazime
became adsorbed onto the column packing material and thereby remained undetected.
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Table 6.3 Effect of three preparations of sodium pertechnetate [99mTc] on the composition
of "mTc-exametazime
Sodium Species % of total activity at times after preparation
pertechnetate (peak no.)
["mTc] 2 min 30 min 60 min 120 min
1 hour-old Unknown 1 (I) 0.1 0.1 0.2 0.4
± 0.0 ± 0.1 ± 0.1 ± 0.2
"mTc-pertech (II) 1.2 1.9 3.0 7.1
± 0.2 ± 0.9 ± 2.4 ± 5.0
2° "mTc-examet (III) 2.6 4.7 6.5 8.8
± 0.3 + 1.4 ± 3.2 ± 5.2
Unknown 2 (IV) 3.3 3.6 4.4 4.5
± 0.1 ± 1.4 ± 1.5 ± 1.4
1 ° "mTc-examet (V) 92.8 89.7 85.9 79.2
± 1.3 ± 2.4 ± 4.1 ± 5.0
Recovery 99.7 100.1 98.3 99.6
± 0.3 ± 1.2 ± 1.9 ± 1.7
6 hour-old Unknown 1 (I) 0.1 0.4 0.7 1.1
± 0.1 ± 0.1 ± 0.2 ± 0.2
"mTc-pertech (II) 1.6 10.2 18.0 30.0
± 1.3 ± 2.4 ± 3.1 ± 3.8
2° "mTc-examet (III) 2.9 6.2 8.7 10.1
± 0.5 ± 0.9 ± 1.2 ± 1.6
Unknown 2 (IV) 2.9 3.1 3.3 2.8
± 1.3 ± 1.1 ± 1.1 ± 0.9
1° "mTc-examet (V) 92.5 80.1 69.3 56.0
± 1.7 ± 2.0 ± 3.2 ± 4.0
Recovery 99.4 100.2 98.9 99.4
± 1.1 ± 2.5 ± 3.0 ± 2.1
6 hour-old Unknown 1 (I) 0.1 0.1 0.1 0.3
± 0.1 ± 0.1 ± 0.0 ± 0.0
+ sodium "mTc-pertech (II) 1.0 1.6 3.2 7.2
± 0.2 ± 0.1 ± 0.6 ± 2.7
iodide 2o99mTc-examet (III) 2.5 5.3 6.7 7.8
± 0.6 ± 1.4 ± 2.3 ± 2.5
Unknown 2 (IV) 3.2 3.7 3.8 3.5
± 1.4 ± 1.7 ± 1.7 ± 1.5
1 ° "mTc-examet (V) 93.2 89.3 86.2 81.2
± 2.0 ± 3.0 ± 4.6 ± 6.4
Recovery 100.6 100.4 100.5 101.1
± 2.3 ± 2.2 ± 2.6 + 3.3
Each value is the mean + standard deviation of five results
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Time after reconstitution (minutes)
1 hour—old "Tc 1 I 6 hour-old "mTc \\1 6 hour-old "mTc + Nal
Figure 6.5 Changes in the levels of secondary "mTc-exametazime complex and vvmTc-99m n
pertechnetate impurity in "mTc-exametazime
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Over the 120 minutes of the study, the level of Unknown 1 did not change in the ""Tc-
exametazime prepared with 1 hour-old sodium pertechnetate [99mTc] or 6 hour-old sodium
pertechnetate [99mTc] + sodium iodide. It did rise significantly when 6 hour-old sodium
pertechnetate [99mTc] was used but at 30 minutes, i.e. at the expiry time of ""Tc-
exametazime, was only 0.4% and does not therefore represent a major impurity.
The level of Unknown 2 did not change in any of the preparations over the course of the
study and at approximately 3.5%, also does not represent a major impurity.
Over 120 minutes, the level of secondary "mTc-exametazime complex rose steadily and
equally in each of the three preparations. Sodium iodide has therefore no effect on the
conversion of primary to secondary "mTc-exametazime complex.
"mTc-pertechnetate impurity rose in "mTc-exametazime prepared by each of the three
techniques. However, the rise was much more rapid in "mTc-exametazime prepared using
6 hour-old sodium pertechnetate [99mTc] than in the other two. The rise in "mTc-
pertechnetate impurity is therefore the cause of the reduced radiochemical purity that is
seen when "mTc-exametazime is prepared using 6 hour-old sodium pertechnetate [99mTc].
The radiochemical purity of "mTc-exametazime prepared according to each of the three
techniques decreased over the 120 minutes of the study. Technique 1 (1 hour-old sodium
pertechnetate [99mTc]) meets all the conditions prescribed by Amersham and was therefore
be assumed to yield "standard" "mTc-exametazime. The radiochemical purities obtained
with 6 hour-old sodium pertechnetate [99mTc] (technique 2) and 6 hour-old sodium
pertechnetate [99mTc] + sodium iodide (technique 3) were therefore compared to those
obtained with technique 1. Since the recommended expiry time for "mTc-exametazime is
30 minutes after preparation, statistical analysis by unpaired Student's t-test was confined to
the 2 and 30 minute results. At 2 minutes after preparation, the radiochemical purities of
"mTc-exametazime prepared according to techniques 2 and 3 did not differ significantly
(P > 0.50) from that prepared according to technique 1. However, at 30 minutes, the
radiochemical purity of "mTc-exametazime prepared with 6 hour-old sodium pertechnetate
[99mTc] was significantly lower (P < 0.01) whereas the radiochemical purity of ""Tc-
exametazime prepared with 6 hour-old sodium pertechnetate [99mTc] + sodium iodide was
not significantly different.
In summary, HPLC has been used to demonstrate that when sodium pertechnetate [99mTc]
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for use in the preparation of "mTc-exametazime is supplied in a sodium iodide kit, its shelf-
life can be extended from the recommended 2 hours to at least 6 hours.
6.4 Effect of sodium pertechnetate [99mTc] source on the stability of "mTc-
exametazime.
As discussed earlier in this chapter, the 2 hour restriction on the age of sodium
pertechnetate [99mTc] used in the preparation of "mTc-exametazime can present a
considerable, if not insurmountable, problem. In an examination of this problem, Ponto
(1990) has challenged the 2 hour restriction by publishing data which show that when five
hour-old sodium pertechnetate [99mTc] from "mTc generators manufactured by Mediphysics
or Mallinckrodt is used, "mTc-exametazime of satisfactory radiochemical purity is
obtained. Although it is suggested, it is not clear from the publication of Ponto (1990) if
these apparently favourable findings are a result of some characteristic of the sodium
pertechnetate [99mTc] that is obtained from Mediphysics and Mallinckrodt "mTc generators.
Also, the conclusion is based solely on measurements made immediately after
reconstitution. Of much greater importance is the radiochemical purity at the time that the
"mTc-exametazime is administered to the patient. Therefore, unless analysis and
administration are performed simultaneously, the radiochemical purity of the "mTc-
exametazime that is injected into the patient is unknown. In practice, there are many
circumstances which delay the administration of a medicine to a patient and make it
impossible to guarantee that "mTc-exametazime will always be administered immediately
after reconstitution of the kit. It is therefore of much greater value to know that the method
of preparation results in a satisfactory radiochemical purity at the expiry time quoted for
the radiopharmaceutical. In the case of "mTc-exametazime, this is 30 minutes after
preparation.
In the work on the use of sodium iodide kits described earlier, I confirmed that the effect
reported by Ponto (1990) is also seen when sodium pertechnetate [99mTc] from a generator
manufactured by Amersham is used to prepare "mTc-exametazime, i.e. radiochemical
purity is high immediately after preparation regardless of the age of the sodium
pertechnetate [99mTc], However, when 6 hour-old sodium pertechnetate [99mTc] is used,
the radiochemical purity of the "mTc-exametazime at 30 minutes after preparation is
significantly lower than when 1 hour-old sodium pertechnetate [99mTc] is used.
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I therefore used HPLC in the following study to establish a) if the phenomenon reported by
Ponto (1990) is peculiar to sodium pertechnetate [99mTc] that is obtained from the
generators used in his study or if it is observed when "mTc from other generators is used,
and b) if the reported insignificance of eluate age is valid at the 30 minute expiry time of
"mTc-exametazime.
6.4.1 Preparation of "mTc-exametazime
The Mediphysics and Mallinckrodt "mTc generators that were used in the study of Ponto
(1990) are not available in Europe. Mallinckrodt does, however, manufacture a "mTc
generator in Europe. The "mTc generators used in this study were therefore the 8.5 GBq
UltraTechneKow (Product Code DRN 4329, Mallinckrodt) and the 15 GBq Amertec II
(Product Code MCC20, Amersham). The generators were eluted 24 hours before being
eluted to provide the sodium pertechnetate [99mTc] that was used in the preparation of
"mTc-exametazime. Eluates from each manufacturer's generators were diluted
immediately after elution as in the previous experiment. "mTc-exametazime injections
(1.1 GBq/5 ml) were prepared according to the following two techniques:
1. 1 hour-old sodium pertechnetate l"mTc]: The volume of generator eluate
that contained 1.3 GBq of "mTc was diluted to 5.5 ml with Sodium Chloride
Injection B.P. and injected into a sterile 10 ml nitrogen-filled vial (Product
Code N46, Amersham). One hour later, 5.0 ml of this solution was injected
into a Ceretec kit.
2. 6 hour-old sodium pertechnetate {"'"TcJ: The volume of generator eluate
that contained 2.4 GBq of "mTc was diluted to 5.5 ml with Sodium Chloride
Injection B.P. and injected into a sterile 10 ml nitrogen-filled vial (Product
Code N46, Amersham). Six hours later, 5.0 ml of this solution was injected
into a Ceretec kit.
Six "mTc-exametazime injections were prepared by each of the two techniques. A different
lot of Ceretec kits was used for each set of four experiments, i.e. reconstitution with 1 hour-
old and 6 hour-old sodium pertechnetate [99mTc] from each manufacturer's generator. For
the experiments involving sodium pertechnetate [99mTc] from the Amersham generator, four
results from the previous experiment were used since vials from the same batches of Ceretec
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kits were available to carry out paired experiments with sodium pertechnetate [99mTc] from
the Mallinckrodt generator. Two fresh experiments were necessary since vials from the
batches of Ceretec kits used in the earlier study were no longer available. Reconstituted kits
were stored at room temperature.
6.4.2 Measurement of radiochemical purity
At 2, 30 and 60 minutes after reconstitution of each kit, the radiochemical purity of the
"mTc-exametazime was measured by HPLC.
As in previous experiments, the mean recovery from the column was satisfactorily high
(99.1 ± 2.7%, n=72). The results of the radiochemical analyses are shown in Table 6.4.
The levels of unidentified species and secondary "mTc-exametazime complex were similar to
those measured in the previous experiment and were similar in "mTc-exametazime prepared
using "mTc from either manufacturer's generator.
Regardless of whether 1 hour-old or 6 hour-old sodium pertechnetate [99mTc] from either
manufacturer's generator was used to prepare "mTc-exametazime, radiochemical purity was
high at 2 minutes after preparation. Analysis by unpaired Student t-test showed no significant
differences (P>0.05). This agrees with the finding of Ponto (1990). However, at 30 and 60
minutes after preparation, the radiochemical purities of the "mTc-exametazime prepared
using 6 hour-old sodium pertechnetate [99mTc] were significantly lower (P<0.05) than those
prepared with 1 hour-old sodium pertechnetate [99mTc], Similar results were found for each
manufacturer's generator. No significant differences in radiochemical purity were found
between corresponding results from "mTc-exametazime prepared with sodium pertechnetate
[99mTc] from each manufacturer's generator.
Of the impurities in "mTc-exametazime, "mTc-pertechnetate was the only one that was found
to differ as a result of the age of the sodium pertechnetate [99mTc] used. The changes in the
levels of "mTc-pertechnetate impurity with time are shown diagrammatically in Figure 6.6.
When 1 hour-old sodium pertechnetate [99mTc] was used, the levels of "mTc-pertechnetate
impurity rose slowly over the one hour of the experiment. In contrast, when 6 hour-old
sodium pertechnetate [99mTc] was used, the levels rose much more rapidly. Comparable
results were obtained when sodium pertechnetate [99mTc] from either manufacturer's
generator was used.
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Table 6.4 Effect of age of sodium pertechnetate [99mTc] from two generators on the
composition of "mTc-exametazime.
Sodium Species % of total activity at times afterpreparation
pertechnetate (peak no.)
l"mTc] Amersham generator Mallinckrodt generator
2 min 30 min 60 min 2 min 30 min 60 min
Unknown 1 (I) 0.1 0.1 0.2 0.2 0.1 0.2
± oo ± 0.0 ± 0.1 ± 0.1 ± 0.1 ± 0.1
"mTc-pertech (II) 1.2 1.8 2.9 1.6 1.3 2.1
± 0.2 ± 00o ± 2.1 ± OOd ± 0.3 ± 0.5
2° "mTc-examet (III) 2.8 6.1 9.5 3.0 6.9 9.9
± 0.3 ± 1.3 ± 3.0 ± 0.7 + 0.9 ± 0.9
Unknown 2 (IV) 3.2 3.5 4.2 2.3 3.0 3.2
± 1.0 ± 1.2 ± 1.4 ± 0.4 ± 0.4 ± 0.5
1° "mTc-examet (V) 92.7 18.5 83.2 92.9 18.7 84.6
± 1.2 ± 2.1 ± 3.7 ± 1.5 + 0.7 ± 0.6
Recovery 100.1 99.2 98.7 98.6 98.2 98.0
± 1.0 + 2.4 ± 1.9 ± 1.8 ± 3.6 ± 2.7
Unknown 1 (I) 0.1 0.4 0.6 0.2 0.3 0.5
± 0.0 + 0.1 ± 0.2 ± 0.1 ± 0.1 ± 0.1
"mTc-pertech (II) 1.8 10.0 17.8 1.7 8.4 15.6
± 1.2 ± 2.2 ± 2.8 ± 0.4 ± 1.7 + 2.6
2° "mTc-examet (III) 2.6 5.6 7.6 3.4 6.1 8.5
± 0.9 ± 0.9 ± 1.1 ± 1.1 ± 1.1 ± 1.7
Unknown 2 (IV) 3.0 3.1 3.2 2.9 3.3 3.4
± 1.2 ± 1.0 ± 1.0 ± 0.4 ± 0.5 ± 0.6
1 ° "mTc-examet (V) 92.5 80.9 70.8 91.8 81.9 72.0
+ 2.0 + 1.8 ± 2.9 + 1.9 ± 2.1 ± 2.7
Recovery 99.8 100.0 99.0 99.6 97.9 100.5
± 1.4 ± 2.3 ± 2.7 ± 5.7 ± 2.9 ± 3.0
Each value is the mean + standard deviation of six results
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6. Radiochemical Purity of"mTc-exametazime Injection
6.5 Summary
In the work described in this chapter I have:
1. validated an HPLC technique for determining the radiochemical purity of
"mTc-exametazime
2. developed a technique for preparing stable kits of sodium iodide
3. demonstrated that the sodium iodide kits can be used successfully to stabilize
sodium pertechnetate [99mTc] that is dispensed for use in the preparation of
"mTc-exametazime
4. confirmed that the radiochemical stability of "mTc-exametazime is influenced
by the age of the sodium pertechnetate [99mTc] used in its preparation
5. demonstrated that the radiochemical stability of "mTc-exametazime is not
influenced by the brand of generator from which the sodium pertechnetate
[99mTc] used in its preparation is obtained
From these findings, it can be concluded that HPLC is a satisfactory technique for
measuring the radiochemical purity of "mTc-exametazime.
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Throughout this thesis, I have discussed the specific aspects of my work in the relevant
chapters. This final discussion will therefore deal with the overall implications of the studies
that I have undertaken.
7,1 Design of the radiation detector
Radiation detectors for HPLC are available commercially from several sources. Although
these can be used for the detection of "mTc, they are designed primarily for use with beta-
emitting radionuclides such as carbon-14 and tritium (3H). Two modes of detection are
used in these instruments. One involves mixing the column eluate with liquid scintillator
and then passing the mixture through a flow-cell in a modified liquid scintillation counter.
This arrangement requires a means by which eluate and scintillator can be mixed on-line
and yet not dilute the eluate to an extent that degrades resolution to an unacceptable level.
The other, more elegant arrangement is the use of a detector flow-cell which consists of a
piece of plastic scintillator coupled to one or two photomultipliers - the use of two allows
coincidence counting to be used. The eluate from the column is passed through a hole
drilled in the scintillator. The radiation emitted from the eluate is then detected when it
interacts with the plastic scintillator. The advantage of this second approach is that it
avoids the complex arrangement that is required to mix liquid scintillator with the column
eluate.
The complexity of these two methods of detection is a consequence of the difficulty of
detecting beta-radiation. This also makes the equipment expensive. The detection of
gamma-radiation such as that emitted by "mTc is a much more straightforward task since a
simple sodium iodide crystal detector can be used. This type of detector is inappropriate
for the detection of beta-emitters since the beta particle has insufficient energy to pass
through the metal can in which a sodium iodide crystal is typically housed. I therefore
constructed a simple detector by positioning a length of column outlet tubing inside the well
or across the face of a sodium iodide crystal. To accommodate the range of radioactive
concentrations at which "mTc radiopharmaceuticals are prepared, the detection efficiency
could be optimised by altering the position of the tubing relative to the crystal. The




Two methods of recording the chromatograms were used. The older system based on a
counter-ratemeter and printer was inexpensive but had the disadvantage of producing long
print-outs if short counting times were used to capitalize on the high resolution of HPLC.
Also, manual calculation of the counts in peaks was necessary. The newer system in which
a computer-based multichannel analyser was used to record the chromatograms had the
advantages of the data being stored on disk and automatic integration of the counts in
peaks. One possible disadvantage of using a multichannel analyser was the possibility of
loss of counts due to dead-time at high count-rates. With HPLC, peaks on chromatograms
should be extremely sharp and this could result in high count-rates for short periods of
time. However, the loss due to dead-time at the highest count-rate of 6,000 counts per
second obtained in the course of my work was found to be only 0.5%. The use of the
multichannel analyser was therefore considered a satisfactory and convenient means of
recording chromatograms from HPLC.
7.2 Choice of "mTc radiopharmaceuticals to be studied
Approximately thirty "mTc radiopharmaceuticals are currently available. When embarking
on a study such as the one described in this thesis, it would be unrealistic to set out with the
aim of investigating the role of HPLC in relation to each one. I therefore chose three for
which an aspect of radiochemical purity was of particular relevance to routine
radiopharmacy practice.
99mTc-MAG3 was a promising new radiopharmaceutical for which an impractical expiry
time of one hour after preparation had been recommended by its manufacturer. The
logistics and economics of using a product with such a short shelf-life were likely to
preclude it from routine use. To establish conditions that result in high radiochemical
purity and stability would increase the likelihood of 99mTc-MAG3 finding a place in routine
nuclear medicine practice.
"mTc-DMSA has been available for approximately 15 years but doubt over the
consequences of preparing it from "mTc with a high "Tc content remained unresolved.
Also, if "mTc-DMSA is to be used in absolute measurement of renal function, high
radiochemical purity is of greater importance than if it is being used solely to obtain static
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images of the kidneys or to provide a measure of relative renal function.
"mTc-exametazime is a new radiopharmaceutical of low stability. To achieve the highest
possible radiochemical purity, its manufacturer specifies several criteria that must be
observed during preparation. One of these is to use "mTc-pertechnetate that has been
eluted from a generator not more than two hours previously. If "niTc-exametazime is
required in a nuclear medicine department that is some distance from the radiopharmacy, a
means of overcoming this requirement is necessary. A recent publication cast doubt on the
necessity for this two hour restriction and this claim required further investigation.
7.3 Recovery from the HPLC column
Throughout, I have emphasized that a valid measurement of radiochemical purity is only
possible if there is complete recovery of the sample from the HPLC column. When
incomplete recovery occurs due to an impurity in the radiopharmaceutical being
irreversibly adsorbed in the column, the impurity will remain undetected and a value for
radiochemical purity that is calculated using the data recorded from an on-line radiation
detector will therefore be erroneously high. Conversely, when incomplete recovery is a
consequence of a proportion of the "chemical form declared" being adsorbed, calculation of
the radiochemical purity will give an erroneously low value.
In the assay of non-radioactive compounds by HPLC, the problem of adsorption is
overcome by comparing the chromatogram obtained from a sample of the compound being
tested with one obtained from a pure reference sample of the compound. With this
technique, adsorption on the column of a proportion of the compound should not affect the
result since test and reference samples will undergo adsorption to the same extent. The
adsorption on the column of an impurity in the test compound is of no consequence since
the purity of the test substance is calculated from a comparison of the sizes of the peaks
obtained with the test and reference samples. For example, if solutions of a reference
compound and a test compound that contains an impurity which is retained on the column
are prepared at equal concentrations, the compound in the reference sample will produce a
larger peak than that in the test sample. The low purity of the test compound will therefore
be revealed although both chromatograms will contain only one peak. When dealing with
radiopharmaceuticals, there are no reference compounds available due to the inherent
instability of these substances - a consequence of their radioactive nature and, in the case of
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most "mTc radiopharmaceuticals, that they are formed by reduction and are therefore
susceptible to oxidation. An assay procedure similar to that used for non-radioactive
compounds cannot therefore be used.
Also in the analysis of non-radioactive compounds by HPLC, an internal standard is
commonly added to both unknown and reference samples. The internal standard is chosen
to give a peak on the chromatogram at a retention time that does not coincide with that of
the test substance or one of the impurities that might be present in the test mixture. The
size of the internal standard peak is then used to normalize any fluctuations in the size of
the peaks due to variations in volume of sample injected, changes in flow-rate, fluctuations
in detector sensitivity, etc. This strategy cannot easily be used in the analysis of
radiopharmaceuticals since, similar to reference compounds, pure radiolabeled compounds
that would be suitable for use as internal standards are not available. More significantly,
an internal standard is only of value if a reference substance is available.
In view of these limitations, successful analysis of "mTc radiopharmaceuticals by HPLC is
dependent upon complete recovery from the column. Several techniques can be used to
measure recovery. Mathis et al. (1986) have described a technique that involves placing a
length of the tubing that connects the injector to the column in the on-line radiation
detector. When the injection is made, the sample passes through the detector and counts
are recorded. The sample then passes along the column where it is separated into its
components which pass through the detector as they are eluted. The recovery is calculated
by expressing the counts detected from the eluted peaks as a percentage of the counts
recorded from the injection. Unless the lengths of tubing that constitute the inlet and outlet
detectors have identical volumes, a correction factor must be applied to account for the
difference. This technique has the attraction of the data for the recovery calculation being
acquired on-line but suffers from two main disadvantages. Firstly, the detector must be
constructed in a manner which ensures that the relative positions of the two pieces of tubing
in relation to the radiation detector are maintained. If this is not achieved, day-to-day
differences in the efficiencies of detection will be introduced due to movement of the
tubing, invalidating any correction factor that has been established. Alternatively, the
relationship between the two detectors would have to be re-established periodically. If the
tubing were particularly prone to movement, calibration would be necessary on each
occasion that the equipment is used. Secondly, a fairly long piece of tubing between the
injector and column is required if it is to be located in the same detector as the outlet
tubing. Conventionally, this tubing is kept as short as possible to minimize spreading of
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the sample as it travels to the column and the consequent reduction in resolution.
An extension of the above concept would be to have two detectors - one positioned over the
column inlet tubing and the other over the outlet tubing. This arrangement would not require
extension of the inlet tubing but each detector would require its own nucleonics and
recording system. Cross-calibration of the detectors would be necessary to account for
differences in detection efficiencies and the volumes of mobile phase being monitored.
Equipment of this type would offer the advantage of on-line data acquisition for the recovery
measurement. A disadvantage would be the cost since two detector systems and associated
nucleonics would be necessary. Also, the potential for fluctuations in the sensitivities of
the two systems, either due to movement of the pieces of tubing in relation to their
detectors or due to instability in the sets of nucleonics, would demand a rigorous
programme of cross-calibration.
A third technique that can be employed for the measurement of recovery is calibration of the
on-line radiation detector for the radionuclide that is present in the radiopharmaceutical.
This can be achieved with a standard solution of the radionuclide in a chemical form that
has been shown to be completely recovered from the chromatographic system. For "mTc
radiopharmaceuticals, this chemical form is likely to be the pertechnetate ion since this
chemical state of "mTc is unreactive and is therefore unlikely to form a complex with the
column packing material. In this technique, the standard and the radiopharmaceutical to be
analysed must be prepared at known radioactive concentrations. In practice, when
radiopharmaceuticals are typically prepared in rubber-capped vials and solutions are
manipulated by means of disposable hypodermic syringes, accurate measurement of
volumes cannot be guaranteed. An accurate measurement of radioactive concentration can
therefore be achieved more easily by weighing the vial before and after addition of the
liquid and expressing the radioactive concentration of the solution in MBq per gram. A
sample of the standard is then injected onto the column and the counts in the detected peak
are recorded. From the ratio of the radioactive concentrations of the radiopharmaceutical
and standard solution, the counts that should be in the chromatogram obtained from the
radiopharmaceutical are calculated. A sample of the radiopharmaceutical is then injected,
the chromatogram is acquired and the counts in the chromatogram are recorded. After
correction of the counts in the chromatogram for the radioactive decay that has occurred
since recording of the standard chromatogram, the recovery is calculated by expressing the
counts in the radiopharmaceutical chromatogram as a percentage of the counts that should
be in the chromatogram. As with the two described previously, this technique has the
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advantage that the data used to calculate recovery are acquired on-line in the course of the
analysis. However, the technique suffers from two principal disadvantages. The first is
that its validity depends on the standard being completely recovered from the column. It is
possible that species adsorbed on a column from previous samples of radiopharmaceuticals
might cause retention of the standard and invalidate the recovery measurement technique.
This is not unlikely with "mTc radiopharmaceuticals since a stannous containing species
adsorbed on the column from a previous analysis could reduce and thereby bring about
complexation and retention of "mTc-pertechnetate that was injected as a standard for a
subsequent analysis. The second disadvantage is that the times of measurement of
radioactive concentrations and injection of samples must be recorded since correction for
radioactive decay is necessary.
In view of the problems that exist with these techniques for measuring recovery, I opted for
what is probably the simplest technique of all. This involves collecting the eluate from the
column and comparing the count-rate from the eluate with the count-rate from an accurately
pipetted sample of the radiopharmaceutical being analysed. As discussed in Chapter 3, this
technique involves cross-calibration of the pipette and loop of the injector but unlike the
technique of passing the eluent and eluate through the same detector, the correction factor
established in the cross-calibration is less likely to change from day to day. Also, unlike the
techniques that depend upon on-line detection for measurement of recovery, the eluate
collection technique is not influenced by any changes in flow-rate that occur during the
analysis.
The consistently high recoveries in the analyses of 99mTc-MAG3 and "mTc-exametazime
indicate that this aspect of the use of HPLC to measure the radiochemical purity of these
radiopharmaceuticals is satisfactory.
The low recoveries encountered throughout the work on "mTc-DMSA demonstrate that the
chromatographic conditions evaluated for the analysis of this radiopharmaceutical are
unsatisfactory. During the studies on "mTc-DMSA, the quite unexpected phenomenon of
sample adsorption in the loop of the valve injector was identified as a potential cause of error
with this technique for measuring recovery. However, adsorption in the loop would
introduce an error in all of the recovery techniques described. In the case of the "mTc-
DMSA work, the washing of the adsorbed material onto the column by the mobile phase
resulted in an apparent recovery of greater than 100%. The impossibility of this situation
prompted the further investigation of the phenomenon. Had the adsorbed fraction not been
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washed onto the column, a recovery of less than 100% would have resulted. Without further
investigation this might have been attributed to an impurity in the radiopharmaceutical
being adsorbed on the column whereas it could be caused by adsorption of a proportion of
the "chemical form declared" in a satisfactory radiopharmaceutical, thereby giving a false
indication of low radiochemical purity. Column scanning would have shown the absence of
adsorbed "mTc on the column and would thereby have prompted an investigation of the
reason for low recovery.
7.4 Characterization of the species responsible for the principal peak
A potential limitation of using HPLC for the analysis of "mTc radiopharmaceuticals is the
difficulty, if not impossibility, in demonstrating that the main peak of the chromatogram
contains only the "chemical form declared". This problem is a consequence of the
extremely low mass of the radiolabeled species that is present in radiopharmaceuticals.
Although radiopharmaceutical kits typically contain milligram quantities of the compounds
to be labelled, only a small fraction becomes associated with "mTc. For example, the
Amersham Ceretec kit contains 500 fig of exametazime. From the structure of the "mTc-
exametazime complex it can be calculated the if the kit is reconstituted with the maximum
1.11 GBq of "mTc, only 20 ng of "mTc-exametazime is formed. This "mTc-exametazime
is contained in the reconstitution volume of 5 ml. A 20 fil sample that might typically be
injected onto an HPLC column therefore contains only 80 pg of radiolabelled compound.
With such a low mass of material being responsible for the peak on the chromatogram,
identification of the structure of the compound is difficult, if not impossible. Radiolabelled
impurities are likely to be present in considerably lower concentration than the
radiopharmaceutical species. Identification of their structures presents even greater
difficulties.
In the analysis of non-radioactive compounds, this problem is much less of a limitation.
Firstly, compounds tend to be present in much higher concentrations and techniques such as
the various forms of spectroscopy, x-ray crystallography and elemental analysis can be
used to determine structure. Secondly, if two species are responsible for a single peak on a
chromatogram obtained with an ultraviolet (UV) detector, it is unlikely that they will have
identical absorptive properties. Comparison of the peak with that from a standard of the
compound under test will show a discrepancy. The presence of two or more species that
co-elute from the column can also be demonstrated with a diode-array UV detector
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providing the species have sufficiently different absorption spectra. None of this is possible
with a radiation detector since the property being detected, i.e. the radiation that is emitted
by the radionuclide, is common to all the radiolabelled species present in the
radiopharmaceutical. Also, as discussed previously no standards are available against
which the radiopharmaceutical can be compared.
HPLC is not alone in suffering from the difficulty of demonstrating that the measurement
that is taken to represent the "chemical form declared", is due solely to that species. All
chromatographic techniques have this limitation. As discussed in Chapter 1, thin-layer and
paper chromatographic techniques in which the radiolabelled species either remain at the
origin or travel with the solvent front and gel filtration techniques in which the
radiolabelled species elute at either the void volume or total volume of the column are
particularly prone to producing misleading results due to an impurity exhibiting the same
behaviour as the species for which the analysis is being undertaken.
For the analysis of "mTc radiopharmaceuticals it is therefore necessary to rely upon the high
resolution of which F1PLC is capable and assume that impurities do not co-elute with the
principal species. It is important, however, to ensure that the principal species does not
elute with the retention time of an unretained solute. This situation is analogous to a
species that migrates with the solvent front in thin-layer and paper chromatography or
elutes at the void volume in gel filtration. More than one constituent of a
radiopharmaceutical can exhibit this behaviour. In an HPLC technique that is based on the
principal species behaving in this way, there is every likelihood that one or more impurities
will co-elute with the principal species. The technique will therefore lead to an over¬
estimate of radiochemical purity due to its lack of specificity. Early reports of the use of
HPLC for the analysis of "mTc radiopharmaceuticals are open to criticism on these grounds
(Russell & Majerik, 1979, Wong et al., 1981). For example, Wong et al. (1981) reported
that with their chromatographic system of an ODS column and phosphate buffer/acetonitrile
mobile phase, "mTc-methylene diphosphonate and "mTc-pertechnetate impurity eluted with
retention volumes of 2 ml and 3 ml respectively. From the dimensions quoted for the
column and the fact that two other radiopharmaceuticals ("mTc-DTPA and "mTc-
pyrophosphate) eluted with retention volumes of 2 ml, it is a reasonable assumption that
this represents the volume for an unretained solute. Many authors, e.g. Srivastava et al.
(1982), Hoch & Pinkerton (1986) and Huigen et al. (1988), have shown that "mTc-
methylene diphosphonate contains several radiolabelled species. The conditions used by
Wong et al. (1981) are incapable of resolving these species as they co-elute as unretained
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solutes. From these results, Wong et al. (1981) concluded that their HPLC conditions
offered "marginal utility" for these radiopharmaceuticals.
In none of the techniques that I used to measure radiochemical purity did the principal
species elute as an unretained species. The principal peaks obtained with 99mTc-MAG3 and
99mTc-exametazime were well separated from the other peaks in the chromatogram and the
assumption was made that these represented the "chemical form declared". In the case of
99mTc-DMSA, the principal species was retained on the column and the technique was of no
value for determination of radiochemical purity.
7.5 Comparison of HPLC with other chromatographic techniques
One of the ways in which I have validated HPLC as a satisfactory technique for measuring
the radiochemical purity of 99mTc radiopharmaceuticals is to compare the results with those
obtained using other chromatographic techniques. I have shown that measurement of the
radiochemical purity of 99mTc-exametazime gives results that are in good agreement with
those obtained using a combination of thin-layer and paper chromatography. From these
findings I have concluded that HPLC is a satisfactory technique for measuring the
radiochemical purity of this radiopharmaceutical. A parallel conclusion that could be
drawn from my results and which would be equally valid is that the thin-layer and paper
chromatography techniques are satisfactory for determining radiochemical purity. This
would be a valuable conclusion since these techniques are more easily performed, much
cheaper and therefore more widely used than HPLC. This situation demonstrates a
drawback of validating a chromatographic technique by comparing it to another
chromatographic technique - there is no certainty that either gives the correct result. It is
possible for an impurity to be present in a radiopharmaceutical and for that impurity to
behave in an identical manner to the radiopharmaceutical species in all chromatographic
systems. With this possibility in mind, the advantage of HPLC is its much higher
specificity and resolution than the other chromatographic techniques that are commonly
used for radiopharmaceuticals. HPLC therefore gives the best opportunity for the detection
of impurities that might be present in radiopharmaceuticals.
My work on 99mTc-MAG3 illustrates the above concept. The species (peak 6 on Figure
4.9) which elutes after the main peak behaves on the thin-layer and paper chromatography
systems in a manner similar to 99mTc-MAG . While all three techniques give similar,
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although statistically different, values of radiochemical purity when the level of this
impurity is small, they would not if the level were greater. In this situation, thin-layer and
paper chromatography would give erroneously high values of radiochemical purity. For
this radiopharmaceutical, therefore, comparison of HPLC with other chromatography
techniques has served to demonstrate its superiority due to its ability to separate the
impurities from the "chemicalform declared".
The samples of 99mTc-MAG3 and "mTc-exametazime that I used in my investigations were
predictable in terms of the impurities that were present. However, as I discussed in
Chapter 1, there have been many reports of problems with "mTc radiopharmaceuticals that
have been caused by seemingly innocuous factors. In the measurement of radiochemical
purity it is therefore important to detect all the impurities that are present. It should not be
a case of using a technique that detects only the predictable impurities but using a technique
that will detect any impurity that is present. HPLC should provide the best opportunity of
achieving this aim.
7.6 Summary
With reference to the objectives that I set in Chapter 1, the work described in this thesis
can be summarized as follows:
An on-line HPLC detector for use with "mTc radiopharmaceuticals has
been constructed and shown to function satisfactorily.
An HPLC technique has been developed and shown to be satisfactory for
measurement of the radiochemical purity of 99mTc-MAG3. The technique
has been used to demonstrate the stability of this radiopharmaceutical,
previously reported as being unstable, and to investigate effects of different
preparative conditions on radiochemical purity and stability.
No satisfactory technique for measurement of the radiochemical purity of
"mTc-DMSA has been established. However, several important facts
relevant to the routine preparation of this radiopharmaceutical have been
discovered: no evidence has been found to suggest that the levels of "Tc
encountered in routine radiopharmacy practice have a deleterious effect on
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the radiochemical purity of "mTc-DMSA; for the first time, 99mTc(V)-
DMSA has been shown to be a common impurity in 99mTc(III)-DMSA; the
"wet labelling" technique is unsatisfactory for the preparation of 99mTc-
DMSA; the concentration of 99mTc(V)-DMSA in 99mTc-DMSA is
influenced by the volume in which the DMSA kit is reconstituted.
An HPLC technique has been developed and shown to be satisfactory for
measurement of the radiochemical purity of 99mTc-exametazime. The
technique has been used to develop a routine method for using sodium
iodide kits to stabilize 99mTc-pertechnetate that is dispensed for the
preparation of 99mTc-exametazime and to confirm that the radiochemical
stability of 99mTc-exametazime is influenced by the age of the 99mTc-
pertechnetate used in its preparation.
The non-silica HPLC columns PLRP-S and PRP-1 have been found to be
of value in the analysis of 99mTc-DMSA and 99mTc-exametazime
respectively. Hypercarb has not been found to be of value although it was
only investigated for the analysis of 99mTc-DMSA.
In accordance with the aim set at the start of this work, quantitative HPLC has been shown
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Summary
A kit for preparing technetium-99m mercaptoacetyltriglycine ("Tcm-MAG3), a new radio¬
pharmaceutical for gamma camera renography, is available commercially. A drawback to the
use of this kit is the recommended lh expiry for "Tcm-MAG3. This short expiry is a
consequence of the possible growth of an impurity which undergoes hepatobiliary excretion
and might interfere with renal imaging.
Radiochemical purity of "Tcm-MAG3 was measured by high performance liquid chroma¬
tography at 0, 1 and 6 h after preparation and was found to be consistently > 95. "Tcm-MAG3
was shown to contain five impurities, one of which increased from 0.5% to 1% over 6 h.
Dilution of "Tcm-MAG3 eliminated this effect.
A two-part clinical study was undertaken. For Part I, "Tcm-MAG3 was prepared at 400 MBq/
4 ml. For Part II, "Tcm-MAG3 was prepared at 1 GBq/4 ml then subdivided and diluted to give
single doses of 175 MBq/2.5 ml. In both parts, 10 patients were injected within 1 h after
preparation and 10 were injected 5-6 h after preparation. From gamma camera images of the
abdomen acquired 30 min after injection, the % injected "Tcm in gall bladder and liver were
calculated. In both parts, the % injected 99Tcm in gall-bladders and livers of the 1 h group were
compared with those in the 5-6 h group and not found significantly different (p > 0.05).
In conclusion, "Tcm-MAG3 prepared according to the methods described, can be used up to
6 h after preparation.
Introduction
Technetium-99m mercaptoacetyltriglycine (99Tcm-MAG3) has been developed as a
radiopharmaceutical for gamma camera renography [1] and a number of publications
have shown it to be a suitable replacement for 123I- and 131I-iodohippurate and "Tcm-
DTPA in the investigation of renal function [2-6]. In response to those encouraging
results, a kit for the preparation of "Tcm-MAG3 has been developed (Mallinckrodt)
and is now commercially available. A severe drawback to the routine use of this kit is
0143-3636/90 $03.00+ .12 © 1990 Chapman and Hall Ltd.
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the manufacturer's recommended expiry of 1 h after preparation. The reason for this
short expiry time is the potential for the formation of radiochemical impurities in the
"Tcm-MAG3 with time. These impurities are excreted through the hepatobiliary
system and might therefore interfere with renal investigations because, in the
posterior view, the gall bladder can lie within the region of interest created for the
right kidney.
It was therefore decided to investigate the stability of the "Tcm-MAG3 prepared in
this department to determine the level of impurities, how these levels change with
time and the effect of the impurities on dynamic renal imaging in patients.
Materials and methods
Preparation of "Tc'"-MAG3
Preparation of "Tcm-MAG3 for Part I of this study was performed strictly according to the
manufacturer's instructions. Under aseptic conditions, sodium pertechnetate [99Tcm] injection
EP (> 400 MBq/ml) from a "Tcm generator (Amersham, Code MCC20) was diluted to 4 ml with
sodium chloride injection EP and injected into a MAG3 kit (Mallinckrodt, Code DRN 4334). The
vial was placed in a boiling water bath for 10 min then cooled in a water bath at room
temperature for 10 min.
For Part II of the study, the "Tcm-MAG3 was prepared as above but at a radioactive
concentration of 1 GBq/4 ml. Individual patient doses containing 175 MBq/2.5 ml were then
dispensed by withdrawing a 0.7 ml aliquot from the kit, diluting it to 2.5 ml with sodium
chloride injection EP and injecting the solution into a sterile 10 ml vial containing one nitrogen
atmosphere (Amersham, Code N46).
High performance liquid chromatography
The radiochemical purity of "Tcm-MAG3 was measured by high performance liquid
chromatography (HPLC) using a method provided by the manufacturer of the MAG3 kit
(Mallinckrodt, personal communication). The equipment consisted of a dual piston recriprocat-
ing pump, a loop-valve injector fitted with a 20 pi loop, a 250x5 mm 5 pm Hypersil ODS
column (Shandon) and a gamma radiation detector. The detector was constructed of 2 pi loop
of stainless steel tubing (0.25 mm internal diameter) positioned inside a well-type sodium
iodide detector coupled to a nucleonic counting system with outputs to both a chart recorder
and a digital printer. The column was eluted at 1 ml min~! with ethanol/0.01 M phosphate
buffer pH6 (5 : 95) for 10 min then methanol/water (90 : 10) for 10 min. The counts in each peak
were calculated from the output of the digital printer and expressed as a percentage of the total
counts detected. The recovery of "Tcm from the HPLC column was determined by collecting
the eluate and comparing its count-rate with the count-rate from a 20 pi sample of the
99Tcm-MAG3 under test. All preparations of "Tcm-MAG3 were stored at room temperature and
radiochemical purity was measured at 0, 1 and 6 h after labelling. Three lots of kits prepared at
400 MBq/4 ml according to the manufacturer's instructions and one lot prepared at 1 GBq/4 ml
followed by subdivision and dilution were each tested on five occasions.
Clinical study
Twenty patients attending for routine diuretic renography were studied in Part 1 of this trial in
which "Tcm-MAG3 prepared at 400 MBq/4 ml was used. Each patient was injected with
100 MBq "Tcm-MAG3. Ten patients were injected within 1 h after preparation of the
"Tcm-MAG3 while the other 10 were injected between 5 and 6 h after preparation. The routine
imaging study was performed, taking 30 min. Anterior and right lateral static images of the
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abdomen were then acquired in the gamma camera system's computer to access activity in the
liver and gall bladder. Urine was collected from six patients and analysed by HPLC to
determine the form in which the "Tcm is excreted. A venous blood sample was taken from each
patient for measurement of plasma creatinine.
In Part II of this trial, a further 20 patients were studied in an identical manner except that the
"Tcm-MAG3 prepared at 1 GBq/4 ml followed by subdivision and dilution was used.
Interpretation of computer images
The percentages of injected "Tcm in the gall bladder and liver at the end of the dynamic study
were calculated from the static images using the following technique. From the anterior image,
the depth of the gall bladder in the right lateral projection was measured. On the right lateral
image, four regions of interest (ROI) were created around a background area, the gall bladder,
the parts of the liver which did not overlap gall bladder or residual renal activity and the whole
liver. The counts and number of pixels in each of the first three ROIs, and the number of pixels
in the whole liver ROI were obtained. The counts in the gall bladder and liver ROIs were
corrected for background. The activity in the gall bladder was then calculated by comparing the
counts in the gall bladder ROI to the counts from a "Tcm source of known activity positioned at
a distance from the face of the gamma camera equal to the depth of the gall bladder. Knowing
the activity of "Tcm-MAG3 injected into the patient, the % injected "Tcm in the gall bladder at
the end of the study was calculated. The % injected "Tcm in the liver was measured in the same
way except that to estimate the counts in the whole liver, it was necessary to multiply the
counts in the part liver ROI by the ratio of the pixels in the whole liver ROI to the part liver
ROI.
Statistical analysis
Wilcoxon's nonparametric test for unpaired comparison was used for statistical analysis.
Values at p > 0.05 were considered to be not significant.
Results
A typical chromatogram of "Tcm-MAG3 is shown in Fig.l. The chromatogram shows
six peaks with four impurity peaks (1-4) appearing before the principal "Tcm-MAG3
0 4 8 12 16 20
Time (min)
Fig. 1. High performance liquid chromatogram of "Tcm-MAG3.
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Table 1. Results of the chromatographic analysis of "Tcm-MAG3 prepared at 400 MBq/4 ml.
Time
after % of the recovered activity in each peak % recovery
Lot preparation from
no. (h) 1 2 3 4 5 6 column
8056 0 0.2±0.2 0.3±0.1 0.6±0.5 0.8±0.1 95.2±0.7 2.9±0.8 100.0±3.2
1 0.3±0.3 0.3±0.2 0.5+0.4 1.2±0.1 94.4±1.2 3.3±0.9 96.3±3.4
6 0.3±0.1 0.3+0.1 0.9+0.6 1.6+0.2 94.2±0.7 2.7±0.7 99.0±3.8
8068 0 0.2±0.1 0.3±0.1 0.6±0.4 0.5+0.1 95.9±0.7 2.5±0.4 100.1±0.9
1 0.2±0.1 0.3+0.1 0.7±0.3 0.7+0.1 95.7±0.6 2.4±0.3 100.5+0.2
6 0.2+0.1 0.3±0.1 0.9±0.4 1.1±0.1 95.2±0.7 2.3±0.2 100.4+0.1
8073 0 0.2+0.1 0.2±0.1 0.4±0.2 0.5±0.1 96.5±0.3 2.2+0.2 100.7±1.1
1 0.2+0.1 0.2±0.0 0.5±0.2 0.7±0.1 96.4±0.2 2.0+0.1 100.8±1.7
6 0.2+0.1 0.3±0.1 0.5+0.2 1.2±0.2 96.0±0.4 1.8+0.3 100.1±4.7
Each value is the mean ± s.D. of 5 results.
peak (5) and then a further impurity peak (6) after the change of solvent. Peak 3 was
shown to have the same retention time as "Tcm-pertechnetate.
The results of the stability studies performed on the three lots of MAG3 kits
prepared according to the manufacturer's instructions are shown in Table 1. Of the
impurity peaks, the only one which changes significantly over the 6 h is peak 4 which
approximately doubles in each case. This increase in peak 4 is accompanied by a
corresponding decrease in the % activity in the main "Tcm-MAG3 peak (5). The other
impurity peaks remain constant throughout the 6 h. Table 1 also shows the recoveries
of "Tcm from the HPLC column. All recoveries are in excess of 95%.
The results of the stability study performed on the "Tcm-MAG3 prepared at
1 GBq/ml followed by subdivision and dilution are shown in Table 2. The results are
Table 2. Results of the chromatographic analysis of "Tcm-MAG3 prepared at 1 GBq/4 ml
followed by subdivision and dilution.
Time
after % of the recovered activity in each peak % recovery
Lot preparation from
no. (h) 1 2 3 4 5 6 column
8073 0 0.1±0.1 0.3±0.1 0.8+0.2 0.4+0.1 96.1±0.3 2.3±0.2 97.8±1.5
1 0.2±0.1 0.3±0.1 0.9±0.4 0.5+0.1 96.0±0.4 2.2±0.3 97.9+2.2
6 0.1±0.1 0.3±0.1 1.1+0.2 0.4±0.1 95.7+0.3 2.4±0.1 98.0±2.6
Each value is the mean ± s.D. of 5 results.
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Table 3. Results of the clinical study.
Time between preparation and injection
Part I - undiluted Part II - diluted
<lh 5-6 h <lh 5-6 h
No. of images showing
gall bladder 5 5 3 4
% injected "Tcm in median 0.1 0.1 0.0 0.0
gall bladder (range) (0.0-0.3) (0.0-0.5) (0.0-0.1) (0.0-0.4)
% injected "Tc m in median 4.8 4.4 4.7 4.0
liver (range) (3.1-12.9) (2.0-8.9) (1.4-12.3) (2.3-12.4)
creatinine median 90 106 97 95
(p.mol/1) (range) (66-529) (79-230) (63-290) (63-324)
No. of patients with 1 1 2 2
creatinine <150 p.mol/1
very similar to those shown in Table 1 for "Tcm-MAG3 prepared according to the
manufacturer's instructions. In this case, however, the % activity in peak 4 does not
double over the 6 h. The recoveries from the HPLC column are again very high.
The incidence of visualization of the gall bladder and the percentages of
administered activity in the gall bladder and liver 30 min after administration of
"Tcm-MAG3 are shown in Table 3. In both parts of the study, the differences in gall
bladder and liver activities in the < 1 h group and the 5—6 h group were found not to
be significant. Similarly, the differences between undiluted "Tcm-MAG3 adminis¬
tered within 1 h of preparation and diluted "Tcm-MAG3 administered 5-6 h after
preparation were not significant.
Table 4 shows the HPLC profile of the "Tcm in the urine of six patients along with
the profile of a preparation of "Tcm-MAG3 for comparison. The two profiles do not
differ markedly.
Table 4. Results of the chromatographic analysis of urine compared to a typical preparation
of "Tcm-MAG3.
% of the recovered activity in each peak % recovery
from
















Appendix II - Published papers
410 MILLARefa/.
Discussion
A compound labelled with "Tcm and with the biological characteristics of
o-iodohippurate has, for many years, been seen as the ideal radiopharmaceutical for
dynamic renal imaging. With this aim in mind, a number of compounds such as
"Tcm-DADS [7], "Tcm-C02DADS [8], "Tcm-thiodiglycolic acid [9] and "Tcm-PAHIDA
[10] have been developed but none have proved to be a suitable replacement for the o-
iodohippurates. The compound to be developed most recently is "Tcm-MAG3 which
shows great promise as a replacement for iodohippurate. A number of publications
have described comparisons between "Tcm-MAG3 and 123I- or 131I-iodohippurate and
there is agreement that it is a suitable replacement for the iodohippurates for routine
gamma camera renography [2-6] but not for the estimation of renal plasma flow [4].
As a result of these encouraging reports, a radiopharmaceutical kit has been
developed for the preparation of "Tcm-MAG3. A limiting factor in the routine use of
this kit is the short expiry of 1 h which the manufacturers recommend for the labelled
product. In central radiopharmacies from which nuclear medicine departments in a
number of hospitals are supplied, this short expiry is a major obstacle to the supply of
"Tcm-MAG3 since 1 h can represent the journey time between the radiopharmacy
and the nuclear medicine department. Even within one department, an expiry time of
1 h would allow only two studies to be performed from each MAG3 kit, making
"Tcm-MAG3 expensive in comparison to other "Tcm radiopharmaceuticals where
many more patient doses can be prepared from a single kit. It was therefore decided
to investigate the stability of "Tcm-MAG3 to see if under the conditions used to
prepare the radiopharmaceutical in this department, the expiry time could be
extended beyond the 1 h recommended.
The HPLC method used to measure the radiochemical purity of the "Tcm-MAG3
demonstrates the presence of six components in the radiopharmaceutical. The
identity of these components is not known but it is reasonable to assume that the
principal peak represents the active form of "Tcm-MAG3 while the others represent
impurities. In the context of this study, the identity of the compound in each peak is
not important since the aim is to look for changes in the composition of the
radiopharmaceutical with time, and from these findings, to determine what
represents a realistic expiry time for "Tcm-MAG3. Testing was performed immedi¬
ately after preparation of "Tcm-MAG3, at the manufacturer's recommended expiry
time of 1 h after preparation and at 6 h after preparation, this being a common expiry
for "Tcm radiopharmaceuticals.
In Part I of the study, when "Tcm-MAG3 was prepared according to the
manufacturer's instructions, only one of the impurities was seen to increase
significantly over a period of 6 h. This was from approximately 0.5% to 1.0% and
occurred in each of the three lots of kits tested. While the increase is statistically
significant, it is improbable that such a small change could be clinically significant.
The method used for the preparation of "Tcm-MAG3 in Part I does not lend itself to
routine practice in a radiopharmacy where it is necessary, in the interests of economy,
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to obtain a number of doses from each kit. In Part II of the study, a means by which
five individual patient doses are obtained from each MAG3 kit was investigated. To
permit an administered activity of 100 MBq per patient, it was decided that single
dose vials containing 175 MBq/2.5 ml would be the minimum which would allow
studies to be performed up to 3 h after preparation. This was achieved by preparing
the kit at a radioactive concentration of 1 GBq /4 ml and then dispensing 0.7 ml
aliquots, diluted with 1.8 ml saline, into empty vials. A greater volume of
reconstituted kit is required if the patient study is to be performed more than 3 h after
preparation of the "Tcm-MAG3. The radiochemical purity of the single doses of
"Tcm-MAG3 prepared in this way was very similar to that found in Part I except that
peak 4 did not double in size over the 6 h period. It would therefore seem that
diluting "Tcm-MAG3 has the effect of increasing its stability but further work is
required to substantiate this. Throughout the stability studies, recovery from the
HPLC column was very high showing that no impurities in the preparations were
irreversibly bound to the column packing and thereby escaped detection.
The stability studies have shown that "Tcm-MAG3 prepared under the conditions
described, appears to be stable for 6 h and this agrees with previously published data
[11]. To confirm that this stability is borne out in practice, a clinical study was
performed. Mallinckrodt's directions for the use of the MAG3 kit include the
statement 'Small amounts (1-2%) of "Tcm-labelled impurities will be formed during
the labelling process. As these impurities are accumulated in the liver and excreted to
the gall bladder they may influence the late phase (after 30 min) of a dynamic renal
study.' In the clinical study, the residual activities in the liver and gall bladder of
patients who had been injected with "Tcm-MAG3 within 1 h of preparation were
compared with those of patients injected 5-6 h after preparation. The technique used
to measure the percentage of injected "Tcm in the liver and gall bladder suffers from
several potential sources of inaccuracy: the measurement of gall bladder depth and
correction for attenuation; the assumption that the liver lies at the same depth as the
gall bladder; the fact that the liver is a large organ of varying thickness; the difficulty
of creating a ROI around the whole liver due to residual activity in the kidneys.
Despite these sources of potential error, the object of the study was to compare the
results from groups of patients. Although the results for the percentage of injected
"Tcm in the liver and gall bladder may not be accurate, they are comparable given that
all images were analysed by the same technique. To ensure that the results of these
clinical studies were not influenced by disparities in the renal function of the patients
in the various groups, the plasma creatinine level of each patient was measured. Table
3 shows that few patients had abnormal renal function as indicated by a plasma
creatinine of greater than 150 g.mol H and that these patients did not predominate in
any one group. The results of the clinical study confirm the findings of the in vitro
stability study in that when "Tcm-MAG3 is administered up to 6 h after preparation,
the incidence of gall bladder visualization and the degree to which "Tcm is
concentrated in the gall bladder and liver, are not increased significantly. Also, the
percentage of administered "Tcm which becomes localized in the gall bladder is very
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low and it is unlikely that it will affect the result of a renal investigation if it is included
in the ROI which is used to represent the right kidney.
Chromatographic analysis of urine from six patients in this study has shown that all
the impurities present in "Tcm-MAG3 are excreted by the kidneys. However, the
concentrations of impurities are lower in the urine than in the original injection (Table
4), showing that they are excreted less efficiently than "Tcm-MAG3.
In conclusion, this study has shown that "Tcm-MAG3, when prepared according to
the methods described in this paper, is stable for 6 h.
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Abstract. Technetium 99m mercaptoacetyltriglycine
(99mTc-MAG3) was prepared from a commercial kit by
various techniques to assess the effect of a number of
variables on radiochemical purity and stability. Its radio¬
chemical purity was determined by high performance
liquid chromatography at 0 and 6 h after preparation
and was found to be consistently >95%. It has been
demonstrated that the radiochemical purity of 99mTc-
MAG3 prepared according to the manufacturer's in¬
structions is not influenced by the volume of 99mTc gen-
eratur eluate used, agitation, the presence of air in the
reaction vial or the use of a 99mTc generator eluate with
a "Tc:"mTc ratio of 16:1. A modified method of prepa¬
ration in which the MAG3 kit is reconstituted with saline
before addition of "mTc-pertechnetate has been shown
to yield a satisfactory product and should help to mini¬
mise the radiation dose to the fingers of radiopharmacy
staff.
Key words: "mTc-MAG3 - Radiochemical purity - Sta¬
bility
Eur J Nucl Med (1990) 16:615-619
Introduction
Technetium 99m mercaptoacetyltriglycine (99mTc-
MAG3) has been developed as a new radiopharmaceuti¬
cal for use in gamma-camera renography (Fritzberg
et al. 1986) and a number of reports have shown it to
be efficacious in clinical practice (Taylor et al. 1987,
1988; Bubeck et al. 1988: Jafri et al. 1988; Al-Nahhas
et al. 1988). A radiopharmaceutical kit for the prepara¬
tion of 99mTc-MAG3 is available commercially and de¬
spite the manufacturer's recommended shelf-life of 1 h
for the labelled product, it has been shown that its radio-
Offprint requests to: A.M. Millar
chemical purity can remain satisfactory for at least 6 h
(Millar et al. 1990). While the instructions for reconsti¬
tuting the MAG3 kit specify a number of conditions
for the labelling procedure, they do not cover all vari¬
ables which might affect the quality of the labelled prod¬
uct. This study was therefore undertaken to determine
the effect of various parameters on the quality of "Tc-
MAG3 and to identify the optimal preparative condi¬
tions for high radiochemical purity and stability.
Materials and methods
Preparation of"mTc-MAG3. 99mTc-MAG3 was prepared from so¬
dium pertechnetate [99mTc] injection (Fission) E.P. from a 99mTc
generator (Amersham International pic. Bucks. UK) and MAG3
kits (Mallinckrodt Diagnostica BV. Petten. Netherlands) using the
following nine techniques. Techniques 1-7 were performed with
kits from the one lot of MAG3. After preparation, vials containing
99mTc-MAG3 were stored at room temperature.
1. 99mTc-pertechnetate (500 MBq/0.1 ml) from a generator
which had been eluted within the previous 24 h was diluted to
4 ml with sodium chloride injection E.P. and injected into a
MAG3 kit. The vial was placed in a boiling water bath for 10 min
and then cooled for 10 min.
2. As in (1) but using 99mTc-pertechnetate (500 MBq/1.0 mi).
3. As in (1) but using 99mTc-pertechnetate (500 MBq/< 1.0 ml).
A 0.7 ml aliquot of the labelled product was transferred to a 10-ml,
nitrogen-filled, sterile vial (Amersham. N46) and diluted to 2.5 ml
with sodium chloride injection E.P. Air (10 ml) was bubbled
through the solution and then the vial was placed on a rotating
axle mixer for 6 h.
4. As in (1) but using 99mTc-pertechnetate (500 MBq/ <1.0 ml)
diluted to 10 ml with sodium chloride injection E.P.
5. As in (4) but 10 ml air was bubbled through the solution
before the vial was placed in the boiling water bath.
6. As in (4) but the 99mTc-pertechnetate was from the first
eluate from a new 99mTc generator.
7. A MAG3 kit was reconstituted with 9.0-9.9 ml sodium chlo¬
ride injection E.P. 99mTc-pertechnctate (500 MBq/< 1.0 ml) was in-
© Springer-Verlag 1990
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jected into the vial to give a total volume of 10 ml. Heating and
cooling were performed as in (1).
8. As in (7) but using kits from five different lots of MAG3.
9. As in (8). A 1.0 ml aliquot of the labelled product was
transferred to a 10-ml. nitrogen-filled, sterile vial and diluted to
2.5 ml with sodium chloride injection E.P.
Analysis of "mTc-MAG3. The radiochemical purity of 99mTc-
MAG3 was measured by high-performance liquid chromatography
(HPLC) using a modification of a method provided by the manu¬
facturer of the MAG3 kit (Mallinckrodt, personal communication).
A loop-valve injector was used to inject a 20 pi sample of "mTc-
MAG3 onto a 250 x 5 mm 5-pm Hypersil ODS column (Shandon).
The radiation detector was constructed from a 2 pi loop of stainless
steel tubing (0.25 mm internal diameter) positioned inside a well-
type sodium iodide detector which was coupled to a nucleonic
counting system with outputs to a chart recorder and digital
printer. The column was eluted at 1 ml/min with ethanol/0.01 M
phosphate buffer pH 6 (5:95) for 10 min and then methanol/water
(90:10) for 10 min. The counts in each peak were calculated from
the output of the digital printer and expressed as a percentage
of the total counts detected. The recovery of "mTc from the HPLC
column was determined by collecting the eluate and comparing
its count rate with that from a 20 pi sample of the "mTc-MAG3
under test. Radiochemical purity was measured at 0 and 6 h after
labelling. "mTc-MAG3 prepared by each procedure was tested
on five occasions.
Results
A typical chromatogram is shown in Fig. 1 and demon¬
strates the presence of six components in a preparation
of "mTc-MAG3. Four peaks (1-4). corresponding to
hydrophilic impurities, appear before the main "mTc-
MAG3 peak (5). One peak (6), corresponding to a lipo¬
philic impurity, appears after the change of mobile
phase. Peak 3 was shown to have the same retention
time as pertechnetate Tc 99m.
The comparison of 99mTc-MAG3 prepared using 0.1
(technique 1) and 1.0 ml (technique 2) 99mTc generator
eluate is shown in Table 1. No difference in the percent-
Table 1. Results of high-performance liquid chromatographic analysis of "mTc-MAG3 prepared at 500 MBq/4 ml
Conditions Time after Percentage of the recovered activity in each peak Percentage
for preparation recovery
preparation (h) 1 2 3 4 5 6 from column
0.1 ml eluate 0 0.2 + 0.2 0.1 +0.1 0.3 + 0.1 0.6 + 0.1 96.4 + 0.4 2.4 + 0.5 99.0 +2.3
6 0.2±0.1 0.2 ±0.1 0.4±0.2 1.3 ±0.3 96.2±0.2 1.8 ± 0.2 99.6 ±2.3
1.0 ml eluate 0 0.1 +0.0 0.1 +0.1 0.2±0.1 0.6±0.1 96.7 ±0.3 2.3 + 0.2 101.5 ± 1.2
6 0.1 ±0.0 0.1 ±0.0 0.5±0.2 1.2 ±0.2 96.2 ±0.2 1.9 ± 0.1 101.5 ± 1.8
< 1.0 ml eluate plus dilution. 0 0.2 + 0.1 0.3 ±0.1 0.8 + 0.5 0.4 + 0.1 95.9 + 0.7 2.4 + 0.3 101.0 ± 2.9
air and agitation 6 0.1 ±0.1 0.3 ±0.1 1.0±0.5 0.5±0.2 95.8 ±0.9 2.3 ±0.3 100.6 ±2.4
MAG3, mercaptoacetyltriglycine
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Fig. 1. High performance liquid chromatogram of mercaptoacetyl¬
triglycine Tc 99m (99mTc-MAG3)
age of activity in each peak was observed. In both cases
the percentage of activity in peak 4 approximately dou¬
bled over the 6-h period. The increase in peak 4 was
accompanied by a corresponding decrease in peaks 5
and 6. Table 1 also shows the effect of diluting, aerating
and agitating 99mTc-MAG3 (technique 3). This treat¬
ment caused an increase in the percentage activity in
peak 3 but eliminated the doubling of peak 4 over the
6-h period.
All four techniques (4-7) used to prepare 99mTc-
MAG3 at a radioactive concentration of 500 MBq/10 ml
resulted in similar percentages of activity in each peak
(Table 2). As before, a doubling of peak 4 over the 6-h
period was observed.
Table 3 shows the comparison of undiluted (tech¬
nique 8) and diluted (technique 9) "mTc-MAG3 pre¬
pared from five lots of kits. As before, a doubling of
peak 4 in 6 h is seen in the undiluted material, while
this effect is eliminated in the diluted preparations.
In all experiments, the recovery of 99mTc from the
HPLC column was approximately 100%.
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Percentage of the recovered activity in each peak Percentage
recovery
from column1 2 3 4 5 6
< 1.0 ml eluate 0 0.1 ±0.1 0.1 ±0.0 0.1 ±0.0 0.5 + 0.1 96.4 + 0.5 2.8 ±0.4 99.0 ±3.0
6 0.1 ±0.0 0.1 ±0.1 0.3 ±0.0 0.9±0.1 96.2 ±0.5 2.5±0.2 99.9 ±3.1
Air before boiling 0 0.1 +0.0 0.1 ±0.1 0.1 ±0.1 0.4 + 0.1 96.8 + 0.5 2.5±0.4 99.8 + 3.5
6 0.0 ±0.0 0.1 ±0.1 0.2±0.1 0.9 ±0.1 96.3 ±0.4 2.5±0.3 99.3 ±2.1
Eluate from 0 0.3±0.1 0.1 ±0.0 0.1 ±0.1 0.3 + 0.1 96.9 ±0.1 2.3 ±0.2 100.1 ±1.3
new generator 6 0.1 ±0.0 0.1 ±0.0 0.2 ±0.1 0.8±0.1 96.7 ±0.3 2.1 ±0.2 99.2 ±0.6
Saline before 0 0.1 +0.0 0.1 +0.0 0.1 +0.0 0.3 + 0.0 97.3 + 0.1 2.1 ±0.1 98.6±3.3
99mTc-pertechnetate 6 0.0 ±0.0 0.0±0.1 0.2±0.1 0.8±0.1 96.8 ±0.2 2.1 ±0.1 101.9 ± 1.5
MAG3, mercaptoacetyltriglycine
Each value is the mean±SD of five results







Percentage of the recovered activity in each peak Percentage
recovery
from column1 2 3 4 5 6
Undiluted 0 0.1 +0.1 0.1+0.1 0.1 +0.1 0.3 + 0.1 97.5 ±0.3 1.9±0.2 96.8 + 2.2
6 0.1 ±0.1 0.1 ±0.1 0.2 + 0.1 0.8±0.1 97.1 ±0.5 1.7 ±0.4 98.0 ±1.2
Diluted 0 0.1 +0.0 0.2 + 0.1 0.1+0.0 0.3 + 0.1 97.5 ±0.4 1.8 + 0.4 98.4 ±1.7
6 0.1 +0.0 0.2±0.1 0.2±0.1 0.3±0.2 97.1 ±0.4 2.1 ±0.3 100.4± 1.3
MAG3, mercaptoacetyltriglycine
Each value is the mean ± SD of five Tesults
Discussion
"mTc-MAG3 is an important new radiopharmaceutical
for the assessment of renal function. Its preparation is
straightforward, using a radiopharmaceutical kit which
is available commercially. The manufacturers of this kit
specify certain conditions for the preparation of "mTc-
MAG3 but do not provide information on all the vari¬
ables which might affect its quality. This investigation
was therefore undertaken to establish how factors such
as the presence of air, concentration of "Tc and volume
of generator eluate influence the radiochemical purity
of 99mTc-MAG3.
The instructions for preparing 99mTc-MAG3 specify
that the kit should be reconstituted with 4 ml pertechne-
tate solution, 0.1-1.0 ml of which is 99mTc generator
eluate. It could be assumed, therefore, that if more than
1.0 ml generator eluate is used, an inferior quality prod¬
uct is obtained. Conversely, it might be that the smaller
the volume of eluate used, the superior the product ob¬
tained. 99mTc-MAG3 prepared using the volumes of
eluate at either end of the recommended range (tech¬
niques 1 and 2) were compared to determine whether
the lower volume resulted in a product with a higher
radiochemical purity. This was not shown to be so.
Within the recommended range of eluate volumes,
"mTc-MAG3 of consistent radiochemical purity was
obtained.
In radiopharmacies which supply a number of nucle¬
ar medicine departments, a policy of preparing individ¬
ual patient doses of radiopharmaceuticals is often
adopted. Subdividing kits of 99mTc radiopharmaceuti¬
cals after preparation is therefore a common practice.
This process of subdivision can be accompanied by dilu¬
tion, during which air can be introduced into the vial.
In some situations, the individual patient doses are trans¬
ported some considerable distance to the nuclear medi¬
cine department. During transport, the radiopharmaceu¬
ticals are invariably subjected to agitation. The effect
of dilution, aeration and agitation of 99mTc-MAG3 was
therefore studied (technique 3). The percentage of activi¬
ty in peak 3 approximately doubled following this treat¬
ment and since peak 3 was found to have the same reten¬
tion time as 99mTc-pertechnetate. this would be consis¬
tent with an increased pertechnetate content caused by
oxidation. Despite this increased level of impurity, the
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radiochemical purity remained satisfactory at greater
than 95%. Unlike the previous experiment, the percent¬
age activity in peak 4 did not double over the 6 h of
the study. This agrees with our previous findings (Millar
et al. 1990).
At this point in the study, the manufacturer of the
MAG3 kit issued new recommendations for preparing
99mTc-MAG3. The total volume of pertechnetate solu¬
tion to be added to the kit was increased from 4 ml
to 10 ml, up to 3 ml of which could be "mTc generator
eluate. Under these revised conditions, the manufactur¬
er's recommended shelf-life for the labelled product was
increased from 1 h to 4 h. The effect of this revised pro¬
cedure was investigated (technique 4), but the volume
of 99mTc generator eluate was maintained at < 1 ml as
in the previous experiments. The radiochemical purity
and stability of the "mTc-MAG3 prepared by this tech¬
nique was comparable to that observed in the previous
experiments.
In an earlier experiment, the effect of bubbling air
through the labelled product was investigated. It was
therefore decided also to study the effect of introducing
air before the boiling step of the labelling procedure
(technique 5) since it is conceivable that this could occur
during the routine preparation of 99nlTc-MAG3. It was
found, however, that this did not affect radiochemical
purity.
On certain days of the week, principally Mondays,
it is not possible to avoid preparing 99mTc radiopharma¬
ceuticals with 99mTc-pertechnetate obtained from a gen¬
erator which has remained uneluted for a few days.
Under these conditions, the level of "Tc in the eluate
becomes high, and it is theoretically possible that this
can be deleterious to the quality of radiopharmaceuticals
prepared from it. The effect of 99Tc was therefore inves¬
tigated by preparing "mTc-MAG3 using the first eluate
from a new 99mTc generator (technique 6). From the
time between the last separation of Mo and Tc per¬
formed by the generator manufacturer and the time of
the first elution it has been possible to calculate the ratio
of "Tc: 99mTc as 16 (Bauer and Pabst 1982). With this
excess of "Tc in the generator eluate no effect was ob¬
served on the radiochemical purity of the 99mTc-MAG3
prepared from it.
During the preparation of 99mTc-MAG3 according
to the manufacturer's revised instructions, the withdraw¬
al of 99mTc-pertechnetate (500 MBq/lOml) into a syr¬
inge followed by the injection of the solution into the
MAG3 kit is a slow process which will result in a radia¬
tion dose to the fingers of the radiopharmacy staff. In
an attempt to minimise handling of the 99raTc. a tech¬
nique in which the contents of the MAG3 kit are dis¬
solved in saline and then the 99mTc-pertechnetate is add¬
ed in a volume of less than 1 ml was investigated (tech¬
nique 7). In this technique, the small volume of 99raTc-
pertechnetate can be transferred quickly to the kit. thus
minimising handling time and therefore finger dose. The
radiochemical purity of the 99mTc-MAG3 prepared by
this modified technique was comparable to that obtained
with the manufacturer's recommended technique. This
modified technique should therefore help to limit finger
radiation dose during the preparation of 99mTc-MAG3.
Clinical experience with "mTc-MAG3 supplied from
this radiopharmacy has shown that adequate renogram
curves can be obtained with 20 MBq. The feasibility of
dispensing 10 x 50 MBq doses from each MAG3 kit was
therefore investigated. 99mTc-MAG3 was prepared as
500 MBq/10 ml (technique 8), and 1.0 ml aliquots were
diluted to give individual patient doses of 50 MBq/
2.5 ml (technique 9). The radiochemical purities of the
undiluted and diluted 99mTc-MAG3 solutions were com¬
pared and found to be very similar. As had been ob¬
served in previous experiments, the undiluted material
showed a doubling of the impurity in peak 4 over 6 h
while the diluted material did not.
When analysing radiopharmaceuticals by HPLC.
some of the radionuclide injected into the chromato-
graph may become irreversibly bound to the column
packing. This adsorbed radionuclide does not appear
as a peak on the chromatogram and therefore remains
undetected. If this undetected material is an impurity,
then a falsely high result for radiochemical purity is ob¬
tained. It is important therefore to measure the recovery
of the radionuclide from the HPLC column. In all parts
of this study the recovery from the HPLC column was
approximately 100%, showing that there are no major
impurities in 99mTc-MAG3 which remain undetected.
In conclusion, this study has demonstrated the fol¬
lowing. The radiochemical purity of "mTc-MAG3 pre¬
pared according to the manufacturer's instructions is not
influenced by the volume of 99mTc generator eluate. agi¬
tation, the presence of air in the reaction vial or the
use of a 99mTc generator eluate with a "Tc:99mTc ratio
of 16:1. A modified method for reconstituting the
MAG3 kit reduces handling of the 99mTc during prepa¬
ration of 99mTc-MAG3 and should therefore help to
minimise the radiation dose to the fingers of radiophar¬
macy staff.
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Summary
When preparing Tcm-exametazime, it is important to use sodium Tcm-pertechnetate that is less than
2 h old. The addition of sodium iodide (Nal) to "Tcm-pertechnetate is known to extend this time to 6 h.
This paper describes a technique for implementing this in routine practice. Sterile kits consisting of
440 Pg Nal and 1.0 ml sodium chloride injection in a vial with a nitrogen atmosphere were prepared and
stored at room temperature, 4°C and -22°C. Titrimetric analysis of iodide showed that under each
storage condition, kits were stable for 8 weeks. To determine the effectiveness of the kits, the radio¬
chemical purity (RCP) of "Tcm-exametazime was measured by high-performance liquid chromatography
(HPLC). The validity of this technique was determined by simultaneous analysis with the conventional
thin-layer/paper chromatography (TLC/PC) technique on 24 occasions, over a range of RCP
(94.5-54.6%). Radiochemical purities measured by HPLC and TLOPC were 81.2 ± 10.2 and
81.5 ± 10.5%, respectively, and did not differ significantly (P>0.30). The correlation between the
techniques was high (r=0.98). "Tcm-exametazime was prepared using 1 h-old "Tcm-pertechnetate,
6 h-old Tcm-pertechnetate and 6 h-old "Tcm-pertechnetate dispensed in a Nal kit. At the recom¬
mended expiry time for this radiopharmaceutical, i.e. 30 min after preparation, RCPs were found to be
88.4 ± 2.4, 80.9 ± 2.0 and 89.3 ± 3.0%, respectively (n=5 for each technique). At this time, the RCPs of
the products prepared from 1 h-old Tc^-pertechnetate and 6 h-old Tcm-pertechnetate were
significantly different (P<0.01) while the RCPs of the products prepared from 1 h-old 99Tcm-pertech-
netate and 6 h-old Tcm-pertechnetate + Nal did not differ significantly (P>0.50). In conclusion, the use
of a Nal kit is a satisfactory means of increasing the stability of "Tcm-pertechnetate that is to be used in





"Tcm-exametazime is a radiopharmaceutical that is used
for brain imaging [1] and radioiabelling of leucocytes [2],
It is prepared using a commercially available freeze-
dried kit. A major limitation in the use of this kit is its
expiry time of 30 min after reconstitution. A consequence
of this short expiry is that the "Tcm-exametazime must
be prepared immediately before it is to be used. This
may mean that reconstitution of the kit cannot be
undertaken in the radiopharmacy but must be carried
out in the department in which the 99Tcm-exametazime
is to be used. The manufacturer also recommends that
the kit is reconstituted with sodium pertechnetate
[99Tcm] injection BP (99Tcm-pertechnetate) obtained from
a generator eluate that is less than 2 h old. This can
represent a logistical problem if the nuclear medicine
department is in a different institution to the radio-
pharmacy or if the "Tcm-exametazime is to be adminis¬
tered more than 2 h after the time at which the "Tcm
generator is eluted routinely. Bayne et al. [3] have
reported that the addition of sodium iodide to the
generator eluate overcomes this problem and extends
the shelf-life of "Tcm-pertechnetate from 2 to 6 h. This
paper describes a method by which this procedure can
be introduced into routine use.
Materials and methods
Preparation of sodium iodide kits
Sodium iodide BP (Thornton Ross) was dissolved in
sodium chloride injection BP to give a solution of
0143-3636/92 $03.00+ .12 © 1992 Chapman and Hall Ltd.
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concentration 440 p.g ml-1. Sodium iodide kits were
prepared by filtering 1.0 ml aliquots of this solution
through a sterile 220 nm filter into weighed, sterile
10 ml nitrogen-filled vials (Code N46, Amersham Inter¬
national pic). The 220 nm filter was primed with sodium
iodide solution before use to avoid adsorption and dead
space problems. Each vial was reweighed and the
weight of solution calculated. From these weights, the
sodium iodide content of each kit was calculated. Five
batches of kits were prepared. From each batch, 10 vials
were stored at room temperature, 10 in a refrigerator at
4°C and 10 in a freezer at -22°C.
Assay of iodide content of kits
At 0, 1, 2, 4 and 8 weeks after preparation, the contents
of two kits that had been kept under each storage
condition were assayed bv the following technique to
determine iodide content. This technique is a miniaturiz¬
ation of the British Pharmacopoeia (BP) assay for
sodium iodide [4]. One vial from each pair was
centrifuged to bring all the solution to the bottom of the
vial. The rubber cap was removed from the vial.
Hydrochloric acid, 1.2 ml, was pipetted into the vial
which was then reweighed. Approximately 0.1 ml 3 mM
potassium iodate solution was added to the vial to
develop a yellow colour and the vial was reweighed.
Amaranth solution (1/100 strength), 0.1 ml, was added
to the vial which was reweighed. Potassium iodate
solution, 3 mM, was added until the colour of the
solution changed from pink to pale yellow. The vial was
reweighed. From the total weight of 3 mM potassium
iodate solution added, the iodide content of the vial was
calculated (each ml of 3 mM potassium iodate is equivalent
to 899 pg of sodium iodide). One drop of starch
mucilage BP was injected into the other vial of the pair.
A blue colour developed if >1% of the iodine was
present in the form of I2.
Preparation of "Tc"'-exametazime
wTcm-pertechnetate solutions for use in the preparation
of "Tcm-exametazime were obtained from a "Tcm
generator (Code MCC20, Amersham International pic)
that had been eluted within the previous 24 h and were
dispensed immediately after elution of the generator.
99Tcr"-exametazime injections were prepared by injecting
5 ml of one of the following solutions into a Ceretec kit
(Code N109, Amersham International pic):
l.l/i "Tc"'-pertechnetate: "Tcm generator eluate was
diluted to a radioactive concentration of 1.3 GBq per
5.5 ml, injected into a sterile 10 ml nitrogen-filled vial
and used 1 h later.
2. 6 h "Tc"'-pertechnetate-. As in 1, but at a radioactive
concentration of 2.6 GBq per 5.5 ml and used 6 h later
bv which time the radioactive concentration had fallen
to 1.3 GBq per 5.5 ml.
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3. 6 h "Tc'"-pertechnetate + Nal: "Tc"1 generator eluate
was diluted to a radioactive concentration of 2.6 GBq
per 5.5 ml in a sodium iodide kit and used 6 h later by
which time the radioactive concentration had fallen to
1.3 GBq per 5.5 ml.
Five "Tcn'-exametazime injections were prepared by
each of the three techniques. "Tcm-exametazime injec¬
tions were stored at room temperature.
Analysis of "Tc'"-exametazime
The radiochemical purity of each "Tcm-exametazirne
injection was measured at 2, 30, 60 and 120 min after
preparation. Radiochemical purity was measured by
high-performance liquid chromatography (HPLC) using
a modification of the method of Neirinckx ct al. [1]. A
loop-valve injector was used to inject a 20 p.1 sample of
"Tcm-exametazirne onto a 150 x 4.6 mm 10 |xm PRP-1
column (Hamilton) which was fitted with a 25 x 3 mm
PRP-1 guard column. The radiation detector was con¬
structed from a 40 mm length of stainless steel column
outlet tubing (0.25 mm internal diameter) placed across
the face of a sodium iodide scintillation detector. The
output from the detector was taken to a Specmate
preamplifier/amplifier (Canberra Nuclear Data) and
from there to an Accuspec PC-based multichannel
analyser (Canberra Nuclear Data) which was operated
in multichannel scaling mode. The column was eluted
with 20 mM phosphate buffer, pH 7.4. A linear gradient
of 0-25% tetrahvdrofuran over 6 min was started when
the sample was injected. The chromatogram was acquired
in the multichannel analyser. A region of interest was
placed around each peak on the chromatogram and the
counts in each region were recorded. The radiochemical
purity was calculated by expressing the counts in the
peak corresponding to the primary 99Tcm-exametazime
complex as a percentage of the total counts in the
chromatogram.
The recovery of "Tcm from the HPLC column was
determined by collecting the eluate and comparing its
count rate with that from a 20 p.1 sample of the "Tcm-
exametazime being tested.
To validate the HPLC technique as a satisfactory
method for determining radiochemical purity, the first
two samples of "Tcm-exametazime prepared from each
of the three solutions of 99Tcm-pertechnetate were
analysed by HPLC and the standard three-system thin-
layer/paper chromatography (TLC/PC) technique re¬
commended by Amersham [1,5].
Results
For each storage condition, the iodide content of the kits
remained >96% throughout the 8 weeks of the study.
No kit was found to contain >1% of the iodine in the
Nuclear Medicine Communications (1992) 13
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counts per second Table 1. The effect of three preparations of "Tcm-pertechnetate
on the radiochemical purity of wTcm-exarnetazime.
Time after Radiochemical puriti/ (%)
750 - preparation
(mitt) 1 h "Tc"' 6 It *»Tr"• 6 h *>Tc'" + Nal
500 - 1 2 92.6 ± 1.3 93.2 ± 1.7 93.1 ± 2.0
30 88.4 ± 2.4 80.9 ± 2.0 89.3 ± 3.0
60 83.2 ± 4.1 70.7 ± 3.2 86.1 ± 4.6
120 74.7 ± 5.0 56.5 ± 4.0 81.2 ± 6.4
250 -
Each value is the mean ± s.D. of five results.
lime (mini
Fig. 1. High-performance liquid chromatogram of u"Tcm-
exametazime.
form of Is. A typical chromatogram of Tcrn-exametazime
is shown in Fig. 1. The chromatogram contains four
major peaks. Peaks 1, 2 and 4 correspond to "Tc"1-
pertechnetate, secondary °Tcm-exametazime complex
and primary U9Tcm-exarnetazime complex, respectively.
The identity of peak 3 remains unknown. Peak 3 was
found to contain approximately 3.5% of the total activity
and this remained unchanged over the 2 h of the study.
The activities in peaks 1 and 2 increased with time.
For the six preparations of Tcm-exarnetazirne analysed
by both techniques, the mean ±standard deviation
radiochemical purity determined bv TLC/PC was 81.5 ±
10.5% and by HPLC was 81.2 ± 10.2%. When compared
using a paired Student's f-test, these results were not
found to be significantly different (P>0.30). The excellent
correlation (r=0.98) between the two techniques is
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Fig. 2. Relationship between the radiochemical purity of
wTcm-exametazime as measured bv HPLC and TLC/PC.
min after preparation
Fig. 3. Increase in the levels of secondary wTcm-exametazime
complex and U9Tcm-pertechnetate impurities in gtTcrn-
exametazime.
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of "Tcm from the HPLC column for the 60 analyses
performed was 99.8 ± 2.0%.
The effects of the three "Tcrn-pertechnetate solutions
on the radiochemical puritv of 99Tcm-exametazime are
shown in Table 1. Using Amersham's specification of
80% being the lowest satisfactory radiochemical purity,
"Tcrn-exametazime prepared with 1 h-old or 6 h-old
"Tcm-pertechnetate containing sodium iodide was satis¬
factory up to 1 h after preparation. The mean radio¬
chemical purity of "Tcn,-exametazime prepared with
6 h-old "Tcm-pertechnetate reached the 80% limit 30 min
after preparation with two of the five results being
<80%. Statistical analysis of the 30 min results using
Dunnet's test for the comparison of group means to a
control group mean [6], demonstrated that the radio¬
chemical purities of the products prepared with 1 h-old
"Tcm-pertechnetate and 6 h-old "Tcm-pertechnetate were
significantly different (P<0.01), but that the radiochemi¬
cal purities of the products prepared with 1 h-old "Tcm-
pertechnetate and 6 h-old Tcm-pertechnetate containing
sodium iodide did not differ significantly (P>0.50).
Figure 3 shows the changes in the levels of "Tcm-
pertechnetate and secondary "Tcm-exametazime im¬
purities with time. With each method of preparation,
the increase in the level of secondary "Tcm-exarnetazime
complex is similar, rising to approximately 10% after
2 h. The level of the "Tcm-pertechnetate impurity
increases much more rapidlv in the "Tcm-exametazime
prepared from the 6 h-old "Tcm-pertechnetate than in
the other two.
Discussion
99Tcm-exametazime is an important new radiopharma¬
ceutical which unfortunately suffers from instability.
After preparation, the primary "Tcm-exametazime com¬
plex, which is the active radiopharmaceutical, converts
slowly to an inactive secondary complex and undergoes
breakdown to release "Tcm in the form of "Tcm-
pertechnetate [1], To minimize this breakdown, stringent
conditions are specified for the preparation of Tc"1-
exametazime: the kit must be reconstituted with "Tcm
which was eluted less than 2 h previously; the generator
from which the "Tcm is obtained must have been eluted
within the previous 24 h; the "Tcm-exametazime must
be used within 30 min of reconstitution of the kit.
Complying with the requirement that the "Tcm must be
obtained from a generator which has been eluted within
the previous 24 h should not be a problem since, in
most radiopharmacies, ^Tc"1 generators are eluted at
least once daily. It is necessary, however, to avoid the
use of "Tcm from the first elution of a newly delivered
generator or from a generator eluted on a Monday
morning if it has lain uneluted over the weekend. The
requirement that the "Tcm-exametazime must be used
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within 30 min of preparation can be achieved by
reconstituting the kit immediately prior to use. This may
mean that a vial of sodium pertechnetate ["Tcm]
injection and an exametazime kit are issued from the
radiopharmacv rather than the labelled product and that
reconstitution is performed in the department in which
the "Tcm-exametazime is to be used. The requirement
that the "Tc^-pertechnetate used to prepare "Tcm-
exametazime must be less than 2 h old is much more
difficult to accommodate. It can be inconvenient if the
"Tcm-exametazime is to be used more than 2 h after a
routine radiopharmacy dispensing session since an ad¬
ditional generator elution will be required. This may
reduce the generator yield at the following dispensing
session. Meeting the 2 h criterion may be impossible if
radiopharmaceuticals are supplied from a central radio-
pharmacy distant from the department in which the
exametazime kit is to be reconstituted and used. Bayne
et al. [3] have shown that the 2 h restriction can be
extended to at least 6 h by the addition of sodium iodide
to "Tcm-pertechnetate that is to be used for preparation
of "Tcm-exametazime but have not described a tech¬
nique by which this finding can be put into routine
radiopharmacy practice.
As a convenient means of using this stabilization
technique routinely, it was decided to investigate a kit
approach by preparing batches of vials containing
sodium iodide. Ideally these kits of sodium iodide
would be stable for several weeks and on each occasion
that 99Tcm-pertechnetate was required for the preparation
of "Tcrn-exametazime, it would be dispensed into a kit
within 30 min of generator elution.
Most commercially manufactured radiopharmaceutical
kits are formulated as freeze-dried products. Since
freeze-drying is not a technique available to most
hospital radiopharmacies, it was decided to investigate
the suitability of a kit containing a solution of sodium
iodide. Bayne et al. [3] demonstrated that 400 jig sodium
iodide was adequate for stabilization of the maximum
activity (1.11 GBq) of "Tcm recommended for the
reconstitution of an exametazime kit. It was therefore
decided to prepare kits containing 440 |xg sodium iodide
in 1.0 ml sodium chloride injection BP. The principle
behind this technique is as follows. "Tcm generator
eluate, diluted to have a radioactive concentration of
1.2 GBq per 4.5 ml at the time when the exametazime
kit will be reconstituted, is injected into a sodium iodide
kit. The kit then contains 1.2 GBq "Tcm and 440 jig
sodium iodide in 5.5 ml. Amersham International re¬
commend that their exametazime kit is reconstituted to
a volume of 5 ml. Using 5 ml of the "Tcm sodium iodide
solution prepared as described above results in the
exametazime kit being reconstituted with 1.1 GBq "Tcm
containing 400 pg sodium iodide.
Aqueous solutions of sodium iodide gradually become
Nuclear Medicine Communications (1992) 13
174
Appendix II - Published papers
310
coloured on exposure to light and air due to the libera¬
tion of iodine [7], Vials containing a nitrogen atmos¬
phere were therefore used in the preparation of the
sodium iodide kits which were then stored in the dark.
Sodium chloride injection BP which has a slightly acidic
pH is not the ideal solvent for sodium iodide which is
most stable under the slightly alkaline conditions of
pH S-9.5 [8]. However, pH adjustment of the solution
used to prepare the sodium iodide kits was considered
inadvisable since pH is known to be important in the
labelling of exametazime. Reconstitution with a pH-
adjusted solution might therefore upset the labelling
reaction and result in low radiochemical purity. In view
of these potential problems, the first step in determining
the feasibility of the sodium iodide kit concept was to
measure the stability of the kits and determine if it is
influenced by the conditions under which they are
stored. To measure stability, a modification of the 1968
BP method for determination of the iodide content of
sodium iodide was used. The modification was necessary
due to the small volume of solution in each kit and the
small amount of sodium iodide present. The 1968
method was preferred to the methods introduced in
more recent editions of the BP since it was more readilv
miniaturized. The analytical technique depends upon
hydrochloric acid converting iodide to iodine which is
then titrated with potassium iodate solution. The level
of iodine present in the kit as a result of degradation of
iodide would not therefore be revealed by this titrimetric
analysis. A separate test for iodine was therefore
performed. Regardless of whether the kits were stored
at room temperature, in a refrigerator or in a freezer,
they were shown to be stable for 8 weeks. Since the kits
are prepared by an aseptic technique, which alwavs
carries a risk of bacterial contamination, it was decided
to store the kits in a refrigerator since this is convenient
and will inhibit the growth of any contamination
introduced during preparation. It was also decided to
err on the side of safetv and give the kits an expiry time
of 4 weeks.
Having established the stability of the sodium iodide
kits, a set of experiments was performed to demonstrate
their effectiveness at prolonging the shelf-life of "Tc"1-
pertechnetate used for the preparation of 9Tcrn-examet-
azime. To do this, it was necessary to measure the
radiochemical purity of "Tcm-exametazime. This was
performed by HPLC rather than the more conventional
TLC'PC technique recommended by Amersham Inter¬
national. High-performance liquid chromatography was
chosen for a number of reasons. A measurement onlv
takes 12 min compared to the 60 min required for TLC/
PC. For a radiopharmaceutical with a shelf-life of onlv
30 min, an analytical technique which takes 60 min to
perform seems inappropriate. High-performance liquid
chromatography is also a specific technique in that it
Nuclear Medicine Communications (1992) 13
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displays a peak for the primary 99Tcm-exametazime
complex. In contrast, the TLC/PC technique is non¬
specific in that it relies on measuring the levels of
impurities in the radiopharmaceutical and assuming
that the remainder of the product is primary complex.
To compare HPLC with TLC/PC, radiochemical purity
in the first six experiments was determined by both
techniques. Figure 2 shows that the correlation between
the techniques is excellent (r=0.98) and the results
obtained were not found to differ significantly. The
excellent recovery of "Tcm from the HPLC column
demonstrates that no significant radiochemical impurities
in "Tcm-exametazime become adsorbed onto the column
packing material and remain undetected. Therefore,
HPLC was considered to be a suitable technique for
determining the radiochemical puritv of "Tcm-examet-
azime.
Having assigned a 4-week expiry to the sodium iodide
kits, it was decided that the most challenging test of
their effect on the radiochemical purity of "Tcm-
exametazime would be to use them 4 weeks after
preparation. In the comparison of the 99Tcn,-exametazime
prepared using the three "Tcm-pertechnetate solutions,
the radiochemical purities of the products prepared
using the 1 h-old 9Tcrn-pertechnetate and the 6 h-old
"Tc'"-pertechnetate with sodium iodide were similar
over the 2 h of the studv and remained satisfactory, i.e.
higher than the 80% limit, up to 1 h after preparation.
In contrast, the radiochemical purities of two preparations
of 99Tcm-exametazime prepared with 6 h-old "Tcm-
pertechnetate were <80% within 30 min. These results
demonstrate the effectiveness of the sodium iodide
kits in prolonging the shelf-life of "Tcm-pertechnetate
which is to be used in the preparation of "Tcm-exameta-
zime.
The results shown in Fig. 3 demonstrate that the rise
in the level of secondary "Tcnl-exametazime complex is
similar in all three preparations and that free "Tc"1-
pertechnetate is the impurity responsible for the rapid
tall in the radiochemical puntv of the "Tcm-exametazime
prepared from 6 h-old "Tcm-pertechnetate.
In conclusion, the sodium iodide kits described in this
paper are suitable for use in routine radiopharmacv
practice as a means of extending the shelf-life of "Tcm-
pertechnetate which is to be used in the preparation of
gTcm-exametazime.
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Effect of source and age of sodium pertechnetate




cal purities of technetium Tc
99m exametazime prepared
with one-hour-old or six-
hour-old sodium pertechne¬
tate Tc 99m from two
manufacturers' generators
were compared.
Eluates from each manu¬
facturer's generators were di¬
luted immediately to provide
two solutions of sodium per¬
technetate Tc 99m. For the
one-hour-old solution, eluate
was diluted with 0.9% sodi¬
um chloride injection to a
concentration of radioactivi¬
ty of 38 mCi in 5.5 mL and
used one hour later. For the
six-hour-old solution, eiuate
was diluted to 65 mCi in 5.5
mL and used six hours later.
Technetium Tc 99m exameta¬
zime was prepared by inject¬
ing 5.0 mL of one of the
solutions into an exameta¬
zime kit to provide 30 mCi of
technetium Tc 99m in 5.0
mL. At 2, 30, and 60 minutes
after reconstitution of each
kit, the radiochemical purity
was measured by high-perfor¬
mance liquid chromatogra¬
phy with radiation detection.
At two minutes, all the
preparations retained high
radiochemical purities. How¬
ever, at 30 and 60 minutes,
the radiochemical purities of
technetium Tc 99m exameta¬
zime prepared with six-hour-
old sodium pertechnetate Tc
99m were significantly lower
than those of technetium Tc
99m exametazime prepared
with one-hour-old sodium
pertechnetate Tc 99m. Simi¬




of technetium Tc 99m exa¬
metazime was affected by the
age of the sodium pertechne¬
tate Tc 99m from which it
was prepared but not by the
generator from which the so¬
dium pertechnetate Tc 99m
was obtained.
Index terms: Drugs; Injec¬
tions; Manufacturers; Purity;
Roentgenographic agents; So¬
dium pertechnetate Tc 99m;
Stability; Technetium Tc 99m
exametazime
Am J Hosp Pharm. 1993;
50:103-6
Technetium Tc 99m exametazime is a radiophar¬maceutical that is used in imaging cerebral bloodflow1 and in labeling autologous leukocytes for
the detection of sites of inflammation.2 Technetium Tc
99m exametazime is prepared by injecting a solution of
sodium pertechnetate Tc 99m into an exametazime kit.
The manufacturer of this kit makes the following rec¬
ommendations about its reconstitution: (1) The sodium
pertechnetate Tc 99m must have been eiuted from a
technetium Tc 99m generator less than two hours be¬
fore being used to reconstitute the kit, (2) the previous
elution of the technetium Tc 99m generator must have
occurred within the preceding 24 hours, (3) not more
than 1.1 gigabecquerels (GBq) (30 mCi) of technetium
Tc 99m must be injected into the kit, and (4) the
radiopharmaceutical must be administered to the pa¬
tient within 30 minutes after preparation.1 Failure to
comply with any one of these recommendations may
result in administration of technetium Tc 99m examet¬
azime of low radiochemical purity.
To comply with recommendation 4, the exameta¬
zime kit must be reconstituted not more than 30 min¬
utes before the radiopharmaceutical is required. When
the radiopharmaceutical is to be used in a department
that is not located close to the pharmacy, the sodium
pertechnetateTc99mandthe exametazime kitmust be
supplied separately. Reconstitution is then performed
in the department where the radiopharmaceutical is to
be administered. In such circumstances, however, it
may not be possible to reconstitute the kit within two
hours of elution. Complyingwith the two-hour restric¬
tion on the age of sodium pertechnetate Tc 99m can
therefore present a real problem. In an examination of
this problem, Ponto4 published data showing that when
five-hour-old sodium pertechnetate Tc 99m eiuted from
a Medi-Physics or Mallinckrodt generator was used,
technetium Tc 99m exametazime of high radiochemi¬
cal purity was obtained immediately after preparation.
During previouswork inmy department, high radio¬
chemical purity was observed immediately after recon¬
stitution when technetium Tc 99m exametazime was
prepared by using sodium pertechnetate Tc 99m from a
generator manufactured by Amersham International.5
However, when six-hour-old sodium pertechnetate Tc
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99m was used, the radiochemical purity of the techne¬
tium Tc 99m exametazime 30 minutes after preparation
was considerably lower than when one-hour-old sodi¬
um pertechnetate Tc 99m was used.
In the study documented here, 1 attempted to estab¬
lish (1) whether the phenomenon reported by Ponto4
was a feature of the sodium pertechnetate Tc 99m
obtained from the generators used in his study and (2)
whether the reported insignificance of eluate age is
valid at the 30-minute expiration time of technetium Tc
99m exametazime.
Methods
The technetium Tc 99m generators used were four
UltraTechneKow 8.5-GBq (230-mCi) generators (prod¬
uct code DRN 4329, Mallinckrodt Medical [U.K.] Ltd.,
Northampton, U.K.), and eight Amertec II 15-GBq (405-
mCi) generators (product code MCC20, Amersham In¬
ternational p.i.e., Amersham, U.K.). Both types of
generators are loadedwith fission molybdenum 99. The
generators were eluted 24 hours before being eluted to
provide sodium pertechnetate Tc 99m for use in the
preparation of technetium Tc 99m exametazime. Elu-
ates from each manufacturer's generators were diluted
immediately after elution to provide two solutions of
sodium pertechnetate Tc 99m. To prepare one-hour-old
solution, generator eluate was diluted with 0.9% sodi¬
um chloride injection to a concentration of radioactiv¬
ity of 1.4 GBq (38 mCi) in 5.5 mL, injected into a sterile
10-mL nitrogen-filled vial (product code N80, Amer¬
sham), and used one hour later. To prepare six-hour-old
sodium pertechnetate Tc 99m, the method was the
same, but eluate was diluted to a concentration of 2.4
GBq (65 mCi) in 5.5 mL and used six hours later.
Technetium Tc 99m exametazime was prepared by
injecting 5.0 mL of one of the solutions into an exa¬
metazime kit (Ceretec, Amersham) at the appropriate
time. The concentrations of radioactivity in the sodium
pertechnetate Tc 99m solutions were chosen to provide
1.1 GBq (30mCi) of technetium Tc 99m in 5.0mL at the
time of kit reconstitution. A different lot of exameta¬
zime kits was used for each set of four experiments (i.e.,
one-hour-oid and six-hour-old sodium pertechnetate
Tc 99m from each manufacturer's generators). Each
experiment was performed six times. Reconstituted kits
were stored at room temperature.
At 2, 30, and 60 minutes after reconstitution of each
kit, the radiochemical purity of the technetium Tc 99m
exametazime was measured by using high-performance
liquid chromatography with radiation detection. This
technique for analyzing technetium Tc 99m exameta¬
zime has been shown to be satisfactory.5 Analysis was
performed by using gradient elution of a 150 x 4.6 mm
column packed with a reversed-phase macroporous
copolymer of styrene and divinylbenzene (PRP-1, Ham¬
ilton Co., Reno, NV). The column was fittedwith a 25 x
3 mm guard column. The column was eluted with 20
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mM phosphate buffer (pH 7.4) at a flow rate of 2 mL/
min. Immediately after injection of a 20-pL sample of
the radiopharmaceutical, tetrahvdrofuran was intro¬
duced into the mobile phase in a linear gradient of 0-
25% over six minutes. The final composition of
buffentetrahydrofuran (75:25) was maintained for a
further four minutes. Recovery from the column was
measured as described previously5 to exclude the possi¬
bility of the presence of species that might be adsorbed
onto the column and remain undetected.
The chromatogram was obtained by acquiring the
counts from the radiation detector in a multichannel
analyzer (Accuspec, Canberra Nuclear Data, Schaum-
burg, IL). The chromatogram contained four peaks. A
region of interest was placed around each peak, and the
counts in each region were recorded and corrected for
background. The counts in each peak were expressed as
a percentage of the total counts in the chromatogram.
The percentage in the peak corresponding to primary
technetium Tc 99m exametazime complex was taken to
be the radiochemical purity. Preparations of techne¬
tium Tc 99m exametazime with radiochemical purities
of greater than 80% were considered acceptable.
Statistical analysis was performed with Student's t
test. The a priori level of significance was <0.05.
Results
The chromatogram contained four peaks, which rep¬
resented pertechnetate Tc 99m impurity, secondary
technetium Tc 99m exametazime complex, an uniden¬
tified impurity, and primary technetium Tc 99m exa¬
metazime complex; these had retention times of 1.3,
3.2, 6.5, and 8.6 minutes, respectively. The mean ± S.D.
recovery of radioactivity from the column of 99.1 ±
2.7% demonstrates that no major undetected species
were present. Secondary technetium Tc 99m exameta¬
zime complex represented approximately 2.5% of the
radioactivity at two minutes and approximately 8% at
one hour. The unidentified impurity represented ap¬
proximately 3.5% and did not change with time. These
levels of secondary technetium Tc 99m exametazime
complex and unidentified impurity did not vary with
the generator used or the age of the sodium pertechne¬
tate Tc 99m.
The radiochemical purities of technetium Tc 99m
exametazime prepared under the various conditions are
shown in Table 1. Each technique resulted in high
radiochemical purity two minutes after preparation.
However, at 30 and 60 minutes, the radiochemical
purities of technetium Tc 99m exametazime prepared
with six-hour-old sodium pertechnetate Tc 99m were
significantly lower than the purities of technetium Tc
99m exametazime prepared with one-hour-old sodium
pertechnetate Tc 99m. Similar results were found for
each manufacturer's generators. No significant differ¬
ences in radiochemical purity were found between cor¬
responding results for technetium Tc 99m exametazime
178
Appendix II - Published papers
Technetium Tc 99m exametazime Reports
prepared with sodium pertechnetate Tc 99m eluted
from generators from different manufacturers.
The changes in the levels of pertechnetate Tc 99m
impurity with time are also shown in Table 1. When
one-hour-old sodium pertechnetate Tc 99m from either
manufacturer's generators was used, the levels of per¬
technetate Tc 99m impurity rose slowly and were not
significantly different at 30 and 60 minutes than at 2
minutes, in contrast, when six-hour-old sodium per¬
technetate Tc 99m from either manufacturer's genera¬
tors was used, the levels rose much more quickly and
were significantly higher at 30 and 60 minutes than at
2 minutes.
Discussion
Amersham International specifies that technetium
Tc 99m exametazime with a radiochemical purity of at
least 80% may be expected if all the recommendations
for reconstitution of its exametazime kit are observed.3
Ponto4 challenged the recommendation that the tech¬
netium Tc 99m used for reconstitution be less than two
hours old by obtaining satisfactory radiochemical puri¬
tywith technetium Tc 99m up to five hours old. Ponto's
result, however, was based solely on measurements
made immediately after reconstitution. Of much great¬
er importance is the radiochemical purity when the
agent is administered. Because it is impossible to guar¬
antee that technetium Tc 99m exametazimewill always
be administered immediately after reconstitution of the
kit, it is best that the method of preparation result in
Table 1.
Levels of Selected Radiochemical Species in
Technetium Tc 99m Exametazime after Use of Sodium
Pertechnetate Tc 99m Eluted from Two Types of
Generators
Mean ± S.D. % of Radiochemical
Species after Reconstitution (n = 6)
Species3 2 min 30 min 60 min
Amersham Eluale,
1 Hour Old
PTEC 92.7 ± 1.2
PI 1.2 ± 0.2
Amersham Eluate,
6 Hours Old


















B8.7 ± 0.7 84.7 ± 0.6
1.3 ±0.3 2.1 ±0.5
81.9 ± 2.1b 72.1 ±2.7°
8.4 ± 1,7C 15.6 ±2.6°
a PTEC = Primary technetium Tc 99m exametazime complex {the indi¬
cator of radiochemical purity), PI = pertechnetate Tc 99m impurity.
D Significantly different (p < 0.05, Student's t test) from corresponding
value for one-hour-old eluate from same manufacturer's generators.
c Significantly different from corresponding value at two minutes.
satisfactory radiochemical purity at the expiration time
quoted for the radiopharmaceutical. In the case of
technetium Tc 99m exametazime. the expiration time
is 30 minutes after reconstitution.
In my study, high radiochemical purity was present
two minutes after reconstitution, regardless of the type
of generator or the age of the sodium pertechnetate Tc
99m. These results agreewith those of Ponto.4 However,
after 30 minutes the technetium Tc 99m exametazime
prepared with one-hour-old sodium pertechnetate Tc
99m retained high radiochemical purity, whereas the
technetium Tc 99m exametazime prepared with six-
hour-old sodium pertechnetate Tc 99m did not. A sim¬
ilar discrepancy was seen at 60 minutes. Although at 30
minutes the radiochemical purity of the technetium Tc
99m exametazime prepared with six-hour-old sodium
pertechnetate Tc 99m was greater than the manufactur¬
er's 80% limit, it is too close to the limit for comfort,
given the inevitable variability between batches of ex¬
ametazime kits. These findings demonstrate that the
age of the sodium pertechnetate Tc 99m used has a
significant effect on the radiochemical purity of the
technetium Tc 99m exametazime prepared.
It is conceivable that Ponto's findings were attribut¬
able to the technetium Tc 99m generators from which
the sodium pertechnetate Tc 99m was obtained. Ponto
used Mallinckrodt and Medi-Phvsics generators. To in¬
vestigate this possibility, I compared technetium Tc
99m exametazime prepared with sodium pertechnetate
Tc 99m from Amersham International generators with
technetium Tc 99m exametazime prepared with sodi¬
um pertechnetate Tc 99m from Mallinckrodt genera¬
tors; the results for the two generators agreed well at all
times after reconstitution. Although Mallinckrodt gen¬
erators were used in both studies, one was manufac¬
tured in Europe and the other was manufactured in the
United States. Nevertheless, sodium pertechnetate Tc
99m from each of the total of four types of generators
used in my study and Ponto's resulted in technetium Tc
99m exametazime of comparable radiochemical purity
immediately after reconstitution. It appears that the
model of technetium Tc 99m generator does not influ¬
ence the radiochemical purity of technetium Tc 99m
exametazime.
Three potential radiochemical impurities determine
the radiochemical purity of technetium Tc 99m exa¬
metazime; pertechnetate Tc 99m, unbound reduced
technetium Tc 99m, and secondary technetium Tc 99m
exametazime complex, i previously showed that the
increase in secondary technetium Tc 99m exametazime
complex is not influenced by the age of the technetium
Tc 99m.5 Similar results were obtained in this study.
Table 1 shows that when technetium Tc 99m exameta¬
zime is prepared from six-hour-old sodium pertechne¬
tate Tc99m, the level of pertechnetate Tc99m impurity
rises rapidly and that this species is the principal cause
of the reduction in radiochemical purity.
Vol SO Ian 1QQ"3 Am I Hn<;n Pharm
179
Appendix 11 - Published papers
Reports Technetium Tc 99m exametazime
Conclusion
The radiochemical purity of technetium Tc 99m
exametazime was affected by the age of the sodium
pertechnetate Tc 99m from which it was prepared but
not by the generator from which the sodium pertechne¬
tate Tc 99m was obtained.
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